0001558370-24-01505010-Q TELA Bio, Inc. 20241108202411081605471605481605480 0 0001558370-24-015050 10-Q 58 20240930 20241108 20241108 TELA Bio, Inc. 0001561921 3841 455320061 DE 1231 10-Q 34 001-39130 241440507 1 GREAT VALLEY PARKWAY, SUITE 24 MALVERN PA 19355 484-320-2930 1 GREAT VALLEY PARKWAY, SUITE 24 MALVERN PA 19355 10-Q 1 tela-20240930x10q.htm 10-Q http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent247171932449467500015619 21--12-312024Q3false00http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember000001561921us-gaap:SubsequentEventMember2024-10-242024-10-240001561921us-gaap:WarrantMemberus-gaap:SubsequentEventMember2024-10-242024-10-240001561921us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-242024-10-240001561921us-gaap:RetainedEarningsMember2024-09-300001561921us-gaap:AdditionalPaidInCapitalMember2024-09-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001561921us-gaap:RetainedEarningsMember2024-06-300001561921us-gaap:AdditionalPaidInCapitalMember2024-06-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001561921us-gaap:RetainedEarningsMember2023-12-310001561921us-gaap:AdditionalPaidInCapitalMember2023-12-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001561921us-gaap:RetainedEarningsMember2023-09-300001561921us-gaap:AdditionalPaidInCapitalMember2023-09-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001561921us-gaap:RetainedEarningsMember2023-06-300001561921us-gaap:AdditionalPaidInCapitalMember2023-06-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001561921us-gaap:RetainedEarningsMember2023-03-310001561921us-gaap:AdditionalPaidInCapitalMember2023-03-310001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001561921us-gaap:CommonStockMember2023-07-012023-09-300001561921us-gaap:CommonStockMember2023-01-012023-09-300001561921us-gaap:CommonStockMember2024-09-300001561921us-gaap:CommonStockMember2024-06-300001561921us-gaap:CommonStockMember2023-12-310001561921us-gaap:CommonStockMember2023-09-300001561921us-gaap:CommonStockMember2023-06-300001561921us-gaap:CommonStockMember2022-12-310001561921us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-240001561921tela:ServiceBasedRestrictedStockUnitsMember2024-09-300001561921tela:PerformanceBasedRestrictedStockUnitsMember2024-09-300001561921tela:ServiceBasedRestrictedStockUnitsMember2023-12-310001561921tela:PerformanceBasedRestrictedStockUnitsMember2023-12-310001561921tela:ServiceBasedRestrictedStockUnitsMember2024-01-012024-09-300001561921tela:PerformanceBasedRestrictedStockUnitsMember2024-01-012024-09-300001561921srt:MinimumMembertela:PerformanceBasedRestrictedStockUnitsMember2024-01-012024-09-300001561921srt:MaximumMembertela:PerformanceBasedRestrictedStockUnitsMember2024-01-012024-09-300001561921us-gaap:EmployeeStockOptionMembertela:EquityIncentivePlan2019Member2024-01-012024-09-300001561921tela:ServiceBasedRestrictedStockUnitMember2024-01-012024-09-300001561921us-gaap:NonUsMember2024-07-012024-09-300001561921tela:OvitexPrsMember2024-07-012024-09-300001561921tela:OvitexMember2024-07-012024-09-300001561921tela:OtherCustomersMember2024-07-012024-09-300001561921us-gaap:NonUsMember2024-01-012024-09-300001561921tela:OvitexPrsMember2024-01-012024-09-300001561921tela:OvitexMember2024-01-012024-09-300001561921tela:OtherCustomersMember2024-01-012024-09-300001561921us-gaap:NonUsMember2023-07-012023-09-300001561921tela:OvitexPrsMember2023-07-012023-09-300001561921tela:OvitexMember2023-07-012023-09-300001561921tela:OtherCustomersMember2023-07-012023-09-300001561921us-gaap:NonUsMember2023-01-012023-09-300001561921tela:OvitexPrsMember2023-01-012023-09-300001561921tela:OvitexMember2023-01-012023-09-300001561921tela:OtherCustomersMember2023-01-012023-09-300001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-01-012024-09-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001561921us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001561921us-gaap:RetainedEarningsMember2024-07-012024-09-300001561921us-gaap:RetainedEarningsMember2024-01-012024-09-300001561921us-gaap:RetainedEarningsMember2023-07-012023-09-300001561921us-gaap:RetainedEarningsMember2023-01-012023-09-300001561921us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001561921us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-01-012024-03-310001561921tela:MimedxGroupIncMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembertela:DisposalGroupTransactionMember2024-09-300001561921tela:MidcapTermLoansMember2024-09-300001561921tela:MidcapTermLoansMember2023-12-310001561921tela:MidcapTermLoansMember2022-05-260001561921us-gaap:WarrantMemberus-gaap:SubsequentEventMember2024-10-240001561921tela:CommonStockWarrantsExpiringIn2028Member2024-09-300001561921tela:CommonStockWarrantsExpiringIn2027Member2024-09-300001561921tela:MidcapTermLoansMember2023-09-300001561921tela:MidcapTermLoansMember2023-01-012023-09-300001561921us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001561921us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001561921us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001561921us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001561921us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001561921us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001561921us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001561921us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001561921us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001561921us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001561921us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001561921us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001561921us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001561921tela:EquityDistributionAgreementMember2023-01-012024-09-300001561921us-gaap:RestrictedStockUnitsRSUMember2024-09-300001561921us-gaap:EmployeeStockOptionMember2024-09-300001561921tela:MimedxGroupIncMember2024-01-012024-09-300001561921tela:ThirdYearMembertela:MidcapTermLoansMember2024-01-012024-09-300001561921tela:SecondYearMembertela:MidcapTermLoansMember2024-01-012024-09-300001561921tela:FirstYearMembertela:MidcapTermLoansMember2024-01-012024-09-300001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2024-09-300001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2024-07-012024-09-300001561921tela:MimedxGroupIncMembertela:DisposalGroupTransactionMember2024-01-012024-09-300001561921tela:MimedxGroupIncMembersrt:MinimumMembertela:DisposalGroupTransactionMember2024-09-300001561921tela:MimedxGroupIncMembersrt:MaximumMembertela:DisposalGroupTransactionMember2024-09-300001561921tela:MimedxGroupIncMembersrt:MinimumMember2024-09-300001561921tela:MimedxGroupIncMembersrt:MaximumMember2024-09-300001561921tela:MidcapTermLoansMember2024-01-012024-09-300001561921tela:EquityIncentivePlan2019Member2024-09-300001561921tela:EquityDistributionAgreementMember2023-11-300001561921tela:CommonStockWarrantsExpiringIn2028Member2024-01-012024-09-300001561921tela:CommonStockWarrantsExpiringIn2027Member2024-01-012024-09-300001561921us-gaap:CommonStockMember2024-01-012024-09-300001561921us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001561921us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001561921us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001561921tela:MidcapTermLoansMember2024-01-012024-09-300001561921srt:MinimumMembertela:MidcapTermLoansMember2024-01-012024-09-300001561921srt:MaximumMembertela:MidcapTermLoansMember2024-01-012024-09-300001561921tela:MidcapTermLoansMember2024-09-300001561921tela:MidcapTermLoansMember2023-12-310001561921tela:MidcapTermLoansMember2024-09-300001561921tela:MidcapTermLoansMember2024-06-300001561921tela:MidcapTermLoansMember2024-03-310001561921tela:MidcapTermLoansMember2023-09-300001561921tela:MidcapTermLoansMember2023-06-300001561921tela:MidcapTermLoansMember2023-03-310001561921tela:MidcapTermLoansMember2022-12-310001561921tela:MidcapTermLoansMember2022-09-300001561921tela:MidcapTermLoansMember2022-06-300001561921tela:MidcapTermLoansMember2022-03-310001561921tela:MidcapTermLoansMember2021-12-310001561921tela:MidcapTermLoansMember2021-09-300001561921tela:MidcapTermLoansMember2021-06-300001561921tela:MidcapTermLoansMember2021-03-310001561921tela:MidcapTermLoansMember2020-12-310001561921tela:MidcapTermLoansMember2020-09-300001561921tela:MidcapTermLoansMember2020-06-300001561921tela:MidcapTermLoansMember2020-03-310001561921tela:MidcapTermLoansMember2019-12-310001561921tela:MidcapTermLoansMember2019-09-300001561921tela:MidcapTermLoansMember2019-06-300001561921tela:MidcapTermLoansMember2019-03-310001561921tela:MidcapTermLoansMember2018-12-310001561921tela:MidcapTermLoansMember2018-09-300001561921tela:MidcapTermLoansMember2018-06-300001561921tela:MidcapTermLoansMember2018-03-310001561921tela:MidcapTermLoansMember2017-12-310001561921tela:MidcapTermLoansMember2017-09-300001561921tela:MidcapTermLoansMember2017-06-300001561921tela:MidcapTermLoansMember2017-03-310001561921tela:MidcapTermLoansMember2016-12-310001561921tela:MidcapTermLoansMember2016-09-300001561921tela:MidcapTermLoansMember2016-06-300001561921tela:MidcapTermLoansMember2016-03-310001561921tela:MidcapTermLoansMember2015-12-310001561921tela:MidcapTermLoansMember2015-09-300001561921tela:MidcapTermLoansMember2015-06-300001561921tela:MidcapTermLoansMember2015-03-310001561921tela:MidcapTermLoansMember2014-12-310001561921tela:MidcapTermLoansMember2014-09-300001561921tela:MidcapTermLoansMember2014-06-300001561921tela:MidcapTermLoansMember2014-03-310001561921tela:MidcapTermLoansMember2013-12-310001561921tela:MidcapTermLoansMember2013-09-300001561921tela:MidcapTermLoansMember2013-06-300001561921tela:MidcapTermLoansMember2013-03-310001561921tela:MidcapTermLoansMember2012-12-310001561921tela:MidcapTermLoansMember2012-09-300001561921tela:MidcapTermLoansMember2012-06-300001561921tela:MidcapTermLoansMember2012-03-310001561921tela:MidcapTermLoansMember2011-12-310001561921tela:MidcapTermLoansMember2011-09-300001561921tela:MidcapTermLoansMember2011-06-300001561921tela:MidcapTermLoansMember2011-03-310001561921tela:MidcapTermLoansMember2010-12-310001561921tela:MidcapTermLoansMember2010-09-300001561921tela:MidcapTermLoansMember2010-06-300001561921tela:MidcapTermLoansMember2010-03-310001561921tela:MidcapTermLoansMember2009-12-310001561921tela:MidcapTermLoansMember2009-09-300001561921tela:MidcapTermLoansMember2009-06-300001561921tela:MidcapTermLoansMember2009-03-310001561921tela:MidcapTermLoansMember2008-12-310001561921tela:MidcapTermLoansMember2008-09-300001561921tela:MidcapTermLoansMember2008-06-300001561921tela:MidcapTermLoansMember2008-03-310001561921tela:MidcapTermLoansMember2007-12-310001561921tela:MidcapTermLoansMember2007-09-300001561921tela:MidcapTermLoansMember2007-06-300001561921tela:MidcapTermLoansMember2007-03-310001561921tela:MidcapTermLoansMember2006-12-310001561921tela:MidcapTermLoansMember2006-09-300001561921tela:MidcapTermLoansMember2006-06-300001561921tela:MidcapTermLoansMember2006-03-310001561921tela:MidcapTermLoansMember2005-12-310001561921tela:MidcapTermLoansMember2005-09-300001561921tela:MidcapTermLoansMember2005-06-300001561921tela:MidcapTermLoansMember2005-03-310001561921tela:MidcapTermLoansMember2004-12-310001561921tela:MidcapTermLoansMember2004-09-300001561921tela:MidcapTermLoansMember2004-06-300001561921tela:MidcapTermLoansMember2004-03-310001561921tela:MidcapTermLoansMember2003-12-310001561921tela:MidcapTermLoansMember2003-09-300001561921tela:MidcapTermLoansMember2003-06-300001561921tela:MidcapTermLoansMember2003-03-310001561921tela:MidcapTermLoansMember2002-12-310001561921tela:MidcapTermLoansMember2002-09-300001561921tela:MidcapTermLoansMember2002-06-300001561921tela:MidcapTermLoansMember2002-03-310001561921tela:MidcapTermLoansMember2001-12-310001561921tela:MidcapTermLoansMember2001-09-300001561921tela:MidcapTermLoansMember2001-06-300001561921tela:MidcapTermLoansMember2001-03-310001561921tela:MidcapTermLoansMember2000-12-310001561921tela:MidcapTermLoansMember2000-09-300001561921tela:MidcapTermLoansMember2000-06-300001561921tela:MidcapTermLoansMember2000-03-310001561921tela:MidcapTermLoansMember1999-12-310001561921tela:MidcapTermLoansMember1999-09-300001561921tela:MidcapTermLoansMember1999-06-300001561921tela:MidcapTermLoansMember1999-03-310001561921tela:MidcapTermLoansMember1998-12-310001561921tela:MidcapTermLoansMember1998-09-300001561921tela:MidcapTermLoansMember1998-06-300001561921tela:MidcapTermLoansMember1998-03-310001561921tela:MidcapTermLoansMember1997-12-310001561921tela:MidcapTermLoansMember1997-09-300001561921tela:MidcapTermLoansMember1997-06-300001561921tela:MidcapTermLoansMember1997-03-310001561921tela:MidcapTermLoansMember1996-12-310001561921tela:MidcapTermLoansMember1996-09-300001561921tela:MidcapTermLoansMember1996-06-300001561921tela:MidcapTermLoansMember1996-03-310001561921tela:MidcapTermLoansMember1995-12-310001561921tela:MidcapTermLoansMember1995-09-300001561921tela:MidcapTermLoansMember1995-06-300001561921tela:MidcapTermLoansMember1995-03-310001561921tela:MidcapTermLoansMember1994-12-310001561921tela:MidcapTermLoansMember1994-09-300001561921tela:MidcapTermLoansMember1994-06-300001561921tela:MidcapTermLoansMember1994-03-310001561921tela:MidcapTermLoansMember1993-12-310001561921tela:MidcapTermLoansMember1993-09-300001561921tela:MidcapTermLoansMember1993-06-300001561921tela:MidcapTermLoansMember1993-03-310001561921tela:MidcapTermLoansMember1992-12-310001561921tela:MidcapTermLoansMember1992-09-300001561921tela:MidcapTermLoansMember1992-06-300001561921tela:MidcapTermLoansMember1992-03-310001561921tela:MidcapTermLoansMember1991-12-310001561921tela:MidcapTermLoansMember1991-09-300001561921tela:MidcapTermLoansMember1991-06-300001561921tela:MidcapTermLoansMember1991-03-310001561921tela:MidcapTermLoansMember1990-12-310001561921tela:MidcapTermLoansMember1990-09-300001561921tela:MidcapTermLoansMember1990-06-300001561921tela:MidcapTermLoansMember1990-03-310001561921tela:MidcapTermLoansMember1989-12-310001561921tela:MidcapTermLoansMember1989-09-300001561921tela:MidcapTermLoansMember1989-06-300001561921tela:MidcapTermLoansMember1989-03-310001561921tela:MidcapTermLoansMember1988-12-310001561921tela:MidcapTermLoansMember1988-09-300001561921tela:MidcapTermLoansMember1988-06-300001561921tela:MidcapTermLoansMember1988-03-310001561921tela:MidcapTermLoansMember1987-12-310001561921tela:MidcapTermLoansMember1987-09-300001561921tela:MidcapTermLoansMember1987-06-300001561921tela:MidcapTermLoansMember1987-03-310001561921tela:MidcapTermLoansMember1986-12-310001561921tela:MidcapTermLoansMember1986-09-300001561921tela:MidcapTermLoansMember1986-06-300001561921tela:MidcapTermLoansMember1986-03-310001561921tela:MidcapTermLoansMember1985-12-310001561921tela:MidcapTermLoansMember1985-09-300001561921tela:MidcapTermLoansMember1985-06-300001561921tela:MidcapTermLoansMember1985-03-310001561921tela:MidcapTermLoansMember1984-12-310001561921tela:MidcapTermLoansMember1984-09-300001561921tela:MidcapTermLoansMember1984-06-300001561921tela:MidcapTermLoansMember1984-03-310001561921tela:MidcapTermLoansMember1983-12-310001561921tela:MidcapTermLoansMember1983-09-300001561921tela:MidcapTermLoansMember1983-06-300001561921tela:MidcapTermLoansMember1983-03-310001561921tela:MidcapTermLoansMember1982-12-310001561921tela:MidcapTermLoansMember1982-09-300001561921tela:MidcapTermLoansMember1982-06-300001561921tela:MidcapTermLoansMember1982-03-310001561921tela:MidcapTermLoansMember1981-12-310001561921tela:MidcapTermLoansMember1981-09-300001561921tela:MidcapTermLoansMember1981-06-300001561921tela:MidcapTermLoansMember1981-03-310001561921tela:MidcapTermLoansMember1980-12-310001561921tela:MidcapTermLoansMember1980-09-300001561921tela:MidcapTermLoansMember1980-06-300001561921tela:MidcapTermLoansMember1980-03-310001561921tela:MidcapTermLoansMember1979-12-310001561921tela:MidcapTermLoansMember1979-09-300001561921tela:MidcapTermLoansMember1979-06-300001561921tela:MidcapTermLoansMember1979-03-310001561921tela:MidcapTermLoansMember1978-12-310001561921tela:MidcapTermLoansMember1978-09-300001561921tela:MidcapTermLoansMember1978-06-300001561921tela:MidcapTermLoansMember1978-03-310001561921tela:MidcapTermLoansMember1977-12-310001561921tela:MidcapTermLoansMember1977-09-300001561921tela:MidcapTermLoansMember1977-06-300001561921tela:MidcapTermLoansMember1977-03-310001561921tela:MidcapTermLoansMember1976-12-310001561921tela:MidcapTermLoansMember1976-09-300001561921tela:MidcapTermLoansMember1976-06-300001561921tela:MidcapTermLoansMember1976-03-310001561921tela:MidcapTermLoansMember1975-12-310001561921tela:MidcapTermLoansMember1975-09-300001561921tela:MidcapTermLoansMember1975-06-300001561921tela:MidcapTermLoansMember1975-03-310001561921tela:MidcapTermLoansMember1974-12-310001561921tela:MidcapTermLoansMember1974-09-300001561921tela:MidcapTermLoansMember1974-06-300001561921tela:MidcapTermLoansMember1974-03-310001561921tela:MidcapTermLoansMember1973-12-310001561921tela:MidcapTermLoansMember1973-09-300001561921tela:MidcapTermLoansMember1973-06-300001561921tela:MidcapTermLoansMember1973-03-310001561921tela:MidcapTermLoansMember1972-12-310001561921tela:MidcapTermLoansMember1972-09-300001561921tela:MidcapTermLoansMember1972-06-300001561921tela:MidcapTermLoansMember1972-03-310001561921tela:MidcapTermLoansMember1971-12-310001561921tela:MidcapTermLoansMember1971-09-300001561921tela:MidcapTermLoansMember1971-06-300001561921tela:MidcapTermLoansMember1971-03-310001561921tela:MidcapTermLoansMember1970-12-310001561921tela:MidcapTermLoansMember1970-09-300001561921tela:MidcapTermLoansMember1970-06-300001561921tela:MidcapTermLoansMember1970-03-310001561921tela:MidcapTermLoansMember1969-12-310001561921tela:MidcapTermLoansMember1969-09-300001561921tela:MidcapTermLoansMember1969-06-300001561921tela:MidcapTermLoansMember1969-03-310001561921tela:MidcapTermLoansMember1968-12-310001561921tela:MidcapTermLoansMember1968-09-300001561921tela:MidcapTermLoansMember1968-06-300001561921tela:MidcapTermLoansMember1968-03-310001561921tela:MidcapTermLoansMember1967-12-310001561921tela:MidcapTermLoansMember1967-09-300001561921tela:MidcapTermLoansMember1967-06-300001561921tela:MidcapTermLoansMember1967-03-310001561921tela:MidcapTermLoansMember1966-12-310001561921tela:MidcapTermLoansMember1966-09-300001561921tela:MidcapTermLoansMember1966-06-300001561921tela:MidcapTermLoansMember1966-03-310001561921tela:MidcapTermLoansMember1965-12-310001561921tela:MidcapTermLoansMember1965-09-300001561921tela:MidcapTermLoansMember1965-06-300001561921tela:MidcapTermLoansMember1965-03-310001561921tela:MidcapTermLoansMember1964-12-310001561921tela:MidcapTermLoansMember1964-09-300001561921tela:MidcapTermLoansMember1964-06-300001561921tela:MidcapTermLoansMember1964-03-310001561921tela:MidcapTermLoansMember1963-12-310001561921tela:MidcapTermLoansMember1963-09-300001561921tela:MidcapTermLoansMember1963-06-300001561921tela:MidcapTermLoansMember1963-03-310001561921tela:MidcapTermLoansMember1962-12-310001561921tela:MidcapTermLoansMember1962-09-300001561921tela:MidcapTermLoansMember1962-06-300001561921tela:MidcapTermLoansMember1962-03-310001561921tela:MidcapTermLoansMember1961-12-310001561921tela:MidcapTermLoansMember1961-09-300001561921tela:MidcapTermLoansMember1961-06-300001561921tela:MidcapTermLoansMember1961-03-310001561921tela:MidcapTermLoansMember1960-12-310001561921tela:MidcapTermLoansMember1960-09-300001561921tela:MidcapTermLoansMember1960-06-300001561921tela:MidcapTermLoansMember1960-03-310001561921tela:MidcapTermLoansMember1959-12-310001561921tela:MidcapTermLoansMember1959-09-300001561921tela:MidcapTermLoansMember1959-06-300001561921tela:MidcapTermLoansMember1959-03-310001561921tela:MidcapTermLoansMember1958-12-310001561921tela:MidcapTermLoansMember1958-09-300001561921tela:MidcapTermLoansMember1958-06-300001561921tela:MidcapTermLoansMember1958-03-310001561921tela:MidcapTermLoansMember1957-12-310001561921tela:MidcapTermLoansMember1957-09-300001561921tela:MidcapTermLoansMember1957-06-300001561921tela:MidcapTermLoansMember1957-03-310001561921tela:MidcapTermLoansMember1956-12-310001561921tela:MidcapTermLoansMember1956-09-300001561921tela:MidcapTermLoansMember1956-06-300001561921tela:MidcapTermLoansMember1956-03-310001561921tela:MidcapTermLoansMember1955-12-310001561921tela:MidcapTermLoansMember1955-09-300001561921tela:MidcapTermLoansMember1955-06-300001561921tela:MidcapTermLoansMember1955-03-310001561921tela:MidcapTermLoansMember1954-12-310001561921tela:MidcapTermLoansMember1954-09-300001561921tela:MidcapTermLoansMember1954-06-300001561921tela:MidcapTermLoansMember1954-03-310001561921tela:MidcapTermLoansMember1953-12-310001561921tela:MidcapTermLoansMember1953-09-300001561921tela:MidcapTermLoansMember1953-06-300001561921tela:MidcapTermLoansMember1953-03-310001561921tela:MidcapTermLoansMember1952-12-310001561921tela:MidcapTermLoansMember1952-09-300001561921tela:MidcapTermLoansMember1952-06-300001561921tela:MidcapTermLoansMember1952-03-310001561921tela:MidcapTermLoansMember1951-12-310001561921tela:MidcapTermLoansMember1951-09-300001561921tela:MidcapTermLoansMember1951-06-300001561921tela:MidcapTermLoansMember1951-03-310001561921tela:MidcapTermLoansMember1950-12-310001561921tela:MidcapTermLoansMember1950-09-300001561921tela:MidcapTermLoansMember1950-06-300001561921tela:MidcapTermLoansMember1950-03-310001561921tela:MidcapTermLoansMember1949-12-310001561921tela:MidcapTermLoansMember1949-09-300001561921tela:MidcapTermLoansMember1949-06-300001561921tela:MidcapTermLoansMember1949-03-310001561921tela:MidcapTermLoansMember1948-12-310001561921tela:MidcapTermLoansMember1948-09-300001561921tela:MidcapTermLoansMember1948-06-300001561921tela:MidcapTermLoansMember1948-03-310001561921tela:MidcapTermLoansMember1947-12-310001561921tela:MidcapTermLoansMember1947-09-300001561921tela:MidcapTermLoansMember1947-06-300001561921tela:MidcapTermLoansMember1947-03-310001561921tela:MidcapTermLoansMember1946-12-310001561921tela:MidcapTermLoansMember1946-09-300001561921tela:MidcapTermLoansMember1946-06-300001561921tela:MidcapTermLoansMember1946-03-310001561921tela:MidcapTermLoansMember1945-12-310001561921tela:MidcapTermLoansMember1945-09-300001561921tela:MidcapTermLoansMember1945-06-300001561921tela:MidcapTermLoansMember1945-03-310001561921tela:MidcapTermLoansMember1944-12-310001561921tela:MidcapTermLoansMember1944-09-300001561921tela:MidcapTermLoansMember1944-06-300001561921tela:MidcapTermLoansMember1944-03-310001561921tela:MidcapTermLoansMember1943-12-310001561921tela:MidcapTermLoansMember1943-09-300001561921tela:MidcapTermLoansMember1943-06-300001561921tela:MidcapTermLoansMember1943-03-310001561921tela:MidcapTermLoansMember1942-12-310001561921tela:MidcapTermLoansMember1942-09-300001561921tela:MidcapTermLoansMember1942-06-300001561921tela:MidcapTermLoansMember1942-03-310001561921tela:MidcapTermLoansMember1941-12-310001561921tela:MidcapTermLoansMember1941-09-300001561921tela:MidcapTermLoansMember1941-06-300001561921tela:MidcapTermLoansMember1941-03-310001561921tela:MidcapTermLoansMember1940-12-310001561921tela:MidcapTermLoansMember1940-09-300001561921tela:MidcapTermLoansMember1940-06-300001561921tela:MidcapTermLoansMember1940-03-310001561921tela:MidcapTermLoansMember1939-12-310001561921tela:MidcapTermLoansMember1939-09-300001561921tela:MidcapTermLoansMember1939-06-300001561921tela:MidcapTermLoansMember1939-03-310001561921tela:MidcapTermLoansMember1938-12-310001561921tela:MidcapTermLoansMember1938-09-300001561921tela:MidcapTermLoansMember1938-06-300001561921tela:MidcapTermLoansMember1938-03-310001561921tela:MidcapTermLoansMember1937-12-310001561921tela:MidcapTermLoansMember1937-09-300001561921tela:MidcapTermLoansMember1937-06-300001561921tela:MidcapTermLoansMember1937-03-310001561921tela:MidcapTermLoansMember1936-12-310001561921tela:MidcapTermLoansMember1936-09-300001561921tela:MidcapTermLoansMember1936-06-300001561921tela:MidcapTermLoansMember1936-03-310001561921tela:MidcapTermLoansMember1935-12-310001561921tela:MidcapTermLoansMember1935-09-300001561921tela:MidcapTermLoansMember1935-06-300001561921tela:MidcapTermLoansMember1935-03-310001561921tela:MidcapTermLoansMember1934-12-310001561921tela:MidcapTermLoansMember1934-09-300001561921tela:MidcapTermLoansMember1934-06-300001561921tela:MidcapTermLoansMember1934-03-310001561921tela:MidcapTermLoansMember1933-12-310001561921tela:MidcapTermLoansMember1933-09-300001561921tela:MidcapTermLoansMember1933-06-300001561921tela:MidcapTermLoansMember1933-03-310001561921tela:MidcapTermLoansMember1932-12-310001561921tela:MidcapTermLoansMember1932-09-300001561921tela:MidcapTermLoansMember1932-06-300001561921tela:MidcapTermLoansMember1932-03-310001561921tela:MidcapTermLoansMember1931-12-310001561921tela:MidcapTermLoansMember1931-09-300001561921tela:MidcapTermLoansMember1931-06-300001561921tela:MidcapTermLoansMember1931-03-310001561921tela:MidcapTermLoansMember1930-12-310001561921tela:MidcapTermLoansMember1930-09-300001561921tela:MidcapTermLoansMember1930-06-300001561921tela:MidcapTermLoansMember1930-03-310001561921tela:MidcapTermLoansMember1929-12-310001561921tela:MidcapTermLoansMember1929-09-300001561921tela:MidcapTermLoansMember1929-06-300001561921tela:MidcapTermLoansMember1929-03-310001561921tela:MidcapTermLoansMember1928-12-310001561921tela:MidcapTermLoansMember1928-09-300001561921tela:MidcapTermLoansMember1928-06-300001561921tela:MidcapTermLoansMember1928-03-310001561921tela:MidcapTermLoansMember1927-12-310001561921tela:MidcapTermLoansMember1927-09-300001561921tela:MidcapTermLoansMember1927-06-300001561921tela:MidcapTermLoansMember1927-03-310001561921tela:MidcapTermLoansMember1926-12-310001561921tela:MidcapTermLoansMember1926-09-300001561921tela:MidcapTermLoansMember1926-06-300001561921tela:MidcapTermLoansMember1926-03-310001561921tela:MidcapTermLoansMember1925-12-310001561921tela:MidcapTermLoansMember1925-09-300001561921tela:MidcapTermLoansMember1925-06-300001561921tela:MidcapTermLoansMember1925-03-310001561921tela:MidcapTermLoansMember1924-12-310001561921tela:MidcapTermLoansMember1924-09-300001561921tela:MidcapTermLoansMember1924-06-300001561921tela:MidcapTermLoansMember1924-03-310001561921tela:MidcapTermLoansMember1923-12-310001561921tela:MidcapTermLoansMember1923-09-300001561921tela:MidcapTermLoansMember1923-06-300001561921tela:MidcapTermLoansMember1923-03-310001561921tela:MidcapTermLoansMember1922-12-310001561921tela:MidcapTermLoansMember1922-09-300001561921tela:MidcapTermLoansMember1922-06-300001561921tela:MidcapTermLoansMember1922-03-310001561921tela:MidcapTermLoansMember1921-12-310001561921tela:MidcapTermLoansMember1921-09-300001561921tela:MidcapTermLoansMember1921-06-300001561921tela:MidcapTermLoansMember1921-03-310001561921tela:MidcapTermLoansMember1920-12-310001561921tela:MidcapTermLoansMember1920-09-300001561921tela:MidcapTermLoansMember1920-06-300001561921tela:MidcapTermLoansMember1920-03-310001561921tela:MidcapTermLoansMember1919-12-310001561921tela:MidcapTermLoansMember1919-09-300001561921tela:MidcapTermLoansMember1919-06-300001561921tela:MidcapTermLoansMember1919-03-310001561921tela:MidcapTermLoansMember1918-12-310001561921tela:MidcapTermLoansMember1918-09-300001561921tela:MidcapTermLoansMember1918-06-300001561921tela:MidcapTermLoansMember1918-03-310001561921tela:MidcapTermLoansMember1917-12-310001561921tela:MidcapTermLoansMember1917-09-300001561921tela:MidcapTermLoansMember1917-06-300001561921tela:MidcapTermLoansMember1917-03-310001561921tela:MidcapTermLoansMember1916-12-310001561921tela:MidcapTermLoansMember1916-09-300001561921tela:MidcapTermLoansMember1916-06-300001561921tela:MidcapTermLoansMember1916-03-310001561921tela:MidcapTermLoansMember1915-12-310001561921tela:MidcapTermLoansMember1915-09-300001561921tela:MidcapTermLoansMember1915-06-300001561921tela:MidcapTermLoansMember1915-03-310001561921tela:MidcapTermLoansMember1914-12-310001561921tela:MidcapTermLoansMember1914-09-300001561921tela:MidcapTermLoansMember1914-06-300001561921tela:MidcapTermLoansMember1914-03-310001561921tela:MidcapTermLoansMember1913-12-310001561921tela:MidcapTermLoansMember1913-09-300001561921tela:MidcapTermLoansMember1913-06-300001561921tela:MidcapTermLoansMember1913-03-310001561921tela:MidcapTermLoansMember1912-12-310001561921tela:MidcapTermLoansMember1912-09-300001561921tela:MidcapTermLoansMember1912-06-300001561921tela:MidcapTermLoansMember1912-03-310001561921tela:MidcapTermLoansMember1911-12-310001561921tela:MidcapTermLoansMember1911-09-300001561921tela:MidcapTermLoansMember1911-06-300001561921tela:MidcapTermLoansMember1911-03-310001561921tela:MidcapTermLoansMember1910-12-310001561921tela:MidcapTermLoansMember1910-09-300001561921tela:MidcapTermLoansMember1910-06-300001561921tela:MidcapTermLoansMember1910-03-310001561921tela:MidcapTermLoansMember1909-12-310001561921tela:MidcapTermLoansMember1909-09-300001561921tela:MidcapTermLoansMember1909-06-300001561921tela:MidcapTermLoansMember1909-03-310001561921tela:MidcapTermLoansMember1908-12-310001561921tela:MidcapTermLoansMember1908-09-300001561921tela:MidcapTermLoansMember1908-06-300001561921tela:MidcapTermLoansMember1908-03-310001561921tela:MidcapTermLoansMember1907-12-310001561921tela:MidcapTermLoansMember1907-09-300001561921tela:MidcapTermLoansMember1907-06-300001561921tela:MidcapTermLoansMember1907-03-310001561921tela:MidcapTermLoansMember1906-12-310001561921tela:MidcapTermLoansMember1906-09-300001561921tela:MidcapTermLoansMember1906-06-300001561921tela:MidcapTermLoansMember1906-03-310001561921tela:MidcapTermLoansMember1905-12-310001561921tela:MidcapTermLoansMember1905-09-300001561921tela:MidcapTermLoansMember1905-06-300001561921tela:MidcapTermLoansMember1905-03-310001561921tela:MidcapTermLoansMember1904-12-310001561921tela:MidcapTermLoansMember1904-09-300001561921tela:MidcapTermLoansMember1904-06-300001561921tela:MidcapTermLoansMember1904-03-310001561921tela:MidcapTermLoansMember1903-12-310001561921tela:MidcapTermLoansMember1903-09-300001561921tela:MidcapTermLoansMember1903-06-300001561921tela:MidcapTermLoansMember1903-03-310001561921tela:MidcapTermLoansMember1902-12-310001561921tela:MidcapTermLoansMember1902-09-300001561921tela:MidcapTermLoansMember1902-06-300001561921tela:MidcapTermLoansMember1902-03-310001561921tela:MidcapTermLoansMember1901-12-310001561921tela:MidcapTermLoansMember1901-09-300001561921tela:MidcapTermLoansMember1901-06-300001561921tela:MidcapTermLoansMember1901-03-310001561921tela:MidcapTermLoansMember1900-12-310001561921tela:MidcapTermLoansMember1900-09-300001561921tela:MidcapTermLoansMember1900-06-300001561921tela:MidcapTermLoansMember1900-03-310001561921tela:MidcapTermLoansMember1899-12-310001561921tela:MidcapTermLoansMember1899-09-300001561921tela:MidcapTermLoansMember1899-06-300001561921tela:MidcapTermLoansMember1899-03-310001561921tela:MidcapTermLoansMember1898-12-310001561921tela:MidcapTermLoansMember1898-09-300001561921tela:MidcapTermLoansMember1898-06-300001561921tela:MidcapTermLoansMember1898-03-310001561921tela:MidcapTermLoansMember1897-12-310001561921tela:MidcapTermLoansMember1897-09-300001561921tela:MidcapTerm

Form 10-K for the year ended December 31, 2023 (our â€œAnnual Reportâ€), our subsequent Quarterly Reports on Form 10-Q and the other documents we file with the Securities and Exchange Commission (the â€œSECâ€).â€‹These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management's beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all.â€‹You should refer to the section titled â€œRisk Factorsâ€ in our Annual Report, this Quarterly Report and any subsequent Quarterly Reports for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.â€‹â€‹â€‹3 Table of ContentsPART I â€” FINANCIAL INFORMATIONItemÂ 1. Financial StatementsTELA Bio, Inc.Consolidated Balance Sheets(In thousands, except share and per share amounts)
(Unaudited)â€‹â€‹â€‹

presents revenue disaggregated by the Companyâ€™s portfolio of products (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended SeptemberÂ 30,Â â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023OviTexâ€‹$ 12,463â€‹$ 10,159â€‹$ 34,122â€‹$ 28,240OviTex PRSâ€‹â€‹ 6,313â€‹â€‹ 4,812â€‹â€‹ 17,054â€‹â€‹ 13,063Otherâ€‹â€‹ 181â€‹â€‹ 81â€‹â€‹ 475â€‹â€‹ 152Total revenueâ€‹$ 18,957â€‹$ 15,052â€‹$ 51,651â€‹$ 41,455â€‹Sales outside of the U.S. were $2.8 million and $1.7 million, respectively, for the three months ended September 30, 2024 and 2023 and $7.5 million and $4.2 million, respectively, for the nine months ended September 30, 2024 and 2023.Fair Value of Financial InstrumentsFair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Companyâ€™s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The carrying amounts of the Companyâ€™s Credit and Security Agreement approximates fair value due to its variable interest rate.The Company follows the provisions of ASC TopicÂ 820, Fair Value Measurement, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:â—Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.â—Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.â—Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,Â supported by little or no market activity).The following fair value hierarchy table presents information about each major category of the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

2024â€‹ 250,149Grantedâ€‹ â€”Vestedâ€‹ â€”Canceled/forfeitedâ€‹ (33,649)Outstanding at SeptemberÂ 30,Â 2024â€‹ 216,500â€‹Included in outstanding RSUs at September 30, 2024 were 115,210 RSUs granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The weighted average grant-date fair value per RSU granted was $6.63 during the nine months ended September 30, 2024. The aggregate intrinsic value of RSUs outstanding was $2.5 million at September 30, 2024. The total unrecognized compensation expense at September 30, 2024 related to RSUs was $4.6Â million, which is expected to be recognized in expense over a weighted-average period of approximately 2.6Â years.â€‹(9) Subsequent Eventâ€‹On October 24, 2024, the Company completed an underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwritersâ€™ option to purchase additional shares of common stock, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so chose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering resulted in gross proceeds of $46.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no subsequent exercise of the pre-funded warrants. The exercise of the pre-funded warrants, if any, is not expected to provide significant additional funding to the Company.â€‹â€‹â€‹â€‹17 Table of ContentsItem 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, as well as other sections in this Quarterly Report, should be read in conjunction with our unaudited interim consolidated financial statements and related notes thereto included elsewhere herein and the consolidated financial statements and notes thereto for the year ended December 31, 2023 and the related Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report filed with the SEC on March 22, 2024. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.OverviewWe are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâ€™s own anatomy. Our growing product portfolio is purposefully designed to leverage the patientâ€™s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.We are dedicated to building true partnerships with surgeons and healthcare providers to deliver solutions that provide both clinical and economic improvements. We believe that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care.Our first portfolio of products, the OviTex Reinforced Tissue Matrix (â€œOviTexâ€) which we first commercialized in the U.S. in July 2016 and in Europe in February 2019, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price.Hernia repair is one of the most common surgeries performed in the U.S., representing approximately 1.1Â million procedures annually. Based on the volume weighted average selling price of our OviTex products, we estimate the annual U.S. total addressable market opportunity for our OviTex products to be approximately $1.5Â billion.Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. In addition, we have also designed an OviTex product specifically for use in laparoscopic and robotic-assisted hernia repair, which we market as OviTex LPR and began commercializing this product in NovemberÂ 2018. In February 2023, we launched two larger configurations of OviTex LPR, designed for ventral and incisional hernias. In April 2024, we launched OviTex IHR Reinforced Tissue Matrix, a new OviTex configuration specifically designed to address inguinal hernia procedures performed robotically and laparoscopically.We have also focused on evaluating and publishing clinical data on the effectiveness and safety of our OviTex products. To date, there have been over thirty published or presented works relating to these clinical findings, either by us or a third-party evaluating the OviTex product. In October 2022, the 24-month results of our single arm, multicenter post-market clinical study, which we refer to as our BRAVO study, were published in the Annals of Medicine and 18 Table of ContentsSurgery. The BRAVO study was designed to evaluate the clinical performance of OviTex for primary or recurrent ventral hernias using open, laparoscopic, or robotic techniques in 92 enrolled patients. The recurrence rate at the 24-month time point was 2.6%, and surgical site occurrences, or SSOs, were observed in 38% of the study population. Of the enrolled patients, 78% were characterized as high risk for experiencing an SSO based on at least one known risk factor, which included obesity, active smoking, COPD, diabetes mellitus, coronary artery disease, or advanced age (â‰¥75 years). The results also indicated that BRAVO patients experienced statistically significant and clinically meaningful improvements in their quality of life and perceived health based on patient responses to the EuroQol-5 Dimension (EQ-5D) health assessment and the validated 12-question Hernia-Related Quality of Life survey (HerQLes). In addition to the BRAVO study and other current clinical initiatives, we also commenced enrollment in May 2021 for our BRAVO II study, a prospective study evaluating the use of OviTex in robot-assisted ventral and inguinal hernia repairs.Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, (â€œOviTex PRSâ€) which we first commercialized in the U.S. in May 2019, addresses unmet needs in plastic and reconstructive surgery. OviTexÂ PRS is indicated for use in implantation to reinforce soft-tissue where weakness exists in patients requiring soft-tissue repair or reinforcement in plastic and reconstructive surgery. Our OviTex PRS portfolio consists of three product configurations with two or three layers of high-quality tissue derived from ovine rumen, which is reinforced with either permanent or resorbable polymer for added strength, stabilization, and controlled stretch. These products are designed to improve outcomes by facilitating functional tissue remodeling while controlling the degree and direction of stretch. In August 2023, we announced the launch of our OviTex PRS Long-Term Resorbable product configuration, which was designed to enhance the OviTex PRS portfolio with specific design features including bi-directional stretch and a fully resorbable, long-term polymer for reinforcement.Our OviTexÂ PRS portfolio is supported by non-human primate data that demonstrated more rapid tissue integration and tissue remodeling compared to the market leading biologic matrix used in this indication. Based on the current sales of biologic matrices in the U.S., we estimate the annual U.S. current addressable market opportunity for our OviTexÂ PRS products to be approximately $700Â million.Our OviTex products have received 510(k)Â clearances from the U.S. Food and Drug Administration, (â€œFDAâ€) which clearances were obtained and are currently held by our exclusive contract manufacturer of these products, Aroa. In April 2019, our first OviTex PRS products received 510(k) clearance from the FDA, which clearance was initially obtained by Aroa and is currently held by us. In March 2023, we received an additional 510(k) clearance for our OviTex PRS Long-Term Resorbable device, which is currently held by us.Â In May 2024, we received clearance of a Special 510(k) related to minor changes to our OviTex PRS Permanent and Short-Term Resorbable devices.Â In October 2024, we received approval from the FDA for our investigationalÂ device exemption application relating to the study of the safety and effectiveness of our OviTexÂ PRS product in implant-based breast reconstruction.Â We continue to evaluate and finalize the clinical study protocolÂ and anticipate additional FDA interactions related to suchÂ to support a pre-market application to obtain an indication for OviTex PRS for use in breast reconstruction.â€‹We also continue to expand our service offerings and diversify our supplier base as we continue to create a soft tissue preservation and restoration portfolio, including through the development of complimentary solutions in our indications such as atraumatic mesh fixation devices or surgical wound management and infection control. In September 2023, we entered into a distribution agreement with Advanced Medical Solutions Limited, a company registered in England, to distribute their LiquiFix Hernia Mesh Fixation Devices (LiquiFix FIX8â„¢ and LiquiFix Precisionâ„¢). In March 2024, we announced the full commercial launch of LiquiFix in the U.S. We previously co-developed and commercialized our NIVIS Fibrillar Collagen Pack, (â€œNIVISâ€) an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding, in partnership with Regenity Biosciences. In March 2024, we sold our distribution rights to MiMedx Group, Inc. in exchange for an initial $5.0 million payment and additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS during the first two years following its launch by MiMedx Group, Inc. We continue to assess additional strategic partnerships with medical device companies whereby we may enter into distribution, product development and/or licensing agreements for new products complimentary to, or related to, existing and future products in our distribution channel.19 Table of ContentsWe have a broad portfolio of intellectual property protecting our products that we believe, when combined with the proprietary manufacturing processes associated with our products and our know-how, provides significant barriers to entry. Our intellectual property applies to our differentiated product construction and materials. In addition, we believe our exclusive manufacturing and long-term supply and license agreement with Aroa creates a competitive advantage by allowing us to secure an exclusive supply of ovine rumen at a low cost. Ovine rumen, the forestomach of a sheep, is the source of the biologic material used in our OviTex and OviTex PRS products. We use biologic material from ovine rumen because of its plentiful supply, optimal biomechanical profile and open collagen architecture that allows for rapid cellular infiltration. Our OviTex products are manufactured by Aroa at their FDA registered and ISOÂ 13485 compliant facility in Auckland, New Zealand. We purchase product from Aroa at a fixed transfer cost as a percentage of Aroaâ€™s cost of goods sold, and, with the exception of our recent IHR-dedicated products, equals 27% of our net sales of licensed products. This revenue sharing arrangement allows us to competitively price our products and pass along cost-savings to our customers.We market our products through a single direct sales force, predominantly in the U.S., as augmented by a smaller number of sales representatives and distributors in certain European countries. We have invested in our direct sales and marketing infrastructure to expand our presence and to promote awareness and adoption of our products. As of September 30, 2024, we had 75 sales territories in the U.S. We believe we can enhance the productivity of our sales force by improving customer segmentation and targeting, implementing and further refining our proprietary training programs, leveraging support from our medical education and medical affairs functions to drive physician awareness, education and clinical understanding of our products, and utilizing engagement analytics to support further product development and enhancement opportunities. Additionally, we have contracted with three national group purchasing organizations, (â€œGPOsâ€) covering our OviTex and OviTex PRS products and plan to continue to contract with additional GPOs and other integrated delivery networks (â€œIDNsâ€) to increase access to and penetration of hospital accounts.We are currently devoting research and development resources to develop additional variations of our OviTex and OviTex PRS product lines, including larger versions of our current product configurations, the development of configurations with longer-acting resorbable polymers and other potential product and packaging enhancements to extend the shelf life of our products. In addition, we also continue to explore the development of lower-cost, higher-margin resorbable polymer-based devices targeting our current indications. We are also exploring additional technologies that may complement our existing products, or expand the number of our product lines, in each case within the hernia, plastic and reconstruction, and broader soft-tissue reconstruction and preservation markets. We intend to continue to make investments in research and development efforts to develop improvements and enhancements to our product portfolio. We are also assessing strategic partnerships with medical device companies whereby we may enter into distribution, product development and/or licensing agreements for products complimentary to, or related to, existing and future products in our distribution channel, which could result in the payment by us of single digit percentage royalties or other product acquisition costs.The vast majority of our revenue to date has been generated by the sale of our OviTex products. Our revenue increased by $3.9 million, or 26%, from $15.1 million for theÂ three months ended September 30, 2023 to $19.0Â million for the three months ended September 30, 2024 and by $10.2 million, or 25%, from $41.5 million for theÂ nine months ended September 30, 2023 to $51.7Â million for the nine months ended September 30, 2024. Our net loss decreased by $0.6 million, or 5%, from $11.0 million for theÂ three months ended September 30, 2023 to $10.4Â million for the three months ended September 30, 2024. Our net loss decreased by $5.1 million, or 15%, from $33.8 million to $28.6Â million for the nine months ended September 30, 2024 due to the gain on sale of NIVIS. We have not been profitable since inception and as of September 30, 2024, we had an accumulated deficit of $349.5 million. Starting in the third quarter of 2024, we implemented certain cost-cutting measures which are expected to result in reduced operating expenses in future periods. However, we expect to incur losses for the foreseeable future.Business Update Regarding Macroeconomic Conditions and COVID-19Our business, results of operations and commercial operations have been impacted by macroeconomic conditions, including the COVID-19 pandemic, as well as, to a lesser extent, inflationary pressures, fluctuations in foreign currency 20 Table of Contentsin the jurisdictions in which we operate, banking instability, monetary policy changes and geopolitical conflicts. These factors have and may continue to impact us in the following ways:COVID-19: Our business was directly impacted by the COVID-19 pandemic, including due to government restrictions on elective procedures and surgical staffing challenges that lead to the deferral of elective surgeries and lower surgical procedural volumes overall. We believe that surgical procedures have started to normalize to pre-pandemic levels and that hospital systems have begun to address any remaining backlog of procedures previously delayed due to the COVID-19 pandemic. However, the true economic effects of the COVID-19 pandemic may have created other labor and financial strains on healthcare systems that continue to reduce procedural volumes. General Economic Uncertainty: Continued concerns about the systemic impact of a potential economic downturn or recession, increasing interest rates, further economic downturn or banking instability, monetary policy changes and geopolitical issues, including the ongoing Russia-Ukraine conflict, the current conflict in Israel and Gaza (including any escalation or expansion) and increasing tensions between China and Taiwan, have contributed to increased market volatility and diminished expectations for economic growth in the world. Due to this uncertainty and other factors, we have experienced high volatility in our stock price over the prior year. Continued uncertainty, perception of worsening market conditions and the introduction of new products which may, or may be perceived to, negatively impact the demand for our products now or in the future could result in a decline in our stock price, high inflation, an increase in our cost of capital and an adverse effect on our ability to access the capital markets in the future on terms acceptable to us or at all.External Cybersecurity Events: The sale of our medical products is correlated to the frequency of surgical procedural volumes at current and prospective hospital accounts. During the second quarter of 2024, we became aware of multiple cybersecurity events, including ransomware attacks and other similar system disruptions and outages, in the U.S. and Europe that adversely impacted the procedural volumes at current customer accounts, including those affiliated across one of our GPOs. To the extent current or future cybersecurity events continue to impact the hospital systems we serve, or otherwise affect third-party payors or other vendors within the healthcare industry critical to the patient care, we may experience additional reductions in procedural volumes that lead to lower sales volume for our products.External Supply Constraints for Critical Surgical Supplies: Any disruptions to the supply of critical surgical supplies, including, for example, IV fluids, could lead to deferrals of elective surgical procedures, including those utilizing our products. To the extent that our current and prospective hospital customers experience significant shortages of these critical supplies, whether due to extreme weather events, labor or work stoppages, or other supply chain disruptions, we may experience reductions in procedural volumes that lead to lower sales volume for our products.Financial Strain: Market acceptance of our medical products in the U.S. and other countries is dependent upon the procurement practices of our customers, patient need for our products and procedures and the reimbursement of patientsâ€™ medical expenses by government healthcare programs and third-party payors. The continuing uncertainty surrounding macroeconomic conditions and financial markets, including the financial strain suffered by hospital customers during the COVID-19 pandemic, may adversely affect demand for our products and procedures and result in lower reimbursement rates or coverage for our products, resulting in lower sales volume and downward pricing pressure on our products and slower adoption of new products.Components of Our Results of OperationsRevenueThe majority of our revenue consists of direct sales of our products to hospital accounts in the U.S. Depending on the terms of our agreements with our customers, we recognize revenue related to product sales when control transfers, which generally occurs when the product is shipped to the customer, or when the product is utilized in a surgical procedure in the case of consignment agreements. Fees charged to customers for shipping are recognized as revenue. Recent revenue growth has been driven by increasing revenue from product sales due to our expanding customer base, although macroeconomic pressures described in this Quarterly Report may impair our ability to continue to generate revenue and expand our customer base at historic rates. 21 Table of ContentsCost of RevenueCost of revenue primarily consists of the costs of licensed products, charges related to excess and obsolete inventory adjustments, royalties and costs related to shipping. We purchase product from Aroa at a fixed transfer cost as a percentage of Aroaâ€™s cost of goods, which, with the exception of our recent IHR-dedicated products, equals 27% of our net sales of licensed products. The initial term of our Aroa License terminates on the expiration of the last patent covering bovine and ovine products, with an option to extend for an additional ten-year period. We expect our cost of revenue to increase in absolute dollars as, and to the extent, our sales

volume grows. Any delay in volume growth, whether due to macroeconomic pressures or otherwise, could lead to additional charges to excess and obsolete inventory. Amortization of Intangible AssetsAmortization of intangible assets relates to the amortization of capitalized milestone amounts paid to Aroa related to license fees or commercialization rights after future economic benefit has been established for a product. These capitalized milestone amounts relate to regulatory clearances, the receipt of certain supply quantities of product, and amounts based upon aggregate net sales thresholds within a specified territory, and are amortized over the remaining useful life of the intellectual property.Gross Profit and Gross MarginOur gross profit is calculated by subtracting our cost of revenue and amortization of intangible assets from our revenue. We calculate our gross marginÂ percentage as our gross profit divided by our revenue. Our gross margin has been, and we expect it will continue to be, affected by a variety of factors, including sales volume, royalties and inventory excess and obsolescence costs. Our gross profit may increase to the extent our revenue grows.Sales and Marketing ExpensesSales and marketing expenses consist of commercial activities related to the sale of our products, along with the salaries and related benefits, including sales commissions and stock-based compensation for employees focused on these efforts. Other significant sales and marketing expenses include costs incurred with post-market clinical studies, conferences and trade shows, promotional and marketing activities, market research, as well as travel and training expenses.We expect future sales and marketing expenses will primarily depend on our ability to drive operational leverage and efficiencies from our expanded commercial organization. We expect our sales and marketing expenses to continue to decrease as aÂ percentage of revenue, as and to the extent, our revenue grows.General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation for personnel in executive, finance, information technology and administrative functions. General and administrative expenses also include professional service fees for legal, accounting, consulting, investor and public relations, insurance costs and direct and allocated facility-related costs.We expect future general and administrative expenses will primarily depend on our ability to efficiently execute on our growth initiatives. We expect our general and administrative expenses to decrease as aÂ percentage of revenue primarily as, and to the extent, our revenue grows.Research and Development ExpensesResearch and development expenses consist primarily of product research, engineering, product development, regulatory compliance and clinical development. These expenses include salaries and related benefits including stock-based compensation, for employees focused on these efforts, consulting services, costs associated with our preclinical studies, costs incurred with our manufacturing partner under development agreements related to technology transfer, costs incurred from license agreements with no alternative future uses, laboratory materials and supplies and an allocation of related facilities costs. We expense research and development costs as they are incurred.22 Table of ContentsWe expect future research and development expenses will primarily depend on our ability to efficiently develop new products, enhance existing products and conduct research to generate clinical data in support of new or expanded indications for our products. We expect research and development expenses as aÂ percentage of revenue to vary over time depending on the level and timing of new product development and clinical trial initiatives.Gain on Sale of Product LineIn March 2024, we entered into an asset purchase agreement with MiMedx Group, Inc. to sell certain assets related to NIVIS. These assets mainly included our existing inventory of NIVIS, with a net carrying value of $0.8 million, and certain intellectual property rights to sell NIVIS, with no carrying value. We transferred control of the nonfinancial asset group in March 2024 and recognized a gain of $7.6 million on the consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2024. At each reporting date, we assess the constraint of variable consideration and record increases in the transaction price in the period that the estimate of variable consideration changes.Interest ExpenseInterest expense consists of cash interest under our credit facilities and non-cash interest attributable to the amortization of final payment fees and the amortization of deferred financing costs related to our indebtedness.Other IncomeOther income consists primarily of income earned on our cash and cash equivalents offset by miscellaneous tax expenses and foreign currency exchange gains and losses.Results of OperationsComparison of the Three Months Ended September 30, 2024 and 2023â€‹Three months ended

| SeptemberÂ 30,Â â€‹ | ChangeÂ â€‹Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarÂ Â Â Â PercentageÂ â€‹â€‹(inÂ thousands,Â exceptÂ percentages)Â Revenueâ€‹$ 18,957â€‹$ 15,052â€‹$ 3,905Â 26%Cost of revenue (excluding amortization of intangible assets)Â Â â€‹Â 6,004â€‹Â 4,568â€‹Â 1,436Â 31â€‹Amortization of intangible assetsâ€‹Â 95â€‹Â 95â€‹Â â€”Â â€”â€‹Gross profitâ€‹Â 12,858â€‹Â 10,389â€‹Â 2,469Â 24â€‹Gross marginâ€‹Â 68%Â Â Â 69%Â Â â€‹â€‹Â Â Â â€‹Operating expenses:â€‹Â â€‹â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Sales and marketingâ€‹Â 16,472â€‹Â 14,474â€‹Â 1,998Â 14â€‹General and administrativeâ€‹Â 3,683â€‹Â 3,728â€‹Â (45)Â (1)â€‹Research and developmentâ€‹Â 2,068â€‹Â 2,368â€‹Â (300)Â (13)â€‹Total operating expensesâ€‹Â 22,223â€‹Â 20,570â€‹Â 1,653Â 8â€‹Loss from operationsâ€‹Â (9,365)â€‹Â (10,181)â€‹Â 816Â (8)â€‹Other expense:â€‹Â â€‹â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Interest expenseâ€‹Â (1,344)â€‹Â (1,334)â€‹Â (10)Â 1â€‹Other income â€‹Â 337â€‹Â 558â€‹Â (221)Â (40)â€‹Total other expenseâ€‹Â (1,007)â€‹Â (776)â€‹Â (231)Â 30â€‹Net lossâ€‹$ (10,372)â€‹$ (10,957)â€‹$ 585Â (5)%â€‹RevenueRevenue increased by $3.9 million, or 26%, to $19.0 million for the three months ended September 30, 2024 from $15.1 million for the three months ended September 30, 2023. The increase in revenue was primarily driven by an increase in unit sales of our products, which resulted in the addition of new customers and growing international sales. This growth was partially offset by a decrease in average selling prices caused by product mix as the share of smaller-sized units 23 Table of Contentsincreased. During the three months ended September 30, 2024, we sold 4,767 units of OviTex as compared to 3,426 units of OviTex during the three months ended September 30, 2023, a 39% increase in unit sales volume. Additionally, we sold 1,293 units of OviTex PRS during the three months ended September 30, 2024 as compared to 896 units during the three months ended September 30, 2023, a 44% increase in unit sales volume.â€‹Cost of RevenueCost of revenue (excluding amortization of intangible assets) increased by $1.4 million, or 31%, to $6.0 million for the three months ended September 30, 2024 from $4.6 million for the three months ended September 30, 2023. The increase in cost of revenue was primarily the result of an increase in products purchased to support demand from our higher unit sales and a higher charge for excess and obsolete inventory.Amortization of Intangible AssetsAmortization of intangible assets was $95,000 for both the three months ended September 30, 2024 and 2023.Gross MarginGross margin decreased to 68% for the three months ended September 30, 2024 from 69% for the three months ended September 30, 2023. The decrease was primarily due to a higher charge for excess and obsolete inventory as a percentage of revenue.Sales and MarketingSales and marketing expenses increased by $2.0 million, or 14%, to $16.5 million for the three months ended September 30, 2024 from $14.5 million for the three months ended September 30, 2023. The increase was primarily due to higher compensation costs, including increased severance costs, and additional consulting and travel expenses.General and AdministrativeGeneral and administrative expenses were $3.7 million for both the three months ended September 30, 2024 and 2023. The slight decrease was due to lower insurance expense, professional fees and compensation and benefits which offset higher software-related costs and banking fees.Research and DevelopmentResearch and development expenses decreased by $0.3 million, or 13%, to $2.1 million for the three months ended September 30, 2024 from $2.4 million for the three months ended September 30, 2023. The decrease was primarily due to lower study and development costs which offset higher compensation and benefits.Interest ExpenseInterest expense was $1.3 million for both the three months ended September 30, 2024 and 2023.Other IncomeOther income decreased by $0.2 million, or 40%, to $0.3 million for the three months ended September 30, 2024 from $0.6 million for the three months ended September 30, 2023. The decrease was primarily due to lower interest income as a result of lower cash balances.â€‹24 Table of ContentsResults of OperationsComparison of the Nine months Ended September 30, 2024 and 2023â€‹Nine months ended

| SeptemberÂ 30,Â â€‹ | ChangeÂ â€‹Â Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â DollarÂ Â Â Â PercentageÂ â€‹â€‹(inÂ thousands,Â exceptÂ percentages)Â Revenueâ€‹$ 51,651â€‹$ 41,455â€‹$ 10,196Â 25%Cost of revenue (excluding amortization of intangible assets)â€‹Â 16,099â€‹Â 12,682â€‹Â 3,417Â 27â€‹Amortization of intangible assetsâ€‹Â 285â€‹Â 285â€‹Â â€”Â â€”â€‹Gross profitâ€‹Â 35,267â€‹Â 28,488â€‹Â 6,779Â 24â€‹Gross marginâ€‹Â 68%Â Â Â 69%Â Â Â Â Â Â â€‹Operating expenses:â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Sales and marketingâ€‹Â 50,691â€‹Â 42,517â€‹Â 8,174Â 19â€‹General and administrativeâ€‹Â 11,133â€‹Â 10,834â€‹Â 299Â 3â€‹Research and developmentâ€‹Â 6,784â€‹Â 6,934â€‹Â (150)Â (2)â€‹Total operating expensesâ€‹Â 68,608â€‹Â 60,285â€‹Â 8,323Â 14â€‹Other operating income:â€‹Gain on sale of product lineâ€‹ 7,580â€‹â€‹ â€”â€‹â€‹ 7,580Â NAâ€‹Loss from operationsâ€‹Â (25,761)â€‹Â (31,797)â€‹Â 6,036Â (19)â€‹Other expense:â€‹Â Â Â â€‹Â Â Â Â Â Â â€‹Interest expenseâ€‹Â (4,007)â€‹Â (3,878)â€‹Â (129)Â 3â€‹Other income â€‹â€‹ 1,135â€‹Â 1,901â€‹Â (766)Â (40)â€‹Total other expenseâ€‹Â (2,872)â€‹Â (1,977)â€‹Â (895)Â 45â€‹Net lossâ€‹$ (28,633)â€‹$ (33,774)â€‹$ 5,141Â (15)%â€‹RevenueRevenue increased by $10.2 million, or 25%, to $51.7 million for the nine months ended September 30, 2024 from $41.5 million for the nine months ended September 30, 2023. The increase in revenue was primarily driven by an increase in unit sales of our products due to our expanded commercial organization, which resulted in the addition of new customers and growing international sales. This growth was partially offset by a decrease in average selling prices caused by product mix as the share of smaller-sized units increased. In addition, we estimate that additional forecasted revenue was negatively impacted as a result of two external cybersecurity events, each of which reduced surgeries at certain facilities during the second quarter of 2024. During the nine months ended September 30, 2024, we sold 13,034 units of OviTex as compared to 9,704 units of OviTex during the nine months ended September 30, 2023, a 34% increase in unit sales volume. Additionally, we sold 3,467 units of OviTex PRS during the nine months ended September 30, 2024 as compared to 2,484 units during the nine months ended September 30, 2023, a 40% increase in unit sales volume.â€‹Cost of RevenueCost of revenue (excluding amortization of intangible assets) increased by $3.4 million, or 27%, to $16.1 million for the nine months ended September 30, 2024 from $12.7 million for the nine months ended September 30, 2023. The increase in cost of revenue was primarily the result of an increase in products purchased to support demand from our higher unit sales and a higher charge for excess and obsolete inventory.Amortization of Intangible AssetsAmortization of intangible assets was $0.3 million for both the nine months ended September 30, 2024 and 2023.25 Table of ContentsGross MarginGross margin decreased to 68% for the nine months ended September 30, 2024 from 69% for the nine months ended September 30, 2023. The decrease was primarily due to a higher charge for excess and obsolete inventory as a percentage of revenue.Sales and MarketingSales and marketing expenses increased by $8.2 million, or 19%, to $50.7 million for the nine months ended September 30, 2024 from $42.5 million for the nine months ended September 30, 2023. The increase was primarily due to higher compensation costs, including increased severance costs from a third quarter reorganization, additional travel and consulting expenses, additional employee-related costs due to an increase in headcount and a marketing distribution fee which offset a decrease in marketing expenses.General and AdministrativeGeneral and administrative expenses increased by $0.3 million, or 3%, to $11.1 million for the nine months ended September 30, 2024 from $10.8 million for the nine months ended September 30, 2023. The increase was primarily due to higher compensation costs and employee-related costs due to an increase in headcount which offset a decrease in professional fees and insurance.Research and DevelopmentResearch and development expenses decreased by $0.2 million, or 2%, to $6.8 million for the nine months ended September 30, 2024 from $6.9 million for the nine months ended September 30, 2023. The decrease was primarily due to lower study and outsourced development costs which offset higher compensation costs due to an increase in headcount.Gain on Sale of Product LineIn March 2024, we entered into an asset purchase agreement with MiMedx Group, Inc. to sell certain assets related to NIVIS. These assets mainly included our existing inventory of NIVIS, with a net carrying value of $0.8 million, and certain intellectual property rights to sell NIVIS, with no carrying value. We transferred control of the nonfinancial asset group in March 2024 and recognized a gain of $7.6 million during the nine months ended September 30, 2024. Interest ExpenseInterest expense increased by $0.1 million, or 3%, to $4.0 million for the nine months ended September 30, 2024 from $3.9 million for the nine months ended September 30, 2023 due to an increase to the variable component of our interest rate.Other IncomeOther income decreased by $0.8 million, or 40%, to $1.1 million for the nine months ended September 30, 2024 from $1.9 million for the nine months ended September 30, 2023. The decrease was primarily due to lower interest income as a result of lower cash balances.26 Table of ContentsLiquidity and Capital Resourcesâ€‹OverviewAs of September 30, 2024, we had cash and cash equivalents of $17.3Â million, working capital of $27.3 million and an accumulated deficit of $349.5Â million. As of December 31, 2023, we had cash and cash equivalents of $46.7 million, working capital of $54.8 million and an accumulated deficit of $320.9Â million. In March 2024, we sold our distribution rights for NIVIS to MiMedx Group, Inc. in exchange for an initial $5.0 million payment and additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS during the first two years following its launch by MiMedx Group, Inc.â€‹Subsequent to September 30, 2024, we completed an underwritten public offering of 14,670,000 shares of our common stock, including the exercise in full of the underwritersâ€™ option to purchase additional shares, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so chose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering resulted in gross proceeds of $46.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. The exercise of the pre-funded warrants, if any, is not expected to provide significant additional funding to us.â€‹We have incurred operating losses since our inception, and we anticipate that our operating losses will continue in the near term as we seek to invest in our sales and marketing initiatives to support our growth in existing and new markets and in additional research and development activities. As of September 30, 2024, we had $40.0Â million of borrowings outstanding under our Credit and Security Agreement (the â€œMidCap Credit Agreementâ€) with MidCap Financial Trust, as agent and certain lender parties thereto. The MidCap Credit Agreement matures in May 2027. Upon closing, we used a portion of the proceeds to repay borrowings under a previous credit facility and intend to use the remaining proceeds to fund operations and other general corporate purposes. â€‹Based on our current business plan, we believe that our existing cash resources, inclusive of the proceeds received in the underwritten public offering described above, will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months from the issuance of this Quarterly Report. Cash used in operating activities during the remaining interim period of 2024 is expected to decrease primarily due to the combination of our forecasted growth in revenue and constraint of operating spend, however, we can provide no assurance that our expectations will be achieved. Starting in the third quarter of 2024, we implemented certain cost-cutting measures which are expected to result in reduced operating expenses in future periods. To the extent that these sources are insufficient to satisfy our liquidity requirements, despite our recent cost-cutting measures, we may seek to sell common or preferred equity or debt securities or enter into a new credit facility. In November 2023, we entered into a new Equity Distribution Agreement (the â€œ2023 Equity Agreementâ€) with Piper Sandler & Co. (â€œPiperâ€) in connection with the establishment of an at-the-market offering program under which we may sell shares of our common stock, from time to time through Piper as sales agent, in an initial amount of up to $50.0 million. No sales were made under the 2023 Equity Agreement during the nine months ended September 30, 2024. If we raise additional funds by issuing equity or equity-linked securities, our stockholders would experience dilution and any new equity securities could have rights, preferences and privileges superior to those of holders of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all, including as a result of market volatility stemming from macroeconomic conditions, including those related to banking instability, monetary policy changes, increasing interest rates or other factors. If we are unable to obtain adequate financing, when needed, we may be required to delay or reduce the current development, commercialization and marketing plans for our products.27 Table of ContentsCash FlowsThe following table summarizes our sources and uses of cash for each of the periods presented:â€‹Nine months ended SeptemberÂ 30,Â (in thousands)Â Â Â Â Â 2024Â Â Â Â 2023Cash used in operating activitiesâ€‹$ (34,064)â€‹$ (29,806)Cash provided by (used in) investing activitiesâ€‹Â 4,641â€‹Â (406)Cash provided by financing activitiesâ€‹Â 149â€‹Â 46,245Effect of exchange rate changes on cash and cash equivalentsâ€‹â€‹ (154)â€‹â€‹ 150Net (decrease) increase in cash and cash equivalents and restricted cashâ€‹$ (29,428)â€‹$ 16,183â€‹Operating ActivitiesDuring the nine months ended September 30, 2024, we used $34.1 million of cash in operating activities, resulting from our net loss of $28.6 million, non-cash items of $1.6 million and the change in operating assets and liabilities of $3.8 million. Our non-cash items were comprised of the gain on sale of NIVIS of $7.6 million offset by stock-based compensation expense of $3.3 million, our excess and obsolete inventory charge of $1.6Â million, depreciation and amortization expense of $0.7Â million and noncash interest expense of $0.5Â million. The change in our operating assets and liabilities was primarily related to changes in inventory and accounts receivable partially offset by increases in accounts payable.During the nine months ended September 30, 2023, we used $29.8 million of cash in operating activities, resulting from our net loss of $33.8 million and the change in operating assets and liabilities of $1.9 million, offset by non-cash items of $5.8 million. Our non-cash items were comprised of stock-based compensation expense of $3.8 million, our excess and obsolete inventory charge of $1.0Â million, depreciation and amortization expense of $0.6Â million and noncash interest expense of $0.4Â million. The change in our operating assets and liabilities was primarily related to increases in accounts receivable and inventory partially offset by increases in accounts payable and accrued expenses and other current and long-term liabilities.Investing ActivitiesDuring the nine months ended September 30,

2024, cash provided by investing activities was $4.6 million consisting of proceeds received from the sale of NIVIS of $5.4 million offset by $0.7 million in purchases of property and equipment.During the nine months ended September 30, 2023, cash used in investing activities was $0.4 million consisting of purchases of property and equipment.Financing ActivitiesDuring the nine months ended September 30, 2024, cash provided by financing activities was $0.1 million, consisting primarily of proceeds received from the exercise of stock options and from the issuance of common stock under the employee stock purchase plan partially offset by the payment of withholding taxes related to stock-based compensation to employees.During the nine months ended September 30, 2023, cash provided by financing activities was $46.2 million, consisting primarily of $46.3 million in proceeds received from the sale of our common stock partially offset by the payment of withholding taxes related to stock-based compensation to employees.IndebtednessOn May 26, 2022, we entered into the MidCap Credit Agreement with MidCap Financial Trust, as agent and certain lender parties thereto. The MidCap Credit Agreement consists of $40.0 million in a term loan. Upon closing, we used a 28 Table of Contentsportion of the proceeds to repay borrowings under a previous credit facility and intend to use the remaining proceeds to fund operations and other general corporate purposes. â€‹Pursuant to the MidCap Credit Agreement, we provided a first priority security interest in all existing and future acquired assets, including intellectual property, owned by us. The MidCap Credit Agreement contains certain covenants that limit our ability to engage in certain transactions that may be in our long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends.â€‹The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts. â€‹In addition, we must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, we would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%.â€‹The MidCap term loan matures on May 1, 2027 and bears interest at a rate equal to 6.25% plus the greater of one-month Term SOFR (as defined in the MidCap Credit Agreement) or 1.0%. We are required to make 36 monthly interest payments beginning on June 1, 2022 (the â€œInterest-Only Periodâ€). If we are in covenant compliance at the end of the Interest-Only Period, we will have the option to extend the Interest-Only Period by 12 months to 48 monthly interest payments, followed by 12 months of straight-line amortization, with the entire principal payment due at maturity. If we are not in covenant compliance at the end of the Interest-Only Period, we are required to make 24 months of straight-line amortization payments, with the entire principal amount due at maturity. â€‹Subject to certain limitations, the MidCap term loan has a prepayment fee equal to 3.0% of the prepaid principal amount for the first year following the closing date of the MidCap term loan, 2.0% of the prepaid principal amount for the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. We are also required to pay an exit fee at the time of maturity or prepayment event equal to 5% of all principal borrowings (or in the event of a prepayment event, the amount of principal being prepaid).â€‹Contractual Obligations and CommitmentsAs of September 30, 2024, there were no significant changes to our commitments and future minimum contractual obligations as set forth in our Annual Report.Critical Accounting Policies and Significant Judgments and EstimatesThe Critical Accounting Policies and Significant Judgments and Estimates included in our Annual Report have not materially changed.Off-Balance Sheet ArrangementsWe did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.ItemÂ 3. Quantitative and Qualitative Disclosures About Market Riskâ€‹Our cash is held on deposit in demand accounts at high-credit-quality financial institutions in amounts in excess of the Federal Deposit Insurance Corporation (â€œFDICâ€) insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Following the events relating to Silicon Valley Bank in 2023, we established a redundant account at a high-credit-quality financial institution to mitigate liquidity risk to our cash and cash equivalents from any 29 Table of Contentsfurther instability in the financial industry. We have reviewed the consolidated financial statements of these financial institutions and believe they have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us.Financial instruments that potentially subject us to concentrations of credit risk principally consist of cash equivalents and accounts receivable. We limit our credit risk associated with cash equivalents by placing investments in highly-rated money market funds. We limit our credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but we do not require collateral to secure amounts owed to us by our customers.As discussed above in the section of this Quarterly Report entitled â€œLiquidity and Capital ResourcesÂ â€” Indebtedness,â€ the MidCap Credit Facility bears interest at a floating rate of interest, which resets monthly and is equal to 6.25% plus the greater of one-month Term SOFR or 1.0%. As a result, we are exposed to risks from changes in interest rates. A 1% increase in interest rates would have resulted in a $0.3 million increase to our interest expense for the nine months ended September 30, 2024.Inflationary factors, such as increases in our cost of revenue and operating expenses, may adversely affect our operating results. Although we do not believe inflation has had a material impact on our financial condition, results of operations or cash flows to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin or decrease our operating expenses as aÂ percentage of our revenue if our selling prices of our products do not increase as much or more than our costs increase.We do not currently have any material exposure to foreign currency fluctuations and do not engage in any hedging activities as part of our normal course of business.Item 4. Controls and Procedures.â€‹Evaluation of Disclosure Controls and Proceduresâ€‹Our management, with the participation and supervision of our Chief Executive Officer and our Chief Operating Officer and Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Operating Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Operating Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.â€‹Changes in Internal Control Over Financial Reportingâ€‹There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.â€‹30 Table of ContentsPART IIâ€”OTHER INFORMATIONâ€‹Item 1. Legal Proceedings.â€‹We are not currently subject to any material legal proceedings.â€‹Item 1A. Risk Factors.â€‹You should carefully consider the risk factors described in our Annual Report, under the caption â€œItem 1A. Risk Factors.â€ There have been no material changes in our risk factors disclosed in our Annual Report.â€‹Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.â€‹Recent Sales of Unregistered Securitiesâ€‹None.â€‹Purchase of Equity Securitiesâ€‹None.â€‹Item 3. Defaults Upon Senior Securities.â€‹None.â€‹Item 4. Mine Safety Disclosures.â€‹Not applicable. â€‹Item 5. Other Information.â€‹Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangementsâ€‹During the three months ended September 30, 2024, none of our directors or officers adopted, terminated or modified a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as defined in Item 408(a) of Regulation S-K of the Exchange Act.â€‹31 Table of ContentsItem 6. Exhibits.â€‹The following exhibits are being filed herewith:â€‹EXHIBIT INDEXâ€‹Exhibit No.Â Â Â Â Exhibitâ€‹â€‹â€‹10.1*â€‹Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated August 1, 2024, by and between the Company and Aroa Biosurgery Ltd. (filed herewith).31.1â€‹Certification of Chief Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).31.2â€‹Certification of Chief Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).32.1â€‹Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).32.2â€‹Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).101 INSâ€‹Inline XBRL Instance Document (filed herewith).101 SCHâ€‹Inline XBRL Taxonomy Extension Schema Document (filed herewith).101 CALâ€‹Inline XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith).101 DEFâ€‹Inline XBRL Taxonomy Extension Definition Linkbase Document (filed herewith).101 LABâ€‹Inline XBRL Taxonomy Extension Label Linkbase Document (filed herewith).101 PREâ€‹Inline XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith).104â€‹Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). â€‹â€‹â€‹*Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.â€‹â€‹â€‹32 Table of ContentsSIGNATURESâ€‹Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.â€‹â€‹â€‹â€‹TELA BIO, INC.â€‹â€‹Date: November 8, 2024By:/s/ ANTONY KOBLISHâ€‹â€‹Antony Koblishâ€‹â€‹President and Chief Executive Officerâ€‹â€‹(Principal executive officer)â€‹â€‹Date: November 8, 2024By:/s/ ROBERTO CUCAâ€‹â€‹Roberto Cucaâ€‹â€‹Chief Operating Officer and Chief Financial Officerâ€‹â€‹(Principal financial officer)â€‹â€‹Date: November 8, 2024By:/s/ MEGAN SMEYKALâ€‹â€‹Megan Smeykalâ€‹â€‹Chief Accounting Officer and Controllerâ€‹â€‹(Principal accounting officer)â€‹â€‹â€‹â€‹33 EX-10.1 2 tela-20240930xex10d1.htm EX-10.1 Exhibit 10.1[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.ADDENDUM TO THE SECOND AMENDED AND RESTATED LICENSE, PRODUCT DEVELOPMENT AND SUPPLY UMBRELLA AGREEMENTThis Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement (this â€œAddendumâ€), is made as of the 1st day of August, 2024, by and between TELA Bio, Inc. (â€œTELA Bioâ€), and Aroa Biosurgery Limited (â€œAroaâ€), and sets out the terms of TELA Bio's and Aroa's agreement with respect to certain terms applicable to the LPR, PRS and IHR Product lines (as defined below in this Addendum).WHEREAS, TELA Bio and Aroa are parties to that certain Second Amended and Restated License, Product Development and Supply Umbrella Agreement dated as of July 16, 2015, as amended through the date hereof and which includes (but without limitation) the addenda thereto dated as of September 21, 2017, January 3, 2019, August 27, 2019, February 21, 2020, and August 13, 2020 (together, the â€œUmbrella Agreementâ€);WHEREAS, TELA Bio and Aroa will, contemporaneously with this Addendum, enter into three separate Development Agreements and Exhibits (Nos. 13, 14 and 15) relating to the development of new product configurations, including those relating to extensions of the partiesâ€™ LPR, PRS and IHR Product lines; andWHEREAS, TELA Bio and Aroa desire to amend the Umbrella Agreement in connection with entering into such Development Agreements to consolidate and clarify the application of certain terms relating to such LPR, PRS and IHR Product lines.NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, TELA Bio and Aroa hereby agree as follows:1.All prior references to the â€œRestella Productâ€ (plural or singular) in the Umbrella Agreement, including any Addenda thereto, shall be deleted and replaced with reference to the â€œPRS Productâ€, provided however that the name of each PRS Product for the purposes of, or within, the Product Exhibit for that Product shall remain unchanged.Reference to â€œRestella Product Clearanceâ€ in clauses 4 and 5 of the 21 February 2020 addendum to the Umbrella Agreement shall be deleted and replaced with â€œthe regulatory clearance or approval for the PRS Productâ€, provided however that the definition of â€œAroa Restella Obligationsâ€ shall remain unchanged. For purposes of the Umbrella Agreement, â€œPRS Productâ€ shall mean any Product configuration set forth on Exhibit A hereto and any future Products that are expressly identified as a â€œPRS Productâ€ in any future Addenda, Development Agreements and/or Product Exhibits between the Parties. 2.References to â€œLPR Productâ€œ (plural or singular) in section 8.5(b) of the Umbrella Agreement shall mean any Product configuration set forth on Exhibit B hereto and any future Products that are expressly identified as a â€œLPR Productâ€ in any future Addenda, Development Agreements and/or Product Exhibits between the Parties.3.The parties agree that the following clarifications and amendments to the Umbrella Agreement, including any Addenda thereto, shall apply to each IHR Product (as defined below):â€‹1a.[***].b.With respect to the IHR Products, the Transfer Price shall equal [***] % of COGS for each such unit of Product, but if agreed by the parties the Transfer Price shall be [***].c.Solely with respect to the IHR Products, the third and fourth sentences of clause 8.5(b) are hereby amended and restated as follows:â€œIf the Annual Revenue Sharing Amount attributable to IHR Products is more than the Actual CY Payments, TELA Bio shall pay such difference to Aroa within thirty (30) days following the date of such summary. If the Annual Revenue Sharing Amount is less than the Actual CY Payments, then, within thirty (30) days following the date of such summary, Aroa shall pay to TELA Bio an amount equal to the lesser of (i) the Actual CY Payments less the aggregate Transfer Prices paid for the IHR Products sold by TELA Bio during such calendar year, or (ii) the Actual CY Payments less the Annual Revenue Sharing Amount attributable to IHR Products. Â For the purposes of this clause 8.5(b), the â€œActual CY Paymentsâ€ means the sum of (i) the aggregate Transfer Prices paid for the IHR Products sold by TELA Bio during such calendar year and (ii) the aggregate Quarterly True Up Amounts attributable to the IHR Products paid to Aroa for such calendar year.â€‹d.For purposes of the Umbrella Agreement, â€œIHR Productâ€ shall mean any Product configuration set forth on Exhibit C hereto and any future Products that are expressly identified as a â€œIHR Productâ€ in any future Addenda, Development Agreements and/or Product Exhibits between the Parties.e.For the avoidance of doubt, this clause 4 of this Addendum shall supersede the terms set forth in clause 9 of the Development Agreement for ERT-G INGUINAL, effective 1 March 2024, in its entirety.Capitalized terms used but not defined in this Addendum have the meanings given to those terms in the Umbrella Agreement.Except as agreed herein, the provisions of the Umbrella Agreement (including any prior addenda thereto) are not amended and continue to be in full force and effect.This Addendum shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to any conflict of law provisions.This Addendum may be executed in separate counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement.Executed signature pages to this Addendum may be delivered by facsimile or electronic mail and any signature page so delivered shall be deemed to be an original. In Witness Whereof, and intending to be legally bound, the parties have caused this Agreement to be executed by their respective authorized officers as of the date first set forth above.â€‹2TELA BIO, INC.â€‹AROA BIOSURGERY LIMITEDâ€‹â€‹â€‹â€‹By:/s/ Antony Koblishâ€‹By:/s/ Brian Wardâ€‹Name:Â Antony Koblishâ€‹Name:Â Brian Wardâ€‹Title:President & CEOâ€‹Title:Chief Executive Officerâ€‹â€‹3Exhibit APRS Products[***]â€‹â€‹4[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.Exhibit BLPR Products[***]â€‹5Exhibit CIHR Products[***]6 EX-31.1 3 tela-20240930xex31d1.htm EX-31.1 EXHIBIT 31.1â€‹CERTIFICATIONPursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934,as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002â€‹I, Antony Koblish, certify that:1.Â Â Â Â I have reviewed this Form 10-Q of TELA Bio, Inc.;2.Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.Â Â Â Â The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Â Â Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Â Â Â Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.Â Â Â Â The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b)Â Â Â Any fraud, whether or not material, that

involves management or other employees who have a significant role in the registrant's internal control over financial reporting.â€‹â€‹â€‹â€‹Date: November 8, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Antony Koblishâ€‹â€‹Antony Koblishâ€‹â€‹President and Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹â€‹ EX-31.2 4 tela-20240930xex31d2.htm EX-31.2 EXHIBIT 31.2â€‹CERTIFICATIONPursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934,as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002â€‹I, Roberto Cuca, certify that:1.Â Â Â Â Â I have reviewed this Form 10-Q of TELA Bio, Inc.;2.Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.Â Â Â Â The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Â Â Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Â Â Â Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.Â Â Â Â The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a)Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b)Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.â€‹â€‹â€‹â€‹Date: November 8, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Roberto Cucaâ€‹â€‹Roberto Cucaâ€‹â€‹Chief Operating Officer and Chief Financial Officerâ€‹â€‹(Principal Financial Officer)â€‹â€‹ EX-32.1 5 tela-20240930xex32d1.htm EX-32.1 EXHIBIT 32.1â€‹CERTIFICATIONPursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), that: Antony Koblish, Chief Executive Officer of TELA Bio, Inc. (the â€œCompanyâ€), hereby certifies that, to the best of his knowledge:(1)Â Â Â The Companyâ€™s Quarterly Report on Form 10-Q for the period ended September 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and(2)Â Â Â The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹Date: November 8, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Antony Koblishâ€‹â€‹Antony Koblishâ€‹â€‹President and Chief Executive Officerâ€‹â€‹(Principal Executive Officer)â€‹â€‹ EX-32.2 6 tela-20240930xex32d2.htm EX-32.2 EXHIBIT 32.2â€‹CERTIFICATIONPursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), that: Roberto Cuca, Chief Operating Officer and Chief Financial Officer of TELA Bio, Inc. (the â€œCompanyâ€), hereby certifies that, to the best of his knowledge:(1)Â Â Â The Companyâ€™s Quarterly Report on Form 10-Q for the period ended September 30, 2024, to which this Certification is attached as Exhibit 32.2 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and(2)Â Â Â The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹Date: November 8, 2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹/s/ Roberto Cucaâ€‹â€‹Roberto Cucaâ€‹â€‹Chief Operating Officer and Chief Financial Officerâ€‹â€‹(Principal Financial Officer)â€‹â€‹ EX-101.SCH 7 tela-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Long-term Debt - Schedule of long term debt (Details) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Risks and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Common Share (Potentially dilutive securities) (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Long-term Debt - MidCap Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Stockholders' Equity - Warrants outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Sale of Product Line - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Stock-Based Compensation - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Stock-Based Compensation - Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Background link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Risks and Liquidity link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Sale of Product Line link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 99920302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 tela-20240930_cal.xml EX-101.CAL EX-101.DEF 9 tela-20240930_def.xml EX-101.DEF EX-101.LAB 10 tela-20240930_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Consolidated Balance Sheets Statement [Table] Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Receivables, Net, Current Accounts receivable, net of allowances of $230 and $416 Inventory, Net Inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Operating Lease, Right-of-Use Asset Right-of-use assets Other Assets, Noncurrent Other long-term assets Restricted Cash, Noncurrent Restricted cash Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' (deficit) equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Total accrued expenses and other current liabilities Accrued expenses and other current liabilities Liabilities, Current Total current liabilities Long-Term Debt, Excluding Current Maturities Long-term debt Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Equity, Attributable to Parent [Abstract] Stockholders' (deficit) equity: Preferred Stock, Value, Issued Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common stock; $0.001 par value: 200,000,000 shares authorized; 24,717,193 and 24,494,675 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance at Ending period Balance at Beginning of period Total stockholders' (deficit) equity Liabilities and Equity Total liabilities and stockholders' (deficit) equity Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, Allowance Preferred Stock, Par or Stated Value Per Share Preferred stock, Par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock, Par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Common stock, shares issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) Consolidated Statements of Operations and Comprehensive Loss Revenue from Contract with Customer, Excluding Assessed Tax Revenue Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Cost of revenue (excluding amortization of intangible assets) Cost, Amortization Amortization of intangible assets Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: Selling and Marketing Expense Sales and marketing General and Administrative Expense General and administrative Research and Development Expense Research and development Operating Expenses Total operating expenses Component of Operating Income [Abstract] Other operating income: Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Gain on sale of product line Gain on sale of product line Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other expense: Interest Expense, Nonoperating Interest expense Other Nonoperating Income (Expense) Other income Nonoperating Income (Expense) Total other expense, net Net loss Net loss Earnings Per Share, Basic Net loss per common share, basic Earnings Per Share, Diluted Net loss per common share, diluted Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Accumulated other comprehensive income Retained Earnings [Member] Accumulated deficit Shares, Outstanding Balance at Ending period (in shares) Balance at Beginning of period (in shares) Amount of increase to additional paid-in capital (APIC) for vesting of Restricted Stock Units and Exercise of Stock Options under share-based payment arrangement. APIC, Share-Based Payment Arrangement, Vesting of Restricted Stock Units and Exercise of Stock Options Vesting of restricted stock units and exercise of stock options Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Vesting of restricted stock units and exercise of stock options (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under the employee stock purchase plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under the employee stock purchase plan (in shares) Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Shares withheld for employee taxes Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares withheld for employee taxes (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Value, New Issues Gross proceeds Sale of common stock, net of underwriting discounts, commissions and offering costs Stock Issued During Period, Shares, New Issues Common stock issued and sold (in shares) Shares issued and sold Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares) Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation expense Paid-in-Kind Interest Noncash interest expense Amount of net changes in operating lease right-of-use assets and liabilities. Net Changes in Operating Lease Right-of-use Assets And Liabilities Net changes in operating lease ROU assets and liabilities Inventory Write-down Inventory excess and obsolescence charge Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable, net Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current and long-term liabilities Gain (Loss), Foreign Currency Transaction, before Tax Foreign currency transaction gain (loss) Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Proceeds from Sale of Productive Assets Proceeds from the sale of product line Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from sale of common stock, net Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses Proceeds from Stock Options Exercised Proceeds from exercise of stock options Payment, Tax Withholding, Share-Based Payment Arrangement Payment of withholding taxes related to stock-based compensation to employees Proceeds from Stock Plans Proceeds from issuance of common stock under the employee stock purchase plan Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents and restricted cash, end of period Cash and cash equivalents and restricted cash, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid during the period for interest Noncash Investing and Financing Items [Abstract] Supplemental disclosures of noncash investing and financing activities: Capital Expenditures Incurred but Not yet Paid Property and equipment in accounts payable and accrued expenses and other current liabilities Background Organization, Consolidation and Presentation of Financial Statements Disclosure

[Text Block] Background Risks and Liquidity Concentration Risk Disclosure [Text Block] Risks and Liquidity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Debt Long-Term Debt [Text Block] Debt Stockholders' Equity Equity [Text Block] Stockholders' Equity Sale of Product Line Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Sale of Product Line Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Subsequent Event. Subsequent Events [Text Block] Subsequent Event Disclosure of accounting policy for the preparation of interim financial statements in conformity with generally accepted accounting principles. Interim Financial Statements Policy [Policy Text Block] Interim Financial Statements Use of Estimates, Policy [Policy Text Block] Use of Estimates Revenue [Policy Text Block] Revenue Recognition Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of fair value of assets and liabilities measured on recurring basis Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of dilutive securities excluded Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses and Other Current Liabilities Schedule of Debt [Table Text Block] Schedule of long term debt Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrants outstanding to purchase common stock Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock based compensation expense categories in statement of operations Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of weighted average assumptions Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of restricted stock units (RSUs) Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Schedule of performance-based (RSUs) Unusual Risk or Uncertainty [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to MiMedx Group, Inc. MiMedx Group, Inc [Member] MiMedx Group, Inc. Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Unusual Risk or Uncertainty [Line Items] The future revenue-sharing payments based on the net sales of NIVIS during the first two years following its launch by MDXG. Disposal Group, Future Revenue Sharing Payments Revenue sharing payments Period of net sales considered for calculating additional future payments receivable on sale of distributions rights of the product sold. Period of Net Sales Considered for Calculating Additional Future Payment Receivable On Sale of Distribution Rights Period of net sales considered for calculating additional future payment receivable Shares Issued, Price Per Share Offering price (in dollar per share) Disaggregation of Revenue [Table] Customer [Axis] Customer [Domain] OviTex [Member] OviTex [Member] OviTex OviTex PRS [Member] OviTex PRS [Member] OviTex PRS Represents the information pertaining to other customers. Other [Member] Other Geographical [Axis] Geographical [Domain] Non-US [Member] Disaggregation of Revenue [Line Items] Represents incremental costs incurred in obtaining a contract. Incremental Costs Of Obtaining A Contract Incremental costs of obtaining a contract Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Financial Instrument [Axis] Financial Instruments [Domain] Money Market Funds [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Restricted Stock Units (RSUs) [Member] Unvested restricted stock units Represents information pertaining to common stock warrants. Common Stock Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities excluded from computation of diluted weighted average shares Employee-related Liabilities, Current Compensation and related benefits Accrued Professional Fees, Current Third-party and professional fees Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to contract manufacturer due. Accrued Expenses, Amount Due To Contract Manufacturer Amounts due to contract manufacturer Operating Lease, Liability, Current Current portion of operating lease liabilities Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Carrying value of current portion of obligation payable pertaining to Research and development. Research And Development Expenses Payable Current Research and development expenses Other Accrued Liabilities, Current Other Schedule of Long-Term Debt Instruments [Table] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Represents information pertaining to MidCap Term loans. MidCap term loan Debt Instrument [Line Items] Long term Debt Debt Instrument, Face Amount MidCap term loan Debt amount Debt Instrument, Unamortized Premium End of term charge Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Unamortized end of term charge and issuance costs Long-Term Debt Long-term debt Scenario [Axis] Scenario [Domain] Represents the information first year of term loan. First Year [Member] First year Represents the information second year of term loan. Second Year [Member] Second year Represents the information third year of term loan. Third Year [Member] Third year Percentage of penalty to be paid on the event of default in meeting the obligation. Interest Penalty, Percentage Interest due to unpaid obligation Debt Instrument, Interest Rate, Stated Percentage Interest Rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Variable Interest Rate (as a percent) Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] The Interest-Only Period of debt instrument interest payment. Debt Instrument Interest Payment Term Interest-Only Period Additional extension for interest only payment period. Additional Extension for Interest Only Payment Period Extension for interest only payment period Percentage of penalty to be paid on principal amount of debt for the third year after closing date and thereafter. Percentage Of Prepayment Penalty On Prepaid Principal Amount Percentage of prepayment penalty on prepaid principal amount Percentage of the principal amount paid as an exit fee at the time of maturity or prepayment. Percentage Of Exit Fee Exit fee (as a percent) Interest Expense, Debt Interest expenses Amortization of Debt Issuance Costs Amortization of debt issuance costs Temporary Equity, by Class of Stock [Table] Sale of Stock [Axis] Sale of Stock [Domain] Equity Distribution Agreement [Member] Equity Distribution Agreement Temporary Equity [Line Items] Stockholders' Equity The maximum amount of shares that can be sold under the at-the-market programs. Common Stock Available Under ATM The number of warrants granted. Class of Warrant or Right, Granted Number of warrants granted The number of warrants exercised. Class of Warrant or Right, Exercised Number of share exercised The number of warrants cancelled. Class of Warrant or Right, Cancelled Number of share cancelled Value Of Shares Sold Under Equity Distribution Agreement Value Of Shares Sold Under Equity Distribution Agreement Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to common stock warrants expiring in 2028. Common stock warrants expiring in 2028 Represents information pertaining to common stock warrants expiring in 2027. Common stock warrants expiring in 2027 Class of Warrant or Right, Outstanding Warrants outstanding Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price Exercise Price Class of Warrant or Right, Date from which Warrants or Rights Expire Class of Warrant or Right, Date from which Warrants or Rights Expire Expiration dates Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Domain] Asset Purchase Agreement ("APA") with MiMedx Group, Inc. ("MDXG") to sell certain assets (the "Transaction") related to NIVIS Fibrillar Collagen Pack Device ("NIVIS"). Disposal Group, Transaction [Member] Transaction Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group, Not Discontinued Operations [Member] Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operation, Inventory Net carrying value Disposal Group, Including Discontinued Operation, Intangible Assets Carrying value Any consideration in excess consideration is considered variable consideration that is fully constrained. Disposal Group, Future Revenue Sharing Payments, Variable Consideration Variable consideration Disposal Group, Including Discontinued Operation, Consideration Consideration determined Amount of minimum revenue share payments receivable. Minimum Revenue Share Payments Receivable Amount minimum revenue share payments receivable Amount of minimum revenue share payments receivable classified as current. Minimum Revenue Share Payments Receivable Current Amount minimum revenue share payments receivable current Amount of minimum revenue share payments receivable classified as non-current. Minimum Revenue Share Payments Receivable Non-Current Amount minimum revenue share payments receivable non-current The amount of increase (decrease) in the variable consideration during the period. Disposal Group Future Revenue Sharing Payments, Increase (Decrease) in Variable Consideration Variable Consideration Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Plan Name [Axis] Plan Name [Domain] This member stands for 2019 Equity Incentive Plan. 2019 Equity Incentive Plan Represents information relating to service based restricted stock units. Performance Based Restricted Stock Units [Member] Performance based restricted stock units Represents information relating to service based restricted stock unit Service Based Restricted Stock Unit [Member] Service based restricted stock unit Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-Based Compensation Represents about number of equity incentive plans. Equity Incentive Plans, Number Number of equity incentive plans Common Stock, Capital Shares Reserved for Future Issuance Shares available for future issuance Common Stock Capital Shares Reserved For Future Annual Issuance Common Stock Capital Shares Reserved For Future Annual Issuance Potential Common Shares Added Annually To Equity Plan Evergreen Option, Percentage Of Shares Outstanding Last Day Of Fiscal Year Potential Common Shares Added Annually To Equity Plan Evergreen Option, Percentage Of Shares Outstanding Last Day Of Fiscal Year Potential common shares outstanding on the last day of the immediately preceding fiscal year Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Contractual term Number of inducement restricted stock units outstanding. Share-based Compensation Arrangement by Share-based Payment Award, Options, Inducement Grants in Period Inducement grants Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Options (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate intrinsic value of exercised options Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average period for recognition of unrecognized expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Equity Instruments (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vest Range Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Aggregate intrinsic value Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Research and Development Expense [Member] Share-Based Payment Arrangement, Expense Total stock-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Balance at end of period Balance at beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Canceled/forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable at end of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at end of period (in dollars per share) Balance at beginning of period (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled/forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Service Based Restricted Stock Units [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding at end of period Outstanding at beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Canceled/forfeited Subsequent Event [Table] Class of Stock [Axis] Class of Stock [Domain] Common Class A [Member] Common stock Warrant [Member] Subsequent Event [Line Items] Subsequent Event EX-101.PRE 11 tela-20240930_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Securities Act File Number 001-39130 Â Entity Registrant Name TELA Bio, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 45-5320061 Â Entity Address, Address Line One 1 Great Valley Parkway, Suite 24 Â Entity Address, City or Town Malvern Â Entity Address, State or Province PA Â Entity Address, Postal Zip Code 19355 Â City Area Code 484 Â Local Phone Number 320-2930 Â Title of 12(b) Security Common Stock, $0.001 par value per share Â Trading Symbol TELA Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 39,388,443 Entity Central Index Key 0001561921 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name:

dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 17,301 $ 46,729 Accounts receivable, net of allowances of $230 and $416 11,222 9,737 Inventory 13,600 13,162 Prepaid expenses and other current assets 2,009 2,098 Total current assets 44,132 71,726 Property and equipment, net 2,423 1,984 Intangible assets, net 1,834 2,119 Right-of-use assets 1,796 1,954 Other long-term assets 2,566 Â Restricted cash 265 265 Total assets 53,016 78,048 Current liabilities: Â Â Accounts payable 2,479 1,667 Accrued expenses and other current liabilities 14,379 15,300 Total current liabilities 16,858 16,967 Long-term debt 40,970 40,515 Other long-term liabilities 1,460 1,685 Total liabilities 59,288 59,167 Stockholders' (deficit) equity: Â Â Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding Common stock; $0.001 par value: 200,000,000 shares authorized; 24,717,193 and 24,494,675 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 25 24 Additional paid-in capital 343,076 339,655 Accumulated other comprehensive income 149 91 Accumulated deficit (349,522) (320,889) Total stockholders' (deficit) equity (6,272) 18,881 Total liabilities and stockholders' (deficit) equity $ 53,016 $ 78,048 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_ReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Consolidated Balance Sheets Â Â Accounts receivable, Allowance $ 230 $ 416 Preferred stock, Par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, Par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 200,000,000 200,000,000 Common stock, shares issued (in shares) 24,717,193 24,494,675 Common stock, shares outstanding (in shares) 24,717,193 24,494,675 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Consolidated Statements of Operations and Comprehensive Loss Â Â Â Â Revenue $ 18,957 $ 15,052 $ 51,651 $ 41,455 Cost of revenue (excluding amortization of intangible assets) 6,004 4,568 16,099 12,682 Amortization of intangible assets 95 95 285 285 Gross profit 12,858 10,389 35,267 28,488 Operating expenses: Â Â Â Â Sales and marketing 16,472 14,474 50,691 42,517 General and administrative 3,683 3,728 11,133 10,834 Research and development 2,068 2,368 6,784 6,934 Total operating expenses 22,223 20,570 68,608 60,285 Other operating income: Â Â Â Â Gain on sale of product line Â Â (7,580) Â Loss from operations (9,365) (10,181) (25,761) (31,797) Other expense: Â Â Â Â Interest expense (1,344) (1,334) (4,007) (3,878) Other income 337 558 1,135 1,901 Total other expense, net (1,007) (776) (2,872) (1,977) Net loss $ (10,372) $ (10,957) $ (28,633) $ (33,774) Net loss per common share, basic $ (0.42) $ (0.45) $ (1.16) $ (1.51) Net loss per common share, diluted $ (0.42) $ (0.45) $ (1.16) $ (1.51) Weighted average common shares outstanding, basic 24,703,578 24,483,664 24,648,933 22,322,256 Weighted average common shares outstanding, diluted 24,703,578 24,483,664 24,648,933 22,322,256 Comprehensive loss: Â Â Â Â Net loss $ (10,372) $ (10,957) $ (28,633) $ (33,774) Foreign currency translation adjustment 51 51 58 (15) Comprehensive loss $ (10,321) $ (10,906) $ (28,575) $ (33,789) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCost of product sold and service rendered, excluding depreciation, depletion, and amortization. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period

Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands Common Stock [Member] Additional Paid-in Capital [Member] Accumulated other comprehensive income Accumulated deficit Total Balance at Beginning of period at Dec. 31, 2022 $ 19 $ 288,361 $ 150 $ (274,225) $ 14,305 Balance at Beginning of period (in shares) at Dec. 31, 2022 19,165,027 Â Â Â Â Vesting of restricted stock units and exercise of stock options Â 101 Â Â 101 Vesting of restricted stock units and exercise of stock options (in shares) 119,240 Â Â Â Â Issuance of common stock under the employee stock purchase plan Â 88 Â Â 88 Issuance of common stock under the employee stock purchase plan (in shares) 10,602 Â Â Â Â Shares withheld for employee taxes Â (285) Â Â (285) Shares withheld for employee taxes (in shares) (26,481) Â Â Â Â Foreign currency translation adjustment Â Â (15) Â (15) Stock-based compensation expense Â 3,791 Â Â 3,791 Sale of common stock, net of underwriting discounts, commissions and offering costs $ 5 46,336 Â Â 46,341 Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares) 5,219,190 Â Â Â Â Net loss Â Â Â (33,774) (33,774) Balance at Ending period at Sep. 30, 2023 $ 24 338,392 135 (307,999) 30,552 Balance at Ending period (in shares) at Sep. 30, 2023 24,487,578 Â Â Â Â Balance at Beginning of period at Jun. 30, 2023 $ 24 336,939 84 (297,042) 40,005 Balance at Beginning of period (in shares) at Jun. 30, 2023 24,475,504 Â Â Â Â Vesting of restricted stock units and exercise of stock options Â 1 Â Â 1 Vesting of restricted stock units and exercise of stock options (in shares) 2,002 Â Â Â Â Issuance of common stock under the employee stock purchase plan Â 88 Â Â 88 Issuance of common stock under the employee stock purchase plan (in shares) 10,602 Â Â Â Â Shares withheld for employee taxes Â (5) Â Â (5) Shares withheld for employee taxes (in shares) (530) Â Â Â Â Foreign currency translation adjustment Â Â 51 Â 51 Stock-based compensation expense Â 1,369 Â Â 1,369 Net loss Â Â Â (10,957) (10,957) Balance at Ending period at Sep. 30, 2023 $ 24 338,392 135 (307,999) 30,552 Balance at Ending period (in shares) at Sep. 30, 2023 24,487,578 Â Â Â Â Balance at Beginning of period at Dec. 31, 2023 $ 24 339,655 91 (320,889) 18,881 Balance at Beginning of period (in shares) at Dec. 31, 2023 24,494,675 Â Â Â Â Vesting of restricted stock units and exercise of stock options $ 1 225 Â Â 226 Vesting of restricted stock units and exercise of stock options (in shares) 217,267 Â Â Â Â Issuance of common stock under the employee stock purchase plan Â 281 Â Â 281 Issuance of common stock under the employee stock purchase plan (in shares) 58,994 Â Â Â Â Shares withheld for employee taxes Â (358) Â Â (358) Shares withheld for employee taxes (in shares) (53,743) Â Â Â Â Foreign currency translation adjustment Â Â 58 Â 58 Stock-based compensation expense Â 3,273 Â Â 3,273 Net loss Â Â Â (28,633) (28,633) Balance at Ending period at Sep. 30, 2024 $ 25 343,076 149 (349,522) (6,272) Balance at Ending period (in shares) at Sep. 30, 2024 24,717,193 Â Â Â Â Balance at Beginning of period at Jun. 30, 2024 $ 25 341,897 98 (339,150) 2,870 Balance at Beginning of period (in shares) at Jun. 30, 2024 24,675,832 Â Â Â Â Vesting of restricted stock units and exercise of stock options (in shares) 14,702 Â Â Â Â Issuance of common stock under the employee stock purchase plan Â 117 Â Â 117 Issuance of common stock under the employee stock purchase plan (in shares) 31,025 Â Â Â Â Shares withheld for employee taxes Â (19) Â Â (19) Shares withheld for employee taxes (in shares) (4,366) Â Â Â Â Foreign currency translation adjustment Â Â 51 Â 51 Stock-based compensation expense Â 1,081 Â Â 1,081 Net loss Â Â Â (10,372) (10,372) Balance at Ending period at Sep. 30, 2024 $ 25 $ 343,076 $ 149 $ (349,522) $ (6,272) Balance at Ending period (in shares) at Sep. 30, 2024 24,717,193 Â Â Â Â X - DefinitionAmount of increase to additional paid-in capital (APIC) for vesting of Restricted Stock Units and Exercise of Stock Options under share-based payment arrangement. + ReferencesNo definition available. + Details Name: tela_ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (28,633) $ (33,774) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation expense 461 362 Noncash interest expense 455 447 Amortization of intangible assets 285 285 Net changes in operating lease ROU assets and liabilities (73) (33) Inventory excess and obsolescence charge 1,563 992 Stock-based compensation expense 3,273 3,791 Gain on sale of product line (7,580) Â Change in operating assets and liabilities: Â Â Accounts receivable, net (1,745) (1,456) Inventory (2,356) (3,503) Prepaid expenses and other current assets 524 361 Accounts payable 636 1,535 Accrued expenses and other current and long-term liabilities (967) 1,373 Foreign currency transaction gain (loss) 93 (186) Net cash used in operating activities (34,064) (29,806) Cash flows from investing activities: Â Â Purchase of property and equipment (725) (406) Proceeds from the sale of product line 5,366 Â Net cash provided by (used in) investing activities 4,641 (406) Cash flows from financing activities: Â Â

Proceeds from sale of common stock, net Â 46,341 Proceeds from exercise of stock options 226 101 Payment of withholding taxes related to stock-based compensation to employees (358) (285) Proceeds from issuance of common stock under the employee stock purchase plan 281 88 Net cash provided by financing activities 149 46,245 Effect of exchange rate on cash and cash equivalents (154) 150 Net (decrease) increase in cash and cash equivalents and restricted cash (29,428) 16,183 Cash and cash equivalents and restricted cash, beginning of period 46,994 42,019 Cash and cash equivalents and restricted cash, end of period 17,566 58,202 Supplemental disclosure of cash flow information: Â Â Cash paid during the period for interest 3,552 3,431 Supplemental disclosures of noncash investing and financing activities: Â Â Property and equipment in accounts payable and accrued expenses and other current liabilities $ 175 $ 23 X - DefinitionAmount of net changes in operating lease right-of-use assets and liabilities. + ReferencesNo definition available. + Details Name: tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -

Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Background 9 Months Ended Sep. 30, 2024 Background Â Background (1)Â BackgroundTELA Bio,Â Inc. (the â€œCompanyâ€) was incorporated in the state of Delaware on AprilÂ 17, 2012 and wholly owns TELA Bio Limited, a company incorporated in the United Kingdom and TELA Bio GmbH, a company incorporated in Germany. The Company is a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâ€™s own anatomy. OviTex Reinforced Tissue Matrix (â€œOviTexâ€), the Companyâ€™s first portfolio of products, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. OviTex PRS Reinforced Tissue Matrix (â€œOviTex PRSâ€), the Companyâ€™s second portfolio of products, addresses unmet needs in plastic and reconstructive surgery. The Companyâ€™s principal corporate office and research facility is located in Malvern, Pennsylvania. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Risks and Liquidity 9 Months Ended Sep. 30, 2024 Risks and Liquidity Â Risks and Liquidity (2)Â Risks and LiquidityThe Companyâ€™s operations to date have focused on commercializing products, developing and acquiring technology and assets, business planning, raising capital and organization and staffing. The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $349.5Â million as of September 30, 2024. The Company anticipates incurring additional losses until such time, if ever, it can generate sufficient revenue from its products to cover its expenses. In March 2024, the Company sold its distribution rights for NIVIS Fibrillar Collagen Pack to MiMedx Group, Inc. in exchange for an initial $5.0 million payment and additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS during the first two years following its launch by MiMedx Group, Inc.â€‹Subsequent to September 30, 2024, the Company completed an underwritten public offering which is described in Note 9, Subsequent Event.â€‹The operations of the Company are subject to certain risks and uncertainties including, among others, the uncertainty of product development, the impact of macroeconomic conditions, including any lingering effects of the COVID-19 pandemic or other public health crises, general economic uncertainty, including as a result of inflationary pressures and the measures undertaken by various governments to address them, banking instability, monetary policy changes, geopolitical factors such as the ongoing Russia-Ukraine conflict, the current conflicts in the Middle East (including any escalation or expansion) and increasing tensions between China and Taiwan, cybersecurity events affecting or disrupting normal hospital operations, constraints on the supply of critical surgical and hospital supplies necessary to facilitate the surgical procedures in which our products are utilized, technological uncertainty, commercial acceptance of any developed products, alternative competing technologies, dependence on collaborative partners, uncertainty regarding patents and proprietary rights, comprehensive government regulations, and dependence on key personnel.â€‹ X - DefinitionThe entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_ConcentrationRiskDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies (3)Â Summary of Significant Accounting PoliciesThe Companyâ€™s complete summary of significant accounting policies can be found in â€œNoteÂ 3, Summary of Significant Accounting Policiesâ€ in the consolidated financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to generally accepted accounting principles (â€œGAAPâ€) in the U.S. as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUâ€) promulgated by the Financial Accounting Standards Board (â€œFASBâ€).Interim Financial StatementsThe accompanying unaudited interim consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and RuleÂ 10-01 of RegulationÂ S-X promulgated by the Securities and Exchange Commission (â€œSECâ€), which permits reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying consolidated balance sheets and statements of operations and comprehensive loss, stockholdersâ€™ equity and cash flows have been made. Although these interim consolidated financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements, management believes the disclosures are adequate to make the information presented not misleading. The unaudited interim results of operations and cash flows are not necessarily indicative of the results that may be expected for the fullÂ year. The unaudited interim consolidated financial statements and footnotes should be read in conjunction with the consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2023. Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Companyâ€™s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.Revenue RecognitionUnder ASC Topic 606, Revenue from Contracts with Customers, (â€œASC 606â€), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)Â identify the contract(s)Â with a customer, (ii)Â identify the performance obligations in the contract, (iii)Â determine the transaction price, (iv)Â allocate the transaction price to the performance obligations in the contract, and (v)Â recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.A significant portion of the Companyâ€™s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Companyâ€™s customer contracts, the only

identified performance obligation is providing the product to the customer.Revenue is recognized at the estimated net sales price, which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records these rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.Payment terms with customers do not exceed oneÂ year and, therefore, the Company does not account for a financing component in these arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than oneÂ year. Fees charged to customers for shipping are recognized as revenue.The following table presents revenue disaggregated by the Companyâ€™s portfolio of products (in thousands):â€‹â€‹â€‹

http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Sale of Product Line 9 Months Ended Sep. 30, 2024 Sale of Product Line Â Sale of Product Line (7) Sale of Product LineIn March 2024, the Company entered into an Asset Purchase Agreement (â€œAPAâ€) with MiMedx Group, Inc. (â€œMDXGâ€) to sell certain assets (the â€œTransactionâ€) related to NIVIS Fibrillar Collagen Pack Device (â€œNIVISâ€). These assets mainly included the Companyâ€™s existing inventory of NIVIS, with a net carrying value of $0.8 million, and certain intellectual property rights to sell NIVIS, with no carrying value. MDXG assumed the Companyâ€™s existing supply agreements, including the minimum obligations for NIVIS that the Company entered into in 2022 ahead of the initial sales of NIVIS. In exchange for entering into the Transaction, the Company received an initial $5.0 million upfront payment and is entitled to receive future revenue-sharing payments based on the net sales of NIVIS during the first two years following its launch by MDXG, which revenue-sharing payments would range from a minimum of $3.0 million to a maximum of $7.0 million in the aggregate. Any consideration in excess of $3.0 million up to $7.0 million is considered variable consideration that is fully constrained. The Company accounted for the Transaction as a sale of a nonfinancial asset group in accordance with ASC 610-20 and followed the principals of ASC 606 to determine the consideration of $8.4 million related to the Transaction. The Company transferred control of the nonfinancial asset group in March 2024 and recognized a gain of $7.6 million on the consolidated statement of operations and comprehensive loss during the three months ended March 31, 2024. Additionally, the Company recorded the minimum revenue-share payment of $3.0 million as a receivable at September 30, 2024, with $0.4 million representing the current portion in prepaid expenses and other assets in the consolidated balance sheet and $2.6 million representing the long-term portion in other long-term assets in the consolidated balance sheet. At each reporting date, the Company assesses the constraint of variable consideration and records increases in the transaction price in the period that the estimate of variable consideration changes. For the three and nine months ended September 30, 2024, no changes were made to the variable consideration. X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Stock-Based Compensation (8)Â Stock-Based CompensationThe Company has two equity incentive plans: the 2012 Stock Incentive Plan and the Amended and Restated 2019 Equity Incentive Plan. New awards can only be granted under the Amended and Restated 2019 Equity Incentive Plan (the â€œPlanâ€). At September 30, 2024, 907,293 shares of common stock were available for future issuances under the Plan. The Plan is subject to an annual increase, subject to prior approval by the Companyâ€™s board of directors, equal to the lesser of (i) 432,442 shares, (ii) 4% of the shares outstanding on the last day of the immediately preceding fiscal year and (iii) such smaller number of shares as determined by the board of directors. The Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Companyâ€™s board of directors. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense ratably over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of the accompanying consolidated statements of operations and comprehensive loss (in thousands):â€‹Three months ended SeptemberÂ 30,Â â€‹Nine months ended SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹2024â€‹2023Sales and marketingâ€‹$ 318â€‹$ 507â€‹$ 993â€‹$ 1,375General and administrativeâ€‹â€‹ 607â€‹Â 670â€‹Â 1,804â€‹Â 1,861Research and developmentâ€‹Â 156â€‹Â 192â€‹Â 476â€‹Â 555Total stockâ€based compensationâ€‹$ 1,081â€‹$ 1,369â€‹$ 3,273â€‹$ 3,791â€‹Stock OptionsThe Companyâ€™s stock options vest based on the terms in each award agreement and generally vest over four years and have a term of 10 years. â€‹â€‹The following table summarizes stock option activity:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Interim Financial Statements Interim Financial StatementsThe accompanying unaudited interim consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and RuleÂ 10-01 of RegulationÂ S-X promulgated by the Securities and Exchange Commission (â€œSECâ€), which permits reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying consolidated balance sheets and statements of operations and comprehensive loss, stockholdersâ€™ equity and cash flows have been made. Although these interim consolidated financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements, management believes the disclosures are adequate to make the information presented not misleading. The unaudited interim results of operations and cash flows are not necessarily indicative of the results that may be expected for the fullÂ year. The unaudited interim consolidated financial statements and footnotes should be read in conjunction with the consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Companyâ€™s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates. Revenue Recognition Revenue RecognitionUnder ASC Topic 606, Revenue from Contracts with Customers, (â€œASC 606â€), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i)Â identify the contract(s)Â with a customer, (ii)Â identify the performance obligations in the contract, (iii)Â determine the transaction price, (iv)Â allocate the transaction price to the performance obligations in the contract, and (v)Â recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer.A significant portion of the Companyâ€™s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Companyâ€™s customer contracts, the only identified performance obligation is providing the product to the customer.Revenue is recognized at the estimated net sales price, which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records these rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue.Payment terms with customers do not exceed oneÂ year and, therefore, the Company does not account for a financing component in these arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than oneÂ year. Fees charged to customers for shipping are recognized as revenue.The following table presents revenue disaggregated by the Companyâ€™s portfolio of products (in thousands):â€‹Three months ended SeptemberÂ 30,Â â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023OviTexâ€‹$ 12,463â€‹$ 10,159â€‹$ 34,122â€‹$ 28,240OviTex PRSâ€‹â€‹ 6,313â€‹â€‹ 4,812â€‹â€‹ 17,054â€‹â€‹ 13,063Otherâ€‹â€‹ 181â€‹â€‹ 81â€‹â€‹ 475â€‹â€‹ 152Total revenueâ€‹$ 18,957â€‹$ 15,052â€‹$ 51,651â€‹$ 41,455â€‹Sales outside of the U.S. were $2.8 million and $1.7 million, respectively, for the three months ended September 30, 2024 and 2023 and $7.5 million and $4.2 million, respectively, for the nine months ended September 30, 2024 and 2023. Fair Value of Financial Instruments Fair Value of Financial InstrumentsFair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Companyâ€™s financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The carrying amounts of the Companyâ€™s Credit and Security Agreement approximates fair value due to its variable interest rate.The Company follows the provisions of ASC TopicÂ 820, Fair Value Measurement, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:â—‹ LevelÂ 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.â—‹ LevelÂ 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.â—‹ LevelÂ 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,Â supported by little or no market activity).The following fair value hierarchy table presents information about each major category of the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Disaggregation of Revenue The following table presents revenue disaggregated by the Companyâ€™s portfolio of products (in thousands):â€‹Three months ended SeptemberÂ 30,Â â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023OviTexâ€‹$ 12,463â€‹$ 10,159â€‹$ 34,122â€‹$ 28,240OviTex PRSâ€‹â€‹ 6,313â€‹â€‹ 4,812â€‹â€‹ 17,054â€‹â€‹ 13,063Otherâ€‹â€‹ 181â€‹â€‹ 81â€‹â€‹ 475â€‹â€‹ 152Total revenueâ€‹$ 18,957â€‹$ 15,052â€‹$ 51,651â€‹$ 41,455 Schedule of fair value of assets and liabilities measured on recurring basis The following fair value hierarchy table presents information about each major category of the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis (in thousands):â€‹FairÂ valueÂ measurementÂ atÂ reportingÂ dateÂ usingâ€‹â€‹QuotedÂ pricesÂ inâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹activeÂ marketsâ€‹SignificantÂ ot 30, 2024:â€‹Cash equivalentsÂ â€“ money market fundâ€‹$ 13,786â€‹$ â€”â€‹$ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹December 31, 2023:â€‹Cash equivalentsÂ â€“ money market fundâ€‹$ 41,561â€‹$ â€”â€‹$ â€” Schedule of dilutive securities excluded â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023Stock options â€‹ 2,128,862Â 2,202,264Unvested restricted stock unitsâ€‹ 971,439â€‹ 864,427Common stock warrantsâ€‹ 88,556â€‹ 88,556TotalÂ 3,188,857Â 3,155,247 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Accrued Expenses and Other Current Liabilities Â Schedule of Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Compensation and related benefitsâ€‹$ 7,854â€‹$ 9,216Third-party and professional feesâ€‹Â 2,828â€‹Â 2,828Amounts due to contract manufacturerâ€‹â€‹ 2,314â€‹â€‹ 2,024Current portion of operating lease liabilitiesâ€‹â€‹ 559â€‹â€‹ 565Research and development expensesâ€‹â€‹ 16â€‹â€‹ 140Otherâ€‹Â 808â€‹Â 527Total accrued expenses and other current liabilitiesâ€‹$ 14,379â€‹$ 15,300â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Long-term Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Â Schedule of long term debt Long-term debt consisted of the following (in thousands):â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹Â Â Â Â 2024Â Â Â Â 2023MidCap term loanâ€‹$ 40,000â€‹$ 40,000End of term chargeÂ â€‹ 2,000Â â€‹ 2,000Unamortized end of term charge and issuance costsÂ â€‹ (1,030)Â â€‹ (1,485)Long-term debt â€‹$ 40,970â€‹$ 40,515 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Â Schedule of warrants outstanding to purchase common stock â€‹Exerciseâ€‹Expirationâ€‹Â Â Â Â Outstandingâ€‹Â Â Â Â priceÂ Â Â Â datesCommon stock warrants Â 8,379â€‹$ 28.65Â 2028Common stock warrants Â 80,177â€‹Â 28.65Â 2027â€‹Â 88,556â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Schedule of stock based compensation expense categories in statement of operations â€‹Three months ended SeptemberÂ 30,Â â€‹Nine months ended SeptemberÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹2024â€‹2023Sales and marketingâ€‹$ 318â€‹$ 507â€‹$ 993â€‹$ 1,375General and administrativeâ€‹â€‹ 607â€‹Â 670â€‹Â 1,804â€‹Â 1,861Research and developmentâ€‹Â 156â€‹Â 192â€‹Â 476â€‹Â 555Total stockâ€‘based compensationâ€‹$ 1,081â€‹$ 1,369â€‹$ 3,273â€‹$ 3,791 Schedule of stock option activity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

srt_CounterpartyNameAxis=tela_MimedxGroupIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Revenue Disaggregated (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Revenue $ 18,957 $ 15,052 $ 51,651 $ 41,455 Incremental costs of obtaining a contract Â Â 0 Â Non-US [Member] Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 2,800 1,700 7,500 4,200 OviTex Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 12,463 10,159 34,122 28,240 OviTex PRS Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 6,313 4,812 17,054 13,063 Other Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue $ 181 $ 81 $ 475 $ 152 X - DefinitionRepresents incremental costs incurred in obtaining a contract. + ReferencesNo definition available. + Details Name: tela_IncrementalCostsOfObtainingContract Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tela_OvitexMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tela_OvitexPrsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=tela_OtherCustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] Â Â Fair Value of Financial Instruments Â Â Cash equivalents $ 13,786 $ 41,561 X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Net Loss per Common Share (Potentially dilutive securities) (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Potentially dilutive securities Â Â Potentially dilutive securities excluded from computation of diluted weighted average shares 3,188,857 3,155,247 Employee Stock Option Â Â Potentially dilutive securities Â Â Potentially dilutive securities excluded from computation of diluted weighted average shares 2,128,862 2,202,264 Unvested restricted stock units Â Â Potentially dilutive securities Â Â Potentially dilutive securities excluded from computation of diluted weighted average shares 971,439 864,427 Common Stock Warrants Â Â Potentially dilutive securities Â Â Potentially dilutive securities excluded from computation of diluted weighted average shares 88,556 88,556 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tela_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Expenses and Other Current Liabilities Â Â Compensation and related benefits $ 7,854 $ 9,216 Third-party and professional fees 2,828 2,828 Amounts due to contract manufacturer 2,314 2,024 Current portion of operating lease liabilities $ 559 $ 565 Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities Research and development expenses $ 16 $ 140 Other 808 527 Total accrued expenses and other current liabilities $ 14,379 $ 15,300 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to contract manufacturer due. + ReferencesNo definition available. + Details Name: tela_AccruedExpensesAmountDueToContractManufacturer Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of current portion of obligation payable pertaining to Research and development. + ReferencesNo definition available. + Details Name: tela_ResearchAndDevelopmentExpensesPayableCurrent Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes current operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2 + Details Name: us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Long-term Debt - Schedule of long term debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 May 26, 2022 Long term Debt Â Â Â End of term charge $ 2,000 $ 2,000 Â Unamortized end of term charge and issuance costs (1,030) (1,485) Â Long-term debt 40,970 40,515 Â MidCap term loan Â Â Â Long term Debt Â Â Â MidCap term loan $ 40,000 $ 40,000 $ 40,000 X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name

Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt premium. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Long-term Debt - MidCap Term Loan (Details) - MidCap term loan - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 May 26, 2022 Long term Debt Â Â Â Â Â Â Debt amount $ 40,000 Â $ 40,000 Â $ 40,000 $ 40,000 Interest due to unpaid obligation Â Â 2.00% Â Â Â Interest Rate (as a percent) 6.25% Â 6.25% Â Â Â Variable Interest Rate (as a percent) Â Â 1.00% Â Â Â Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Â Â us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Â Â Â Interest-Only Period Â Â 36 months Â Â Â Exit fee (as a percent) Â Â 5.00% Â Â Â Interest expenses $ 1,300 $ 1,300 $ 4,000 $ 3,900 Â Â Amortization of debt issuance costs $ 200 $ 200 $ 500 $ 400 Â Â Maximum [Member] Â Â Â Â Â Â Long term Debt Â Â Â Â Â Â Extension for interest only payment period Â Â 48 months Â Â Â Minimum [Member] Â Â Â Â Â Â Long term Debt Â Â Â Â Â Â Extension for interest only payment period Â Â 12 months Â Â Â First year Â Â Â Â Â Â Long term Debt Â Â Â Â Â Â Percentage of prepayment penalty on prepaid principal amount Â Â 3.00% Â Â Â Second year Â Â Â Â Â Â Long term Debt Â Â Â Â Â Â Percentage of prepayment penalty on prepaid principal amount Â Â 2.00% Â Â Â Third year Â Â Â Â Â Â Long term Debt Â Â Â Â Â Â Percentage of prepayment penalty on prepaid principal amount Â Â 1.00% Â Â Â X - DefinitionAdditional extension for interest only payment period. + ReferencesNo definition available. + Details Name: tela_AdditionalExtensionForInterestOnlyPaymentPeriod Namespace Prefix: tela_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe Interest-Only Period of debt instrument interest payment. + ReferencesNo definition available. + Details Name: tela_DebtInstrumentInterestPaymentTerm Namespace Prefix: tela_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of penalty to be paid on the event of default in meeting the obligation. + ReferencesNo definition available. + Details Name: tela_InterestPenaltyPercentage Namespace Prefix: tela_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the principal amount paid as an exit fee at the time of maturity or prepayment. + ReferencesNo definition available. + Details Name: tela_PercentageOfExitFee Namespace Prefix: tela_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of penalty to be paid on principal amount of debt for the third year after closing date and thereafter. + ReferencesNo definition available. + Details Name: tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount Namespace Prefix: tela_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates type of variable interest rate on debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=tela_MidcapTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=tela_FirstYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=tela_SecondYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=tela_ThirdYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Public Stock Offerings (Details) - USD ($) $ in Thousands 9 Months Ended 21 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Nov. 30, 2023 Stockholders' Equity Â Â Â Â Number of warrants granted 0 Â Â Â Number of share exercised 0 Â Â Â Number of share cancelled 0 Â Â Â Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses Â $ 46,341 Â Â Equity Distribution Agreement Â Â Â Â Stockholders' Equity Â Â Â Â Common Stock Available Under ATM Â Â Â $ 50,000 Value Of Shares Sold Under Equity Distribution Agreement Â Â $ 0 Â X - DefinitionThe number of warrants cancelled. + ReferencesNo definition available. + Details Name: tela_ClassOfWarrantOrRightCancelled Namespace Prefix: tela_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants exercised. + ReferencesNo definition available. + Details Name: tela_ClassOfWarrantOrRightExercised Namespace Prefix: tela_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants granted. + ReferencesNo definition available. + Details Name: tela_ClassOfWarrantOrRightGranted Namespace Prefix: tela_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe maximum amount of shares that can be sold under the at-the-market programs. + ReferencesNo definition available. + Details Name: tela_CommonStockAvailableUnderAtm Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue Of Shares Sold Under Equity Distribution Agreement + ReferencesNo definition available. + Details Name: tela_ValueOfSharesSoldUnderEquityDistributionAgreement Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=tela_EquityDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Warrants outstanding (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Stockholders' Equity Â Warrants outstanding 88,556 Common stock warrants expiring in 2028 Â Stockholders' Equity Â Warrants outstanding 8,379 Warrants exercise price | $ / shares $ 28.65 Expiration dates 2028 Common stock warrants expiring in 2027 Â Stockholders' Equity Â Warrants outstanding 80,177 Warrants exercise price | $ / shares $ 28.65 Expiration dates 2027 X - DefinitionClass of Warrant or Right, Date from which Warrants or Rights Expire + ReferencesNo definition available. + Details Name: tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire Namespace Prefix: tela_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=tela_CommonStockWarrantsExpiringIn2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Sale of Product Line - Narrative (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2024 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Proceeds from the sale of product line Â Â $ 5,366,000 Gain on sale of product line Â Â 7,580,000 MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Proceeds from the sale of product line Â Â 5,000,000.0 Minimum [Member] | MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Revenue sharing payments $ 3,000,000.0 Â 3,000,000.0 Maximum [Member] | MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Revenue sharing payments 7,000,000.0 Â 7,000,000.0 Transaction | MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Amount minimum revenue share payments receivable 3,000,000.0 Â 3,000,000.0 Amount minimum revenue share payments receivable current 400,000 Â 400,000 Amount minimum revenue share payments receivable non-current 2,600,000 Â 2,600,000 Variable Consideration 0 Â 0 Transaction | Minimum [Member] | MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Revenue sharing payments 3,000,000.0 Â 3,000,000.0 Variable consideration 3,000,000.0 Â 3,000,000.0 Transaction | Maximum [Member] | MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Revenue sharing payments 7,000,000.0 Â 7,000,000.0 Variable consideration 7,000,000.0 Â 7,000,000.0 Transaction | Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | MiMedx Group, Inc. Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Net carrying value 800,000 Â 800,000 Carrying value 0 Â 0 Proceeds from the sale of product line Â Â 5,000,000.0 Consideration determined $ 8,400,000 Â $ 8,400,000 Gain on sale of product line Â $ 7,600,000 Â X - DefinitionThe future revenue-sharing payments based on the net sales of NIVIS during the first two years following its launch by MDXG. + ReferencesNo definition available. + Details Name: tela_DisposalGroupFutureRevenueSharingPayments Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of increase (decrease) in the variable consideration during the period. + ReferencesNo definition available. + Details Name: tela_DisposalGroupFutureRevenueSharingPaymentsIncreaseDecreaseInVariableConsideration Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAny consideration in excess consideration is considered variable consideration that is fully constrained. + ReferencesNo definition available. + Details Name: tela_DisposalGroupFutureRevenueSharingPaymentsVariableConsideration Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of minimum revenue share payments receivable. + ReferencesNo definition available. + Details Name: tela_MinimumRevenueSharePaymentsReceivable Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of minimum revenue share payments receivable classified as current. + ReferencesNo definition available. + Details Name: tela_MinimumRevenueSharePaymentsReceivableCurrent Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of minimum revenue share payments receivable classified as non-current. + ReferencesNo definition available. + Details Name: tela_MinimumRevenueSharePaymentsReceivableNonCurrent Namespace Prefix: tela_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These

concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=tela_MimedxGroupIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=tela_DisposalGroupTransactionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Narratives (Details) 9 Months Ended Sep. 30, 2024 USD ($) item $ / shares shares Stock-Based Compensation Â Number of equity incentive plans | item 2 Employee Stock Option Â Stock-Based Compensation Â Inducement grants | shares 319,684 Weighted average grant date fair value, Options (per share) | $ / shares $ 4.67 Aggregate intrinsic value of exercised options | $ $ 41,000 Unrecognized compensation expense | $ $ 2,800,000 Weighted average period for recognition of unrecognized expenses 2 years 2 months 12 days Restricted Stock Units (RSUs) [Member] Â Stock-Based Compensation Â Inducement grants | shares 115,210 Unrecognized compensation expense | $ $ 4,600,000 Weighted average period for recognition of unrecognized expenses 2 years 7 months 6 days Weighted average grant date fair value, Equity Instruments (per share) | $ / shares $ 6.63 Aggregate intrinsic value | $ $ 2,500,000 Performance based restricted stock units | Minimum [Member] Â Stock-Based Compensation Â Vest Range 0.00% Performance based restricted stock units | Maximum [Member] Â Stock-Based Compensation Â Vest Range 110.00% Service based restricted stock unit Â Stock-Based Compensation Â Vesting period 4 years 2019 Equity Incentive Plan Â Stock-Based Compensation Â Shares available for future issuance | shares 907,293 Common Stock Capital Shares Reserved For Future Annual Issuance | shares 432,442 Potential common shares outstanding on the last day of the immediately preceding fiscal year 4.00% 2019 Equity Incentive Plan | Employee Stock Option Â Stock-Based Compensation Â Vesting period 4 years Contractual term 10 years X - DefinitionCommon Stock Capital Shares Reserved For Future Annual Issuance + ReferencesNo definition available. + Details Name: tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance Namespace Prefix: tela_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents about number of equity incentive plans. + ReferencesNo definition available. + Details Name: tela_EquityIncentivePlansNumber Namespace Prefix: tela_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPotential Common Shares Added Annually To Equity Plan Evergreen Option, Percentage Of Shares Outstanding Last Day Of Fiscal Year + ReferencesNo definition available. + Details Name: tela_PotentialCommonSharesAddedAnnuallyToEquityPlanEvergreenOptionPercentageOfSharesOutstandingLastDayOfFiscalYear Namespace Prefix: tela_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of inducement restricted stock units outstanding. + ReferencesNo definition available. + Details Name: tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod Namespace Prefix: tela_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tela_PerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tela_ServiceBasedRestrictedStockUnitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=tela_EquityIncentivePlan2019Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Expenses (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock-Based Compensation Â Â Â Â Total stock-based compensation $ 1,081 $ 1,369 $ 3,273 $ 3,791 Selling and Marketing Expense [Member] Â Â Â Â Stock-Based Compensation Â Â Â Â Total stock-based compensation 318 507 993 1,375 General and Administrative Expense [Member] Â Â Â Â Stock-Based Compensation Â Â Â Â Total stock-based compensation 607 670 1,804 1,861 Research and Development Expense [Member] Â Â Â Â Stock-Based Compensation Â Â Â Â Total stock-based compensation $ 156 $ 192 $ 476 $ 555 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Stock Option Activity (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Number of shares Â Balance at beginning of period | shares 2,162,453 Granted | shares 259,900 Exercised | shares (38,431) Canceled/forfeited | shares (255,060) Balance at end of period | shares 2,128,862 Vested and expected to vest at end of period | shares 2,099,563 Exercisable at end of period | shares 1,612,281 Weighted average exercise price per share Â Balance at beginning of period (in dollars per share) | $ / shares $ 11.48 Granted (in dollars per share) | $ / shares 6.86 Exercised (in dollars per share) | $ / shares 5.88 Canceled/forfeited (in dollars per share) | $ / shares 12.35 Balance at end of period (in dollars per share) | $ / shares 10.91 Vested and expected to vest at end of period (in dollars per share) | $ / shares 10.94 Exercisable at end of period (in dollars per share) | $ / shares $ 11.45 Weighted average remaining contractual term (years) Â Weighted average remaining contractual term, outstanding 6 years 1 month 13 days Weighted average remaining contractual term, Vested and expected to vest 6 years 29 days Weighted average remaining contractual term, Exercisable 5 years 4 months 6 days X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Weighted average assumptions (Details) 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Expected volatility 73.20% Risk-free interest rate 4.29% Expected term (in years) 6 years 1 month 20 days X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Restricted Stock Units (Details) 9 Months Ended Sep. 30, 2024 shares Service Based Restricted Stock Units [Member] Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Outstanding at beginning of period 657,054 Granted 411,825 Vested (178,836) Canceled/forfeited (135,104) Outstanding at end of period 754,939 Performance Based Restricted Stock Units [Member] Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Outstanding at beginning of period 250,149 Canceled/forfeited (33,649) Outstanding at end of period 216,500 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=tela_ServiceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=tela_PerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Event (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended Oct. 24, 2024 Sep. 30, 2023 Subsequent Event Â Â Gross proceeds Â $ 46,341 Subsequent Event [Member] Â Â Subsequent Event Â Â Gross proceeds $ 46,000 Â Subsequent Event [Member] | Common stock Â Â Subsequent Event Â Â Shares issued and sold 14,670,000 Â Offering price (in dollar per share) $ 2.25 Â Subsequent Event [Member] | Warrant [Member] Â Â Subsequent Event Â Â Shares issued and sold 5,800,000 Â Offering price (in dollar per share) $ 2.2499 Â Exercise Price $ 0.0001 Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220

-Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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g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{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e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

/0E@'YHW8QVS5VD)JL%;QC602<2;F37A[4HMVQOH=^P-WN8OYHQ(.\@&&& MX 8K49E#.(JM>X5*."4-6N70YNQ%9R #^D024(:C'R4:Y2+7*^=-<2PPN-99 M<
M;_I$=%+N2]"3$VP"X535+'^"JU,5Q.;CA(W\ PBZ1HSDHH&YGOFX.H@K M,D%1VI#M Z.T;SFI,J2MP$";[!DB!!Q*);>EL6VPP2<[>79]"SZ7M\+@*]61 MV=30YM_;
$,Y9%!9QL:J=CLY/.JB!&UAA,B'@,,I)7TK97UWO+G+EJ#C$_\6Z+1,?ZSFEOH"$(TF\=B(^>%>0+ P-;U^.3.76; M*J;,AVD@S.J$^JTJF\06:F0X=S"3*
MU3AK(@TQ/,&9H/6YUH(S$$EWRVMGC>XZCT6%AY=@.D), 3*Q^(((V\[A,U6 T2;QEI6\S8I\Z) '##7D^Z M?-:K * OX-N7FOT#ME1'3Y /O(,B>&MI5LYE=A(E:;!'8&":CV?-H8#)-1N-Q-#
^2\;380#U\=-\#Z.39#*:[(U.D[/1 M>&]T=)H,9]/]X4DR!%X?V(;V)L]&>V,'AJ:GL_VMLS'RHII3+J=:$>EGR?/9 M:3PP VXQZ;-16<;9.G4B$}>S:?G4^-@.>&71
M=7T0\S7G=HI64D'FRS=N+,$3:N,R#>/<:]3HB K JC%52:$$/O0!ZH!"KZVQ M@%['J(+,N. 6BGV LAKQ*G,]+*=;LO;5)W>B#I:J"6=C\-/"T4T*8)%4+9K4_@(O9GC0K9 M(_:9^AGIZ%9<(*
[GL4#2%'^VN;6W#&" M@ 25B/W$QL7]X!I0!G!.0BAU]2L\:Q)[FY^5)(5D-'[X[OG)Z?-S\1-\>2Y& M+U#\NN8H].*WIJRY\H/'L^Y0Z^SD=+#$["9]:XJ.4J1O T6):U/Y9A(<%Q"MJ<(WE+=[
M)\^,@Y(^W2=?;W32SUS!F/Z[EA M/+,+K&>^[6BD9&&HIWE[*#GIAD^OZ'=\/O$NZ6GX-6Y_T>7P7F;UYTGZ:B,+WQM^*:.R9Y(ZV2OE +C,QD.DZS@N1.@*F(WWOA[[NR)<29+MNHC3[SW2
M#DLIJ4W79 M:[;3B13I BC?VNEZ1G=Q+-P1P"^D=#/LX]7B?K$Y[.E?(',0E?EQ*G@%D,$ M[NCL[I@[PM2MO\AJN]C4&6JZ.]R R9W"CX3==A^]4-O;QL0W>+:^?[50.WS[
M5I/[]N;%W*FN3_/;]60T/DO.3L;XA67)^&2*9.]:6>=>=;,/P4 M5?]DZVFP209X?ML=DJ_9K-D/.W: M!I\4=6$A[W=.5>/W-:8L\#N-WE:TKQQ(@04FS(J+,%/>4'_4S;+4,K7417?1
M^0]40I"WJ<6'QHA+"LO4GIO34%-9',L=Q?%P-!9/: /A-QZ>_^/#Y9PF^9/? M?[@+(X;IYY([$ F/C#*52Y2/&0F)W=,-Y6)&(7_OOZ>Q[0,4;[>4D\(AJRX/ M5 5"?
6B1]Y$@(#F07/#2SI4@-4)1TX&E$G9+H)!Y7)/YMHCV"XTÜ]O([1F?N M#75MU^"YNJV=EG+SP%V@^=YG^T* JR5N!SR&4$Y\V:S=/1Y1YIP4F;YT[TT.@ MJV:1>Q^SA[NGG-
DC3:Y=3Z&]B'771C5RQ:?N]@B>J5A1@7FG!A':3S36R^52 M]RM3:2/7FQ\-2K]S4#BJ]"'[XSIXM/? MEC+*AE,POG()3/%=(Y)(]U[@;I%4?6.3'!X]UP-7=@3#@?"B6:&)%\T=+&# M7DL% ,;V8?
Q'ORP'//J.+U3=JX9OM5R78ZEQ^J[J'&&\5RUM>^F_%W ME;&DGD47LF#F6Z!?=]7%AQL,N8&18#S?E]?.K9+7/(PIS3P;GB;BW8;$
MY3D!IKKG$+FE'@3M7J"*\,I;7;VT"G/]T]Y5K$W#HE@9]445R MU?[1#E2!:B6JY5"\4UBJW;L5ZH!:>EM$-DW7S=$+OTZ"?/OC7G^$L+=08+"[M&5DBL>]{&OBN$6ZH(*0\&E#-
M]P5JX0+KT7TE0KU?%. MQHDKR=9H?!P>B+>2>I;.A_I[4'X\%A[a%(.&DOG8\ADMJKNY4;83$U&(:^E MSEG&7/]@DI@VV TI[?/'# %6,6HO#@X]Z3V.7F637^.WYW0(3-P]T&Y'V^?M%^Y5=[?
S(V'<>W/W49<5O_%& E>7& ZY5F"CH068IR='X8,.:!_]O_XO4$L# M!!0 (+2 :%GF;#WT!P, -<' 9 >&PO=V]R:W-H965T:BIRKF9-I74Y<5\49%%2=BA(X M_DF%+*A&46Y<54J@B74J&OQF
ML%5[>V(B60MQ9X3OR)R#RO(+IQ M@[^L\?TW\,?4G"=*7+!$TB>^KO(M2/LMX27_D' &RA/2»UB. YX0&\H$M M8/&" Y: &C]\'=]$+>=T9G#OOFPIK'C7F>9QX+O.!*HX-(^5J15.0X*1C?
D&/&42,JA0CJ9$*. M/HU\+SC[L!5;24.Q1F*FGUKM.<2-LK]3FF8SGX"L1&'BHO5,P= DŸ-307P.' ME&G5^7PFP]XH"O?D<<_Ö#\AMQP3RI:12/UJ 4HH4E)ER-"Z042NL=>IC#,;8@+W./[+PIS3]
<5S+TS-"U7H-9W6 M:D;>+B&1/R2W0F/6Z/MZ;E>1?M@+AN-]1=0+/*]5O'9#W;UA6X#)94;QA5F.457[W08.436ST@M:%':T;T6&A\"N\WP MY05I#/! *H1N!7-]Y;/_P%02P,$% @
M(!H6&ULQ5AK;]LV%/TKA)<.">#:\B-] MY0&TZ8H5:+&B:;?/M'1M=>7NM\ M:]V-7Q,%<5MJXR\ZQ"]%^.QS]=42C^R%1F\65I7RH"E6XU]Y4@64:C4XVF6 M/1F74IG!Y7G<^^^
NSVT=M#+TP0E?EZ5T=Z3](V^W%8#)H-SZJU3KPQOCRO)(K MNJ;PN?K@L!IW6@I5DO'*&N%H>3%X.7GQ:L[GXX'?%6U][UEP) MK;WCQMK@8 M9.P0:90<$ MIHW -
/J=#$4O7\L@+\^=W0K'IZ&-'V*H41K.*<-)N0X.;Q7DPN4[:U:/ [E2 MO*9%.!\'Z.0WX[R1?Y7DIP?DGXOWUH2U%[^8@HI]^3%\Z1R:M@Z]FCZH\)JJ MD9AE0S'-IO,'],VZ &=1W^R OD-A):GY_5)
<"B]\)7.Z&(#KGMR&!I<__S1Y MDIT]X-.\\VG^D/:#/CTL=?QZ(O;3U5L6O,PMBL4'H1=BK FL;0:5:?,2APK M@QU;>VD*?_)"_/S3LVDV._O/_B-M@4_ ,%>*5>R MC ;:7ICAR)>3;,LNS;#=
L!LWTDFDU6B $,H M\MI<@)Z/OA._G@RS&;927\]?[:7@0CYGH//GW[E\>GDM-MH@OW$HN\XV-^, M>"_OQ/1Y/IT&#-V97U->.Q7NQ,N5(T*'#.*8 MC["E:7;6&&H$NC/Q[>3L!
TFK%MOWBB#V)74XI-#LQD*Z05ZL>$G6,K)!31V MH8$=LEA)0$F>_7$4[$A\@M4#YEHR>L;\:)Z-,K0OK;D30Z'<)7TD/E?8S+7U M(.H^"K4'!%)4G$*<:5A=.9L3%?
##XEZH@.'". A=Y[D4=/86,HXT"WT6>'%^O* M7&D&+>8 M &.*F!Z^XTEN-P1"!::(#$*K$N=[ZAB8R=,SX+A(R0 P9%9@3 GD5*PTK$\:3?)AHZTRWW*>(!P&+$X\J/H]^W M5?VFG8T]KPHE@;K\[02#!U,Q?
6#H=KO/,R_35XG= M\?1MYSV8ST.+IB5$L]'3TX%PZ7M)6@1;Q6\4"QLPJ\3'-4G<07P [Y?6AG;! M!KJ/5I=_ U!+ P04 " "T@&A90>VP7^4# #:"0 &0 'AL+W=OQ85ZCH9*N-
9(ZVIHAM99#E04B*.$V2TU@RKJ+U,M!NS7JI:R>X MPEL#MI:JF<=+%'] JBR911C"B])Y0KQ>5JS .W2_5;>&=G&/DG.)RG*MP.!V M%5U,SB]//']@^)WCW@[^7?NRT?K>;S[F]RCQ!J'
S'D$1LL.KU (#T1F?&\Q MHUZE%QS^=^@_!]_)EPVS>*7%-YZ[44@;0728'>C*%AYS1Q;+XW>@_'E%CD:^Q/US&CI#]>9RU*)<-2OH* MR@?XI)4K+=RH''/G\C%9U)N5=F9=I@*
C2>]C2>'T/^VC8=1CD_?P1#I MZ,T\G9PM6CSXJ.!7O4.Y0>-C.QV!*Q&NM*R8>@14#@WFP)73P%0G=,VM,WQ3 MASZZ* PBM:6#8R_J\=-DX;$Z]IXCG$T6[ZBF70FWO"*E=TSE@M8C)JL%*1[!
M<0L1SGI1KK8+R&#32K7-&P"\.K2.;02W9;! ;[V5S+VGH_=.\R"98*D:8(I-_)FDT5<<<>9 "9UW9A95Q[@[2P9)]3&0I!38_A*UKP8 M.)J1!&Z1FHG@RHD"G6.;!?>JQ[H__+-:R.N0 M4<^@J-Y!-
M,&_;0!FA6N<:0;&![,:QG#-V8,4Y35KX/$EZP)Y%8+NI,\\+YC MHVN+"DSE09N&C9923/_65%0O;V@\SP$+IDN_K?UY@%-QBT."!4W+*2](WT> M^-/1*L,S##5@?4B>_.JC,!]-SS[T_&\AG8]/9]
[+^6L"R6AR=M9+]/Q/I/E\ M-)N=_F,?*6U40"7;(6P0E:^V[@< ;;N4\GMH_7"Z:^_J)O7GU?&*FX&2UP"V))N.S602F>4DT&Z>K<'MO MM*.W0/@MZ?&%QC/0^59KUVV\@OXYM_X#4$L#!!0 (+2
:%E2JH!,CP4 M)(- 9 >&PO=V]R:W-H965TO3O2YQOKOOO*^(C[4AM_,2I"J-Y/)CXMJ)1^;"LR6%E;5)(M9G%3J2>S)#F>E%*9T?P\?K=T\W-;!ZT,+9WP=5E*M[TD;3<7H^FH^^*+RHO
M7TSFYY7,Z9;"']72X6W2HV2J)..5-<+1^F*TF+Z_/&+[:/!-T<8/G@5GLK+V M.[]<9Q>CA ,B36E@!(F/.[HBK1D(8?S=8HYZE[QQ-RA?XRY(Y>5]'1E]9\J
M"\7%Z'0D,EK+6H,5YJM8__Q::QG<%C6OM@RW8SWDMEFD]YW_(P MV"':/+%AUFZ8Q;@;1S'#*S+(^;FS&^'8&FC\$%.-NQ&<,ER4V^"PJK OS&^E M)F'78NEL5J=!_(;U\TD
,J]/TA;ELD&9/8'RB[BQ)A1>_&HRRG;W3Q!1']:L M"^MR]BS@+55C<9@94"98(8U8>(\9L:QAC2X24.0\9[#H3N#>/WJQ>ELEIPMEHOX-#U[M Q&'0MRH&\KNQ2=GZ^H
KM)Q;WOSX:]/O3'PT:9:I.0"QHB0[,F+UQQ-:__5 M2>-E;.1^FR,M P+$]M^OOUW?BH]JY936TB$'?.1DQ%*FW\4'NE,I];ZC<8PC_+%@3CF/NOROP'U=5(O0]76/6'1U#4":GZ" B-=P"BG<.*K^K
M3T;YP^ SD,JQ1 MTR.+VRMQ/$W>SI)8^Z82;6]4(#I5E=0QW6B9''..&4&!)<]&-MM-B(DY'1_U M+ PFT*.P=S,,O+ FQUP!,3@<\VUC/)?/PV2.\4.L-C?]'Y:\R'EJ-&4^[N-I M!LHZ'KQLO#TL_Z
\U!D(QS(L+!"9OM$LYH_->#Q5Z+ M[#[1GIVF7,9!I+C2\,8VG#H!O?1*2M"*1L]G &${X47([I&4>?/=C\;'M M[T99[-]PH^U(;%^1^;!K,,0& P=C+J.NZ?;[('(M]%[+)X)Y9!@_
MS96Y_[;_P;%H[MD/YLVO%71"KM!&FM;8FHQ/WH:X[I[";:*M^Z5#;C#QT<^ M$,FQ =;7UH;NA1WT/\F_P)02P,$% @ M(!H605&1T*4"0 @AT !D M !X;"]W;W)K&ULS5EK;]LX%OTKA*<=)
(!JZ^E' M\P":;G=V%IA.D;2=S[1$VYQ*HDM*<;R_?L\E)5F.[;0I!CO[Q1:IR\O[OH?4 MY4;I+V8E1,4>BKPT5X-55:U?CT8F78F"FZ%:BQ)O%DH7O,)0+T=FK07/[*(B M'X6^/QX57):#ZTL[]T%?
7ZJZRF4I/FAFZJ+@>GLCY$]6GJ06,TZKADLA"ED:ID6BRN!F^"US ZZ+6EA_[GE_D^K.W29JOP/ MF56KJ\%TP#*QX'5>W:K-OT2C3T+\4I4;^\LVCC9,!BB3TC>68^&3I_OE# M8X?>@JE_8D'8+
BMW&XC*^4_>,6O+[7:,$W4X$8/5E6[&L+)DIQR5VFV\E5A7 M7=]5*OWRZ@9Z9>RM*N!KP\EL MVB@FOM:RVC)9IJ*D;&'KG)?F-:M &_I!Z+BQ7[OW' ">\3*S%&^0K'"]'=* M4_$* RR;L7>.
[_ZZ(7N/I.4;KC/#4O!19;YE<\&6FI>TM 8W_2.6QF3_QPEG$S(K#H4PM6*J* E8R5N&- MT(+Q>RYS/L\%0RUDB[JJ,2F-J3DV-SUIG7(?FR>0H.3-_T098I5BUEYES7.R M,LJH$5[_]5I+,.?
KM5;WH)EO+^0X+P((6 MY,(@+(GB3)ZS. J]. X;[3S,T>1+>DW$K=U!)2FB4 M-+BR4?-0K9X9R2(RPU*R/E':,"]J7;@Z;ZDU!3CT+"%5)1$+B3T>O8,0E99I MU;UQ@7CD15W*RI!B(VS^D225/A-
V1Y4:QSM15DXIYCR"0* FNV%MK8 MS8]J_VTG#_>2%G)*M"5GD860%(\08\4K)BLF'M989-!.\IRI-*V=;WCV)YJ* ML:]+XT(9G9%"I\)%.O]#8*DR8BJVCLF^" 7BU]*WFML]8/9N;.WU:F[+3Y/J
MD,^Z[E4&X=F"2\T0ZK5;"TV5K0?]4M4*J]'AY@@]==]DVCW9 1'HY&RCU.ZS M+ZACV[JTD>?H'HWF"Y4#KQ#O]D4*:9=*2U<>[#YIZM@360K'JEQFW 4_E"S M*DL+!*7M)C:*[+9:K
C8(&1S90PRAG95M<%[<_[:EBX_NOC;_C^N-'Q7N'[N M2N]^O(6>FJ^LB3+7+TJY5@WR. OX>.JBS]1/LSO4'$[G@NG(4 #[\(Z]B6X 6+@FEOE/B3W0F'V MBWJCP(LF"7M2N+!ZW@0]$DTBK;FM$H^U'?
>8C2=^]QQX4S_NC\8!=1^4.50V MXIN)>Z#:-3EZ1Y:,=\^SL'N.)[OY)$G81U5!.AN.=GIV<20H^TKYTV!?R?&L M;QXOG$1[X\EL1^_:]N^N]O43HRLV>]71YA5S\C2=@(J5+0N"D_*488PQ$256
M>3+&TADOY&6M#YJY\P78)VC??Q)N}!Z%?2:W6ZH M8,@0UPNLB]H73HL(;;+>"\: \E> MB@;#>,I^:7!>F,R\F;_+N %P.F;O&O$)Z*!%?T!^2Y]AM,I>TNH*Q?9J&E; M1!@FB>>/_1UE$ ZCY+&
A_B/9 RGR.^P+Z,_1 :-AT"]GQ'0#?IT;14#M'L; MYZ<8^K.9EXRC1PQC,/2GK7(VKH\S"+QQ$'KA?L[#:@FTATKM)'!O7E/916;N MX;>!H_ROP6>Q,SH*VVU760UC2XRS@F!0?-NM8$@JL6?+[G
M)N-?(5)6IZX^.*@F'E+A=G\6G@ M;OOP$H5H26!"(H(E^FK:(I(/P?T.FX:Z\V='JKY#< 9<"[8:6] MR[&G@617\QV2M"8-AU-6 .1BWF.;E41[DF8O3^>"]421.P%LC^*==U^UWMW! M27L0>[
P&XTM'(9MQ[(=:N=YD-K&V,A'@K7PO&NA-EI Z)*A-FT,\0\!KFZ;CFGZ[8?;XF'N^2#$H?EY%UK MZTS2"0VR;]7(W9(@W#'MZ.X5'"]S.KA/(MCT);N5IH5!"XI*Q+B@@QA!?L'B M83@#4;?
>=B?"S$'T'0I&.#U2XW9WC'/SY9,]QCZ\JZ !/B%WH>[2W]J0"'1 $ M]LZS[&9/G S/FHN&V[M/9G?1\+DYFK1G[#W^1$I1^DR(A14[E/4(8!WL>"A_ MNVOONH%QBOQEL!J"JH.KEBCP[[N(.
DE@72L(W8T(70%O]+>@%,3^2%AW0._? M"1"KIH@5]G8L3DAG3Z_VR&J;*JT*(5L0Z NM"N:))F#P. ^N+G >6\H2&^TN M&"R?IN@.;V6RZ1|H\QDY)Z.KB;GK(8N^J88'
MP=;NH=UEUO98*3PMY0XG?P,?GPBXU@;4S)!?&@Z19(,+OX' LZ27J9K"#

CBW0$CC M3XOI]2ZMX?:Z0 _B8L=8EE3#A>2_66:*F3?R2 8YK;FYE>NOT,:36+Q426MM9-D:(X.2B>9/'JL\;!F,@G<,PM8@=+P;1X[E)35T/E5R390] MC6AVX4)UUDB."5N4A5&XR]#.S,_25-60D:M'++,&3:C(R]3@"(7M5(@#/G. MZ))Q9ACN'MS1)0=],/4-.K<0?MHZ.F\|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`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| M%+8MM3;MO3.X?V"4))^1)7U@69&1'TO(;D%V+O-^W4/7N56UR)9:FVFP8QJ\ M6_2LI6UAM:D6V5)K8]WE*7[OH1W/3O? "PR<&UJ>>IUWIT1AB^BYLG+J-GO M\& \[Y%$^+NDP^ /.KI7,N-OKV2,"<;"JEID2ZW-=)?5^,/W6\DVDY:%5;7(MEEH;ZRX)\M_*@@Y8R2\SC;!C)=M,;B);:A4>=^^*+ .Y+J\:S9D&,[KJTJFI M;:XSS\I+O&?UY_[IHKJ4W,E4=Z1+*M<,,\(45BCI'9_@_,KJVK$J:)&7%W&W M0FN1E8\;H'BB,@WP_4H(_50P#IK+W_G_4$L#!!0 (+2 :%GO0+-S5@0 M (9 9 >&PO=V]R:W-H965T0,T..--3DP/@/L<%8@&]<\HV+J;*3<7KJN2#(_WN-,W:8.M Y=MR3 MJ4;J#G@S[+R*OO#*K&>2$ MEO_HJ7)$@Z!TS 2_(OA=00@,(:@(P4M'"M"^-(1HHI0F.Z6MA>.BY%$JSEP M!\ U6JGIB\+[!5OYDU"J4!:2]M$\>1L42X0P%9@0=:4K$B*J 17:[S'=(=!3 1:KSE>(XF7X&.,)2*9^*00#XL8?/SP"7P A()O M&[83B'[%Q)5]JGI -ZVF=5U.RW]F6@&X8U1N!CHB|-_+B?/^[AN\I%M9_|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|*VRPT\R!NE1=6!3045Y>V;/'4^# !AL@<0=8#H?P%Q!XB= MT+8R)VM*-,E2*;8@;;9ALP/GC4,;-93;75QH:5:IP>ELT>X>B (6=,UI07/" M-5SFN6BXIGP-<|%H3E'!)Y@1*N&>L 9M_HQRPG-*&%QSI65C]E8K.)RB)I2I M(Y- MYC"X<$1' #E|*T4C2)\I5)?F|+MY_V|* *J+3+:5R36)Q `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|$@X!K**Q)ZOY' "Z(>/LO_GAX.T G;8H06+WP&[X5-[-NP&C#J M!S1GP+4J:09S!SJR!?(SN+77_S$>]^G=B2PCO:HU1X-H;^DG+ WH B:?0@--J-K%E8\ZZPR+TTS2-)S/W<+XG M?7%Q'$2GN((["O+; (X%U%">MXF1L M9.6[GIH-ROQ0&4 M88KTM&29&2KK\ZI@NI?Q(.!K2ST26$?[M-4 ^'=OFTS&UCP36T>Y[IJN$]U,9 MO:%S[N#IQ(_"Z871>^+2)Q'9TYQ_^SZV |*?KH%67=_HU+B[:F?Z24:.ZL\ M%EI7=7!2'8QM\@9Q+/TCH77UG^YI N!5Z/^W>?BC?=,X3BY=_E)8+=<]:Q=R MD#O;12EB;_SUW;E=;3NU&]N?7*S?F@[.MB$GF+K]^TSECA6*<-@BI'4';UR[^!5!+ P04 " "T M@&A9: 3!.'$# "^"@ &0 'AL+W=OWIUNL1?RJRH -'FI2JZ67]%U?>/[*BV@HNI:U,#Q M32YD135NY=97M02:6:>J],,@F/@59=Q+%O;9HTP6HM$EX_ HB6]JBLK7.RC% M?NF-O,.#)[8MM'G@)XN:;F$-^DO]*"'GJR@9]X)KCB1D^"]V]'-:A08!VOQ M*X.]:EH3$|&K8*]F\W.V] ++*$\(M8&@^+>+#%92E04(>?W:@7G^F<3Q>']_ MV. QF U5L!+E;RS3Q=*;>22#G#:E2A+[C] %%!N\5)3* I)J9QMX)&V4%E7G MC PJQMM_^M(<>001]]P"#N'\-\Z1)U#9 -MF=FP[JFFR4**/9'&&M',PFIC MO3$:QLTUKK7$MPS]=':*;IK*!C#R\|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|<9)Q/" M>&JZF1^[E]-+L58QX_1>HFR=)$2^7--8;*YZ;N_UP'>V7"ESH#^]3,F2SJCZ MD=Y+_ .M?42*64)XQP9&DBZO>% @FV_J.S% >A?C' .+B-KGJ. MZ1&-Z5P9!-$?3_2&QK$AZ7[\6T)[E4]CN/W]E1[D@]>#>209O1'Q7RQ2]ZO> M60]%=$'6L?HN-G_2SFX?&(XI,+Z78(&E:.YKYDL'FP_:AG.<=_\X['=W*-S;>Z^:1[:S>.("|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a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|_HKHF,RG,L<3SCK$)F)<--=9*'*$Z M*DO)U5^B[&2\E"RYRUB> A?OT<7]AL@']!G=8,XQE0*10 J):4KH>X!XE) M+<[.;*FH-8"=-#2+FL9[AF:*+AF5F4 7(-7TL;VM)+>ZO;WNA3<(N(1RA,;. M)^0YW@2]1382&>8@FF& 8=S>S-PC/_B9OHQ1O$-BGZGVSB*?#^8V=L>1N C(:YSJ)/.OV=[V%L9!X%?F4IN\"[1TGX!N;(,KV#3.\H M.= /$IZQPW#_D1S#]7>'2S4K\[[!O:%B>|>*KL[7-I?DOI @'B:D+46N],N M%,#7IBD2*&$;*NO.H=UM&Z_3NMTX'*[MDO,UX0*E,-*F3JC4,6%UXU0O9"L M-,W'+9,JE3'33#6/P4!]7 %F-PO-$';CL;5!+ P04 " "T@&A9]2OW MO H& !I+@ &0 'AL+W=OTB3CYX.E$/G9<,C#)4DQ/Z8YR>2= M!64!%O*2/0YYS@B.2],T&7],.QFF,.X&\0!GG=L?F,UJ(),(!'4.\2%/,GB]) M0M?G W?PTO I?EP*U3"'F[Q?TW\O@93 /F),KFOP31VJY/I@.4$06N$(]K^@]0!E1T,:<++OVA= M/^L,4%AP0=/:6/8@C;//WZJB=@PD#C=!EYMX+TV&&TQ\&L#?U\/H]I@5#)3 MA5+R$&"!YS-&UXBIIR6:^E&265K+\.-,C?N]8)N+.W$!XG!-$%NF,T*D*! M_I3WT0=TBQG#:D30NX ('"?|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|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

MB&8&UE5KC>(8-UFYTA)7&=KIZ946Z"Z[4BYSR#[*&]B\(;]<&] M^EG0"W@%Y1$)O0,2>$%$U)I*4#VP81.4T,)&G;#REJ5 JK!TQ.'S!10+D% _: MPM +;R[:L2II"A,';Y)",G"FSY_YB?
>J1WS4B(\L>M@EWD2ASNBFYL-&*XW"&5\1JLD"5HQS,Q%+4H)D(FM37&'&%M/4J=MI$@^\.)[MRU: MDD9+TJOE#095_WR.*\+D$6'D^\,@;B<<-(2#7L)K/(GM?(-'?(?^8#@,DW;"
M84,X["4\I3S% IJY6/Z7P#K(ARWD8>Q['>$=->2CIZ0:|+3V)GGT2,8@CD;A MJ%V%[^TJI->K8P[2OG[\3RI"/\=O7AI_K\K[_[DHU + ^LH/!SL'@']2%&G3_ MS 2QYT==9V;W@/C]+\BO79P:Y,'-"
<.DDW[W!/B]-?C)5Z>&>Q 'JXD][R&H&EDIS\ 4$L#!!0 (+2 :%FH M) +,C0, '80 9 >&PO=V]R:W-H965TDD,U># &,[M9FY..F/A|QESDWOH=,'&=9&$Y X2=CI3/ X2D"P M20BM'?IB2T+
[E3YBU]KU?,_%HTP %'K*4B875])4?F7;.DH@(W+$TZ3F!GA#(KG)=C]R*<\T*EE,&]0+*+(,B+^NH:4[Q<6 MMIX'OM!MHLR 'W:C$- ,F*6=(P&9A?<)72QP8@W+&[Q3V M\JB-#,J:\T?
3^35>6([9$:00*2-!]-<.EI"F1DGOXULM:C5K&L/C]K/Z3R6\ MAED3"4N>?J6Q2A;6U$(Q;$B1JB]_PO40&.C%_%4EI]H7\V=>!:*"JEX5AOK M'6245=_DJ3Z((P/LOV'@U@;N2X/Q&P9>;>"5H-
7.2JP;HD@X%WR/A)FMU4RC M/)O26M-09E[C2@G]E&H[%:Z*M81O!3"%;G?F\^(&%*&IO$0_H(?5#;KX<(D^ M(!O)A B0B#+TP*B2' 6@;O^6\|$(2%LNYK?1NC*8=U2LOJY7=-U:>H3O.5"+1
M+8LA;MO;FJ)!<9]1KMU>P<^1&B'7_XAMY_/-F.'5U7"GZW@HG@*YF3"!:6#E$)8@=6^/UW.'!^[,(;2*P%ZS>P?IJZ M^+/@4J)<| B@TQFN> ^U/1:W$@E+,_%#M0C_P?
#RW=QT,XX9AW,OP*A3^N(-L M#>+/+IQ>J5-Q!A)K40<-=?!N-PV&A!U(K 4[:6 G[W3328=G.8[3>%;%T+O* MF0S3AF%ZGINBO]&29YF^&_6M$3UVT?4JG_HB!Q)K'<*L.839N[UV-B3L0&(M
M6.P<+FFG_YW7EZ^4!<1(W[=(\C3N@JZ%QD<.C/U@XKSVX?XEST4ZRCMP+]+G MS08$95L=C30"=*&3B9BG*1$H!U%E&Y>=@)7L] C0';GCEW"]BY\+YQ[@W+-C M]"L1@OS+[=(O?
ZKO#J76/HQ#'H3?GPCA03.AH=3:P(=<"/'M$XB(2D#W MAJ^3)'A-XHSTB\(O20;-;^RCRBX#L2T+7HDB7C!5%7G-:%-4?RI+2?LPO:K(M[XC84B91"AMMZHPF^LA%5>16'<7SLDY<CP# #R$P
#0 'AL+W-T>6QED6O#Q"] MZG1P80 Q\?@P\7W:F/3-MG0] -P*.>(Y1NM[:#;+F@D=C)PJ1B2,15\HCFP,EIPL73A'@2F2B@=&%MSUE 7(M4O M!W==#\JQT2FX5+K.[3*X[TDS? =8]<
@%Z(UV",N,!J4U!BFY9WMU/(KX LH M:-J/R](ZS#5==GO79$VH;S;)1.F4Z39-EZQ"HX%@&=C1/) !W:@R!- 85=A& MRFFN)*T]K!A-P\I.F1 /*Q^S[:T%]G&SG9@7V7;M(::II-Q'=#?5'/:F[+1
MJW2#DC\K\VENIR/K/I0+N]G92F6'P7/9<',W&27'[[$Y MW!V=R; Y9&R<9+;.,6TT@//BD'R#\ZE8)PTFG+*-S81Y,<$C6[:\LY?,B:4?=PT(TH];M+S"];MP>5FTN+E.V8.FX
MZ>I\4C<#V[!9FPL(N\A=??D1C.,P/P(8E@=S@'$<"\OS/\VGC\['89BWOA?I MHYP^RG$L'S*N/U@>/R>QEW^F21)%<8RMZ'CL=3#&UBV.X<>OAGD#!I8',OW9 M6N.[C5?(_CK]G1?A6
SQ2L1FRF^UH#XUPT82>+?;2P/,+!=P&H'\OOS0$WY M.5$$NXIYPYY@'$D2#(%:]-=H'".K$\/'OS_84Q)%2>)' /,[B"(,@:<11S ' MX %#HJA^#^ZC\\+5>RI<_Y=O]!M02P,$% @ M(!H69>*NQS $P(
M L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=..B':5_ 'K8Q78ZQJ_G.:'"9>L3%Y-
+6SN)|^75>=JS\N;> MV,W"F WY42OM)MG:^^WY<.BJM:B9>V&V0L.6I;$U\]"TJZ';6L&X6POA:S4L M1J/QL&929V_?[,>:VV'<,%Y47AH-G:'CBQ3WTL_VT"0[Z>1'*ND?)EG[6XF, MU%++6OX4?)*-
,N+6YOZCL?*GT9ZILK)&J4F6=QN^".ME]:B[#)!W;.':'L\6 MMPQ)MEX! ,NI76^W:,=GP'C3L#.7:OQYKU47M@9|^*#-76942S6DRR_2Z$:4XNM8<@ MD2O=#07[ABN%4U_Q[JH]X$8QM.<2-
M@KWH*G@YQ"VRC)X>R<7##%="5(&UP7 M 18(8-$;(#F9LPB2(I#T/T*6 2(] M04Z96T>08P1RG!;R@E6;%:06S2.>EPC/R{0\M|)M7)MFKN7W1G+(-!'8*P3L
M55JPLJEK9A_:*2976L)A#!+BNZJ"X'D90;Y&(%^GA00:V\!LN_P!GC1!?+& MKX4ET\;&-V\^PA+U*"WFM=&K 7BM)C.Q\#$5JH_$_@B98[,VB@OKGI%+F'T' M;@XM8C9,&'EB8[1Q&UPP!Q-
O:NHP|QY5!9@K M\L2R*)N%$]^;4+Y<[N SYL+TD"?VPYP]D)TCRF!%31I[8&6AJ_E;$F)A \CX-\HW&F)A" M\CX=Q[C83(I>I#)DY#H>B2U58YD[M^@,28FF'*Q
M8)ZH"O7#D@)0S*FZZD5";&Q,Q3)#;/(\Q/DD_9EMR%KNL8 MDV+FH8G-\V1J'Y!YLU"R(F6,B1F(JF&@ ?G*0@5W4+Q1S$&TAY4-8'X.F%[N M8DST]5A/BYS?]#$F9B&:VD+',4..BC$Q"]'4%CJ. ^=?
S.XI9B*:VT'',KT*N M8DS,0C3U^N&PO7W)E;',O=V]R:VJO;VLN>&UL+G)E;'- MV,MNPC 0A>%707D G)GA6@&K;MA6O$ $YB)R4^R]\/-8 $'==$-\EE%MI7)
MO_H4>?'ERR*>FCH<3VT87*JR#LOL&&/[X5S8'GU5A&'3^KH_V3==5<1^V1U< M6VS/Q<${S?.)ZYYG9*O%|\S!YMKZ_TQL]OO3UG\VV^_*U_&/P>ZGZ<[AZ'W,_M!INB._BXS-RE?
&P"=WO(L)^<#=:[9=:M=Y*YU$$*09H^R"#(T@>-(&B4/F@, M0>/T01,(FJ0/FD+0-'W0#()FZ8/F$#1/'R0YRI@3)+U@3:"U(-="X+4@V$(@ MMB#90F"V(-I"H+8@VT+@MB#<0B"W(-U"8+
<@WD*@MZ+>2]"WHMY*H+>^ &P3 MZ*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AMJ+<1
MZ&VHMQ'H;2^7)01Z& ^IM!'H;ZFT$>AOJ;01Z& ^IM!'H;ZFT$>AOJ;>_4.\1K MZ<.CY[[&V\A W4AW[=_WC\[?E?1-Q'MUP=G!9O_H%4$L#!!0 (+2 :%G_ M>6J2GP$!T8 3 6T-O;G1E;G1?5'EP97-
=+GAM;,V9S6Z#,!"$7P5Q MC8)CNTU_E.32]MKFT!=P80DH@"W;29.WKR$_4JL4)4JES@4+O#LS>*7O)/W MK2$7;>JJ<=.X\-X\,N;2@FKE$FVH'3NYMK7RX=8NF%'I4BV(B=%HS%+=>&K|
MT+<:\6SR3+E:53YZV83'KM3--+94N3AZVA6V7M-8&5.5J?)AGZV;[(?+<.^0 MA,ZNQA6E<8-0$+.3#NW.[P;[OK&UL4$L! A0#% @ M(!H6=I&:[/E!!0 X1| !@ M ("!#@@ 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0# M% @ M(!H6<$Z,"ZY!@ .R(!@ ("!9A< 'AL+W=O M !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ M(!H6?4ZT$?B M P K0@ !@ ("!HC 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ M(!H6>9L/?0' P UP< !D M ("!DTL 'AL+W=ODC<"$' # $@ &0 @('13@ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ M(!H65*J@$R/!0 D@T !D ("!15H 'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(!H M6989D"]% @ PP< !D ("!E&T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M(!H6>P,1DB&PO=V]R:W-H965T&UL4$L! A0#% @
M(!H60?)F"YK @ P8 !D M ("! HX 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ M(!H6>] LW-6! @!D !D ("!09H 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M(!H66@$ MP3AQ P
O@H !D ("!,:4 'AL+W=O$" \"P &0 M @('9J >&PO=V]R:W-H965T&UL4$L! A0#% @ M(!H6=K^)_7: P U1(!D M ("!NK('AL+W=O<" ":"@ &0 @('+M@ >&PO M=V]R:W-H965T\"@8 M &DN 9 "
@>FY !X;"]W;W)K&UL4$L! A0#% @ M(!H681"<:.2!0 HAD !D ("! M*L 'AL+W=O&PO=V]R:W-H965T[) !X;"]W;W)K&UL4$L! A0#% M @ M(!H607.Y:EG @ U04 !D ("!.,X 'AL+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ M(!H64[)47H\ M P \A, T (!#=@ 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ M(!H64"[PRV' 0 MO!< !H (!0. 'AL+U]R96QS+W=O XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 136 229 1 false 38 0 false 5 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.telabio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Consolidated Balance Sheets Sheet http://www.telabio.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 995200300 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 995200400 - Statement - Consolidated Statements of Cash Flows Sheet http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - Background Sheet http://www.telabio.com/role/DisclosureBackground Background Notes 7 false false R8.htm 995210201 - Disclosure - Risks and Liquidity Sheet http://www.telabio.com/role/DisclosureRisksAndLiquidity Risks and Liquidity Notes 8 false false R9.htm 995210301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995210401 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 10 false false R11.htm 995210501 - Disclosure - Long-term Debt Sheet http://www.telabio.com/role/DisclosureLongTermDebt Long-term Debt Notes 11 false false R12.htm 995210601 - Disclosure - Stockholders' Equity Sheet http://www.telabio.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 995210701 - Disclosure - Sale of Product Line Sheet http://www.telabio.com/role/DisclosureSaleOfProductLine Sale of Product Line Notes 13 false false R14.htm 995210801 - Disclosure - Stock-Based Compensation Sheet http://www.telabio.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 995210901 - Disclosure - Subsequent Event Sheet http://www.telabio.com/role/DisclosureSubsequentEvent Subsequent Event Notes 15 false false R16.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 16 false false R17.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 17 false false R18.htm 99920302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 99930303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 19 false false R20.htm 99930403 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 20 false false R21.htm 99930503 - Disclosure - Long-term Debt (Tables) Sheet http://www.telabio.com/role/DisclosureLongTermDebtTables Long-term Debt (Tables) Tables http://www.telabio.com/role/DisclosureLongTermDebt 21 false false R22.htm 99930603 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.telabio.com/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.telabio.com/role/DisclosureStockholdersEquity 22 false false R23.htm 99930803 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.telabio.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.telabio.com/role/DisclosureStockBasedCompensation 23 false false R24.htm 99940201 - Disclosure - Risks and Liquidity (Details) Sheet http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails Risks and Liquidity (Details) Details http://www.telabio.com/role/DisclosureRisksAndLiquidity 24 false false R25.htm 99940301 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details) Sheet http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails Summary of Significant Accounting Policies - Revenue Disaggregated (Details) Details 25 false false R26.htm 99940302 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) Sheet http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) Details 26 false false R27.htm 99940303 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Common Share (Potentially dilutive securities) (Details) Sheet http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails Summary of Significant Accounting Policies - Net Loss per Common Share (Potentially dilutive securities) (Details) Details 27 false false R28.htm 99940401 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 28 false false R29.htm 99940501 - Disclosure - Long-term Debt - Schedule of long term debt (Details) Sheet http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails Long-term Debt - Schedule of long term debt (Details) Details 29 false false R30.htm 99940502 - Disclosure - Long-term Debt - MidCap Term Loan (Details) Sheet http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails Long-term Debt - MidCap Term Loan (Details) Details 30 false false R31.htm 99940601 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details) Sheet http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails Stockholders' Equity - Public Stock Offerings (Details) Details 31 false false R32.htm 99940602 - Disclosure - Stockholders' Equity - Warrants outstanding (Details) Sheet http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails Stockholders' Equity - Warrants outstanding (Details) Details 32 false false R33.htm 99940701 - Disclosure - Sale of Product Line - Narrative (Details) Sheet http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails Sale of Product Line - Narrative (Details) Details 33 false false R34.htm 99940801 - Disclosure - Stock-Based Compensation - Narratives (Details) Sheet http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails Stock-Based Compensation - Narratives (Details) Details 34 false false R35.htm 99940802 - Disclosure - Stock-Based Compensation - Expenses (Details) Sheet http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails Stock-Based Compensation - Expenses (Details) Details 35 false false R36.htm 99940803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 36 false false R37.htm 99940804 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details) Sheet http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails Stock-Based Compensation - Weighted average assumptions (Details) Details 37 false false R38.htm 99940805 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) Sheet http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-Based Compensation - Restricted Stock Units (Details) Details 38 false false R39.htm 99940901 - Disclosure - Subsequent Event (Details) Sheet http://www.telabio.com/role/DisclosureSubsequentEventDetails Subsequent Event (Details) Details http://www.telabio.com/role/DisclosureSubsequentEvent 39 false false All Reports Book All Reports tela-20240930.xsd tela-20240930_cal.xml tela-20240930_def.xml tela-20240930_lab.xml tela-20240930_pre.xml tela-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tela-20240930x10q.htm": { "nsprefix": "tela", "nsuri": "http://www.telabio.com/20240930", "dts": { "schema": { "local": ["tela-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-

2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["tela-20240930_cal.xml"] }, "definitionLink": { "local": ["tela-20240930_def.xml"] }, "labelLink": { "local": ["tela-20240930_lab.xml"] }, "presentationLink": { "local": ["tela-20240930_pre.xml"] }, "inline": { "local": ["tela-20240930x10q.htm"] } }, "keyStandard": 201, "keyCustom": 28, "axisStandard": 20, "axisCustom": 0, "memberStandard": 19, "memberCustom": 17, "hidden": { "total": 16, "http://xbrl.sec.gov/dei/2024": 5, "http://www.telabio.com/20240930": 2, "http://fasb.org/us-gaap/2024": 9 }, "contextCount": 136, "entityCount": 1, "segmentCount": 38, "elementCount": 461, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 466, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.telabio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.telabio.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtIToBe_M8dA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtIToBe_M8dA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtIToBe_M8dA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtIToBe_M8dA", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gKxQ89wMEUeXQzwZJzFzLA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gKxQ89wMEUeXQzwZJzFzLA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.telabio.com/role/DisclosureBackground", "longName": "995210101 - Disclosure - Background", "shortName": "Background", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.telabio.com/role/DisclosureRisksAndLiquidity", "longName": "995210201 - Disclosure - Risks and Liquidity", "shortName": "Risks and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210301 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995210401 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.telabio.com/role/DisclosureLongTermDebt", "longName": "995210501 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.telabio.com/role/DisclosureStockholdersEquity", "longName": "995210601 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.telabio.com/role/DisclosureSaleOfProductLine", "longName": "995210701 - Disclosure - Sale of Product Line", "shortName": "Sale of Product Line", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensation", "longName": "995210801 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.telabio.com/role/DisclosureSubsequentEvent", "longName": "995210901 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920302 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "tela:InterimFinancialStatementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "tela:InterimFinancialStatementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930303 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930403 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables",

```
"menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.telabio.com/role/DisclosureLongTermDebtTables", "longName": "99930503 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.telabio.com/role/DisclosureStockholdersEquityTables", "longName": "99930603 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationTables", "longName": "99930803 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "longName": "99940201 - Disclosure - Risks and Liquidity (Details)", "shortName": "Risks and Liquidity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_tela_MimedxGroupIncMember_4g6d1lCOU0-KKfE4WTAIeg", "name": "tela:PeriodOfNetSalesConsideredForCalculatingAdditionalFuturePaymentReceivableOnSaleOfDistributionRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "unique": true } }, "R25": { "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails", "longName": "99940301 - Disclosure - Summary of Significant Accounting Policies - Revenue Disaggregated (Details)", "shortName": "Summary of Significant Accounting Policies - Revenue Disaggregated (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "tela:IncrementalCostsOfObtainingContract", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "unique": true } }, "R26": { "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails", "longName": "99940302 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details)", "shortName": "Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_5IGcXaPNJkSEU2OOySyXnA", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_5IGcXaPNJkSEU2OOySyXnA", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails", "longName": "99940303 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Common Share (Potentially dilutive securities) (Details)", "shortName": "Summary of Significant Accounting Policies - Net Loss per Common Share (Potentially dilutive securities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "99940401 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails", "longName": "99940501 - Disclosure - Long-term Debt - Schedule of long term debt (Details)", "shortName": "Long-term Debt - Schedule of long term debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:DebtInstrumentUnamortizedPremium", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:DebtInstrumentUnamortizedPremium", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "longName": "99940502 - Disclosure - Long-term Debt - MidCap Term Loan (Details)", "shortName": "Long-term Debt - MidCap Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_uSSprsjSKkSwpch2G-iGCQ", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_LongtermDebtTypeAxis_tela_MidcapTermLoansMember_NIrJV9GXrEy-Qrqk9TjYYw", "name": "tela:InterestPenaltyPercentage", "unitRef": "Unit_Standard_pure_svK7baFwHUumvgxXfATAcA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails", "longName": "99940601 - Disclosure - Stockholders' Equity - Public Stock Offerings (Details)", "shortName": "Stockholders' Equity - Public Stock Offerings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "tela:ClassOfWarrantOrRightGranted", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "tela:ClassOfWarrantOrRightGranted", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails", "longName": "99940602 - Disclosure - Stockholders' Equity - Warrants outstanding (Details)", "shortName": "Stockholders' Equity - Warrants outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "longName": "99940701 - Disclosure - Sale of Product Line - Narrative (Details)", "shortName": "Sale of Product Line - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_tela_MimedxGroupIncMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_tela_DisposalGroupTransactionMember_S1tQEWt01UOUEMyejpFDhg", "name": "tela:DisposalGroupFutureRevenueSharingPaymentsIncreaseDecreaseInVariableConsideration", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "tela:DisposalGroupFutureRevenueSharingPaymentsIncreaseDecreaseInVariableConsideration", "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "unique": true } }, "R34": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "longName": "99940801 - Disclosure - Stock-Based Compensation - Narratives (Details)", "shortName": "Stock-Based Compensation - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "tela:EquityIncentivePlansNumber", "unitRef": "Unit_Standard_item_YdzX-NeJcUa9j3McK7jprg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_L8PNCCmVSUOtITo Be_M8dA", "name": "tela:EquityIncentivePlansNumber", "unitRef": "Unit_Standard_item_YdzX-NeJcUa9j3McK7jprg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails", "longName": "99940802 - Disclosure - Stock-Based Compensation - Expenses (Details)", "shortName":
```

"Stock-Based Compensation - Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_SDZRWnRZ5E2JHxGBopIelg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "longName": "99940803 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_12_31_2023_2uGT3RByI0eBGDutUy51Ig", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_2uGT3RByI0eBGDutUy51Ig", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails", "longName": "99940804 - Disclosure - Stock-Based Compensation - Weighted average assumptions (Details)", "shortName": "Stock-Based Compensation - Weighted average assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Unit_Standard_pure_svK7baFwHUumvgxXfATAcA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dRSjlqgTn0KAxQQWdzNExg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Unit_Standard_pure_svK7baFwHUumvgxXfATAcA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "longName": "99940805 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)", "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_tela_ServiceBasedRestrictedStockUnitsMember_zpGNa70ORkOv8UIaEVHxFw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_tela_ServiceBasedRestrictedStockUnitsMember_zpGNa70ORkOv8UIaEVHxFw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_xQ0wqZBnAkWxQToHmD3i-Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.telabio.com/role/DisclosureSubsequentEventDetails", "longName": "99940901 - Disclosure - Subsequent Event (Details)", "shortName": "Subsequent Event (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_RHqSSwutz0e4iC_7WQ13dQ", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_24_2024_To_10_24_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WwSqkN6Sg0-QHNqMoIxOCQ", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "Unit_Standard_USD__3o4EoIkgEi5D9tcbuXUiA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tela-20240930x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r344"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r58", "r662"] }, "tela_AccruedExpensesAmountDueToContractManufacturer": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "AccruedExpensesAmountDueToContractManufacturer", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to contract manufacturer due.", "label": "Accrued Expenses, Amount Due To Contract Manufacturer", "terseLabel": "Amounts due to contract manufacturer" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses and other current liabilities", "verboseLabel": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r60"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Third-party and professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r60"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r22", "r23", "r74", "r128", "r485", "r504", "r505"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r12", "r23", "r363", "r366", "r407", "r500", "r501", "r788", "r789", "r790", "r799", "r800", "r801", "r803"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r723"] }, "tela_AdditionalExtensionForInterestOnlyPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "AdditionalExtensionForInterestOnlyPaymentPeriod", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Additional extension for interest only payment period.", "label": "Additional Extension for Interest Only Payment Period", "terseLabel": "Extension for interest only payment period" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r69", "r662", "r910"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r516", "r799", "r800", "r801", "r803", "r854", "r911"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r736"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r736"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r736"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r736"] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Shares withheld for employee taxes", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r43", "r44", "r309"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r769"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r695", "r705", "r715", "r747"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel":

```
"Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r698", "r708", "r718", "r750" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r770" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r736" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r743" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r699", "r709", "r719", "r743", "r751", "r755", "r763" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r761" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r337", "r342" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, Allowance", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r129", "r196", "r230" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r80", "r274", "r794", "r868" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities excluded from computation of diluted weighted average shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r177" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Potentially dilutive securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r29" ] }, "tela_ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for vesting of Restricted Stock Units and Exercise of Stock Options under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Vesting of Restricted Stock Units and Exercise of Stock Options", "terseLabel": "Vesting of restricted stock units and exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r102", "r109", "r123", "r150", "r180", "r184", "r189", "r190", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r356", "r360", "r386", "r482", "r552", "r624", "r625", "r662", "r686", "r822", "r823", "r870" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r119", "r131", "r150", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r356", "r360", "r386", "r662", "r822", "r823", "r870" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r754" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r754" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r757" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r756" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r755" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r755" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment in accounts payable and accrued expenses and other current liabilities", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r25", "r121", "r615" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r856", "r857" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r25", "r84", "r147" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r84" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r734" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of
```

Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r731"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r729"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r115", "r125", "r126", "r127", "r150", "r171", "r172", "r174", "r176", "r182", "r183", "r227", "r250", "r252", "r253", "r254", "r257", "r258", "r280", "r281", "r284", "r287", "r294", "r386", "r510", "r511", "r512", "r513", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r540", "r561", "r580", "r594", "r595", "r596", "r597", "r598", "r774", "r796", "r804"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r39"] }, "tela_ClassOfWarrantOrRightCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ClassOfWarrantOrRightCancelled", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants cancelled.", "label": "Class of Warrant or Right, Cancelled", "terseLabel": "Number of share cancelled" } } }, "auth_ref": [] }, "tela_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire": { "xbrltype": "gYearItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Date from which Warrants or Rights Expire", "label": "Class of Warrant or Right, Date from which Warrants or Rights Expire", "terseLabel": "Expiration dates" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails", "http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price", "verboseLabel": "Exercise Price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r295"] }, "tela_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants exercised.", "label": "Class of Warrant or Right, Exercised", "terseLabel": "Number of share exercised" } } }, "auth_ref": [] }, "tela_ClassOfWarrantOrRightGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ClassOfWarrantOrRightGranted", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants granted.", "label": "Class of Warrant or Right, Granted", "terseLabel": "Number of warrants granted" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r735"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r735"] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Common stock", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r911"] }, "tela_CommonStockAvailableUnderAtm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "CommonStockAvailableUnderAtm", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of shares that can be sold under the at-the-market programs.", "label": "Common Stock Available Under ATM" } } }, "auth_ref": [] }, "tela_CommonStockCapitalSharesReservedForFutureAnnualIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "CommonStockCapitalSharesReservedForFutureAnnualIssuance", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "documentation": "Common Stock Capital Shares Reserved For Future Annual Issuance", "label": "Common Stock Capital Shares Reserved For Future Annual Issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r68"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r676", "r677", "r678", "r680", "r681", "r682", "r683", "r799", "r800", "r803", "r854", "r909", "r911"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, Par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r68"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r68", "r540"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r68"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r13", "r68", "r540", "r558", "r911", "r912"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.001 par value: 200,000,000 shares authorized; 24,717,193 and 24,494,675 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r68", "r484", "r662"] }, "tela_CommonStockWarrantsExpiringIn2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "CommonStockWarrantsExpiringIn2027Member", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock warrants expiring in 2027.", "label": "Common stock warrants expiring in 2027" } } }, "auth_ref": [] }, "tela_CommonStockWarrantsExpiringIn2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "CommonStockWarrantsExpiringIn2028Member", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock warrants expiring in 2028.", "label": "Common stock warrants expiring in 2028" } } }, "auth_ref": [] }, "tela_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "CommonStockWarrantsMember", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common stock warrants.", "label": "Common Stock Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r740"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r739"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r741"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r738"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r24", "r133", "r135", "r139", "r476", "r493", "r494"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidity"], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Risks and Liquidity", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": ["r88"] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of revenue (excluding amortization of intangible assets)", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": ["r777", "r778"] }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldAmortization", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Cost, Amortization", "terseLabel": "Amortization of intangible assets", "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service." } } }, "auth_ref": ["r791"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r151", "r152", "r262", "r282", "r408", "r428", "r481", "r617", "r619"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable Interest Rate (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "MidCap term loan", "verboseLabel": "Debt amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r259", "r399", "r400", "r629", "r630", "r661"] }, "tela_DebtInstrumentInterestPaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "DebtInstrumentInterestPaymentTerm", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "The Interest-Only Period of debt instrument interest payment.", "label": "Debt Instrument Interest Payment Term", "terseLabel": "Interest-Only Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest Rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r62", "r260"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Long term Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r153", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r628", "r629", "r630", "r631", "r632", "r661", "r797", "r867", "r869"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r19", "r37", "r38", "r45", "r95", "r96", "r153", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r628", "r629", "r630", "r631", "r632", "r661", "r797", "r867", "r869"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized end of term charge and issuance costs", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r265", "r276", "r398", "r399", "r400", "r629", "r630", "r661"] }, "us-gaap_DebtInstrumentUnamortizedPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedPremium", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Premium", "terseLabel": "End of term charge", "documentation": "Amount, after accumulated amortization, of debt premium." } } }, "auth_ref": ["r825", "r866", "r867", "r869"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r480"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r7", "r34"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r298", "r634", "r635", "r636", "r637", "r638", "r639", "r640"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r298", "r634", "r635", "r636", "r637", "r638", "r639", "r640"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r826"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r308", "r310", "r338", "r339", "r341", "r647"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Sale of Product Line" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r117"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": ["r8", "r17"] }, "tela_DisposalGroupFutureRevenueSharingPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "DisposalGroupFutureRevenueSharingPayments", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The future revenue-sharing payments based on the net sales of NIVIS during the first two years following its launch by MDXG.", "label": "Disposal Group, Future Revenue Sharing Payments", "terseLabel": "Revenue sharing payments" } } }, "auth_ref": [] }, "tela_DisposalGroupFutureRevenueSharingPaymentsIncreaseDecreaseInVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "DisposalGroupFutureRevenueSharingPaymentsIncreaseDecreaseInVariableConsideration", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in the variable consideration during the period.", "label": "Disposal Group Future Revenue Sharing Payments, Increase (Decrease) in Variable Consideration", "terseLabel": "Variable Consideration" } } }, "auth_ref": [] }, "tela_DisposalGroupFutureRevenueSharingPaymentsVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "DisposalGroupFutureRevenueSharingPaymentsVariableConsideration", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Any consideration in excess consideration is considered variable consideration that is fully constrained.", "label": "Disposal Group, Future Revenue Sharing Payments, Variable Consideration", "terseLabel": "Variable consideration" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": ["r3", "r8", "r17"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration determined", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Carrying value", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r48", "r54", "r91"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Net carrying value", "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r48", "r54", "r91"] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedLabel": "Gain on sale of product line", "terseLabel": "Gain on sale of product line", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": ["r242", "r794", "r817"] }, "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationsMember", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Not Discontinued Operations [Member]", "documentation": "Disposal group that is not classified as discontinued operations." } } }, "auth_ref": [] }, "tela_DisposalGroupTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "DisposalGroupTransactionMember", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Asset Purchase Agreement (\"APA\") with MiMedx Group, Inc. (\"MDXG\") to sell certain assets (the \"Transaction\") related to NIVIS Fibrillar Collagen Pack Device (\"NIVIS\").", "label": "Disposal Group, Transaction [Member]", "terseLabel": "Transaction" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLine"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Sale of Product Line", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r47", "r90"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r644", "r645"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r690"] }, "dei_DocumentTransitionReport": { "xbrltype":

```
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r722" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r733" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r140", "r159", "r160", "r161", "r162", "r163", "r164", "r169", "r171", "r174", "r175", "r176", "r179", "r351", "r354", "r371", "r372", "r477", "r495", "r621" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r140", "r159", "r160", "r161", "r162", "r163", "r164", "r171", "r174", "r175", "r176", "r179", "r351", "r354", "r371", "r372", "r477", "r495", "r621" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Common Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r29", "r30", "r178" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r865" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and related benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r60" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r340" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period for recognition of unrecognized expenses", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r340" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r688" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r688" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r773" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r688" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r772" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r688" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r688" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r688" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.telabio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r688" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r727" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r768" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r768" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r768" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r116", "r136", "r137", "r138", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r181", "r228", "r229", "r241", "r296", "r346", "r347", "r348", "r349", "r350", "r352",
```

```
"r353", "r354", "r362", "r363", "r364", "r365", "r366", "r367", "r370", "r391", "r392", "r393", "r394", "r395", "r396", "r401", "r402", "r407", "r491", "r500", "r501", "r502", "r516", "r580" ] },
"tela_EquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "EquityDistributionAgreementMember", "presentation":
[ "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Equity Distribution Agreement [Member]", "label":
"Equity Distribution Agreement" } } }, "auth_ref": [] }, "tela_EquityIncentivePlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname":
"EquityIncentivePlan2019Member", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This
member stands for 2019 Equity Incentive Plan.", "label": "2019 Equity Incentive Plan" } } }, "auth_ref": [] }, "tela_EquityIncentivePlansNumber": { "xbrltype": "integerItemType", "nsuri":
"http://www.telabio.com/20240930", "localname": "EquityIncentivePlansNumber", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang":
{ "en-us": { "role": { "documentation": "Represents about number of equity incentive plans.", "label": "Equity Incentive Plans, Number", "terseLabel": "Number of equity incentive plans" } } },
"auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption
Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r737" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r695", "r705", "r715", "r747" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded
Compensation Recovery" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" }
} }, "auth_ref": [ "r743" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and
Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Line items represent financial concepts included in
a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r374", "r375", "r382",
"r651" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and
Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r374", "r375",
"r382", "r651" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table
Text Block]", "terseLabel": "Schedule of fair value of assets and liabilities measured on recurring basis", "documentation": "Tabular disclosure of financial instrument measured at fair value on
recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r651", "r856", "r857", "r862" ] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation":
[ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and
NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r267", "r300",
"r301", "r302", "r303", "r304", "r305", "r373", "r375", "r376", "r377", "r378", "r381", "r382", "r384", "r415", "r416", "r417", "r629", "r630", "r641", "r642", "r643", "r651", "r654" ] }, "us-
gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency
[Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r374", "r375", "r376", "r378", "r651", "r859", "r863" ] }, "us-gaap_FairValueInputsLevel1Member": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1
[Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r267", "r300",
"r305", "r375", "r382", "r415", "r641", "r642", "r643", "r651" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency
[Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r374", "r375", "r376", "r378", "r651", "r859", "r863" ] }, "us-
gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV
[Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r267", "r300", "r301", "r302", "r303", "r304", "r305",
"r373", "r375", "r376", "r377", "r378", "r381", "r382", "r384", "r415", "r416", "r417", "r629", "r630", "r641", "r642", "r643", "r651", "r654" ] }, "us-
gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember",
"presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value,
Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured
at fair value." } } }, "auth_ref": [ "r651", "r856", "r857", "r858", "r859", "r860", "r863" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
"terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r10" ] }, "us-
gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]",
"documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210",
"r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r275",
"r292", "r368", "r385", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r435",
"r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r492", "r627", "r651", "r652", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r663", "r779", "r780", "r781", "r782", "r783",
"r784", "r785", "r810", "r811", "r812", "r813", "r855", "r858", "r859", "r860", "r861", "r863" ] }, "tela_FirstYearMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.telabio.com/20240930", "localname": "FirstYearMember", "presentation": [ "http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails" ], "lang": { "en-us": {
"role": { "documentation": "Represents the information first year of term loan.", "label": "First Year [Member]", "terseLabel": "First year" } } }, "auth_ref": [] }, "us-
gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Gain (Loss), Foreign Currency Transaction, before Tax", "negatedTerseLabel": "Foreign currency transaction gain (loss)", "documentation": "Amount, before tax, of realized and
unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r577" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery
due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r699", "r709", "r719", "r751" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to
Expense of Enforcement, Amount" } } }, "auth_ref": [ "r699", "r709", "r719", "r751" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } },
"auth_ref": [ "r699", "r709", "r719", "r751" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r699", "r709", "r719", "r751" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r699", "r709", "r719",
"r751" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior
Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of
Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r732" ] }, "us-gaap_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense",
"terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity,
which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r78", "r563" ] }, "us-
gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember",
"presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]",
"documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r78" ] }, "us-gaap_GrossProfit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [
"http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit",
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r75", "r76", "r108",
"r150", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r386", "r623", "r624", "r805", "r806", "r807", "r808", "r809", "r822" ] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label":
"Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [
"http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of
disposal group." } } }, "auth_ref": [ "r644", "r645" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [
"http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal
Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [
"http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]",
"documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other
than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r11", "r17", "r21", "r48", "r49", "r50", "r51", "r52", "r53", "r55", "r56", "r57", "r92" ] }, "us-
gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation":
"Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r243", "r244", "r245", "r379", "r380", "r383", "r497", "r499", "r564",
"r612", "r653", "r881" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementLocationDomain", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Statement of
Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r244", "r245", "r379", "r380",
```

"r383", "r497", "r499", "r564", "r612", "r653", "r881"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current and long-term liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r793"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"] }, "tela_IncrementalCostsOfObtainingContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "IncrementalCostsOfObtainingContract", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "documentation": "Represents incremental costs incurred in obtaining a contract.", "label": "Incremental Costs Of Obtaining A Contract", "terseLabel": "Incremental costs of obtaining a contract" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r699", "r709", "r719", "r743", "r751", "r755", "r763"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r761"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r691", "r767"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r691", "r767"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r691", "r767"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r240", "r815", "r816"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expenses", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r80", "r272", "r278", "r631", "r632"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r187", "r792"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r142", "r145", "r146"] }, "tela_InterestPenaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "InterestPenaltyPercentage", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of penalty to be paid on the event of default in meeting the obligation.", "label": "Interest Penalty, Percentage", "terseLabel": "Interest due to unpaid obligation" } } }, "auth_ref": [] }, "tela_InterimFinancialStatementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "InterimFinancialStatementsPolicyPolicyTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the preparation of interim financial statements in conformity with generally accepted accounting principles.", "label": "Interim Financial Statements Policy [Policy Text Block]", "terseLabel": "Interim Financial Statements" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r130", "r616", "r662"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Inventory excess and obsolescence charge", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r239"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r19", "r59", "r60", "r61", "r63", "r64", "r65", "r66", "r150", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r357", "r360", "r361", "r386", "r539", "r622", "r686", "r822", "r870", "r871"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' (deficit) equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r73", "r104", "r487", "r662", "r798", "r814", "r864"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and stockholders' (deficit) equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r61", "r120", "r150", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r357", "r360", "r361", "r386", "r662", "r822", "r870", "r871"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r19", "r103", "r266", "r277", "r629", "r630", "r661", "r879"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r124"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebt"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r93"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r19", "r818", "r819", "r820"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r19", "r35", "r818", "r819", "r820"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r194", "r636", "r672", "r675", "r826", "r880", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r306", "r343", "r378", "r444", "r496", "r498", "r506", "r531", "r532", "r585", "r587", "r589", "r590", "r592", "r610", "r611", "r626", "r633", "r646", "r654", "r655", "r659", "r660", "r673", "r824", "r872", "r873", "r874", "r875", "r876", "r877"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r735"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r735"] }, "tela_MidcapTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "MidcapTermLoansMember", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureLongTermDebtScheduleOfLongTermDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to MidCap Term loans.", "label": "MidCap term loan" } } }, "auth_ref": [] }, "tela_MimedxGroupIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "MimedxGroupIncMember", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to MiMedx Group, Inc.", "label": "MiMedx Group, Inc [Member]", "terseLabel": "MiMedx Group, Inc." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r306", "r343", "r378", "r444", "r496", "r498", "r506", "r531", "r532", "r585", "r587", "r589", "r590", "r592", "r610", "r611", "r626", "r633", "r646", "r654", "r655", "r659", "r673", "r824", "r872", "r873", "r874", "r875", "r876", "r877"] }, "tela_MinimumRevenueSharePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "MinimumRevenueSharePaymentsReceivable", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of minimum revenue share payments receivable.", "label": "Minimum Revenue Share Payments Receivable", "terseLabel": "Amount minimum revenue share payments receivable" } } }, "auth_ref": [] }, "tela_MinimumRevenueSharePaymentsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930",

```
"localname": "MinimumRevenueSharePaymentsReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of minimum revenue share payments receivable classified as current.", "label": "Minimum Revenue Share Payments Receivable Current", "terseLabel": "Amount minimum revenue share payments receivable current" } } }, "auth_ref": [] }, "tela_MinimumRevenueSharePaymentsReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "MinimumRevenueSharePaymentsReceivableNonCurrent", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of minimum revenue share payments receivable classified as non-current.", "label": "Minimum Revenue Share Payments Receivable Non-Current", "terseLabel": "Amount minimum revenue share payments receivable non-current" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r754" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r827" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r762" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r194", "r636", "r672", "r675", "r826", "r880", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r736" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r144" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r144" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r84", "r85", "r86" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "tela_NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of net changes in operating lease right-of-use assets and liabilities.", "label": "Net Changes in Operating Lease Right-of-use Assets And Liabilities", "negatedLabel": "Net changes in operating lease ROU assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r77", "r86", "r105", "r118", "r132", "r134", "r138", "r150", "r157", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r173", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r351", "r354", "r372", "r386", "r490", "r560", "r578", "r579", "r684", "r822" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r735" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r699", "r709", "r719", "r743", "r751" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r726" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r725" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r743" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r762" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r762" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r913", "r914", "r915", "r916" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of noncash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r79" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other expense:" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r108", "r623", "r805", "r806", "r807", "r808", "r809" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r404" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r405" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r403" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Background" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureBackground" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Background", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r46", "r100", "r507", "r508" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r60" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r122" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r5", "r12", "r101" ] }, "tela_OtherCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930",
```

"localname": "OtherCustomersMember", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other customers.", "label": "Other [Member]", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Component of Operating Income [Abstract]", "terseLabel": "Other operating income:" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r64"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r81"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r735"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r697", "r707", "r717", "r749"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r700", "r710", "r720", "r752"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r700", "r710", "r720", "r752"] }, "tela_OvitexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "OvitexMember", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "documentation": "OviTex [Member]", "label": "OviTex [Member]", "terseLabel": "OviTex" } } }, "auth_ref": [] }, "tela_OvitexPrsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "OvitexPrsMember", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "documentation": "OviTex PRS [Member]", "label": "OviTex PRS [Member]", "terseLabel": "OviTex PRS" } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Paid-in-Kind Interest", "terseLabel": "Noncash interest expense", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r7"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r724"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payment of withholding taxes related to stock-based compensation to employees", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r141"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r83"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r734"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r734"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r726"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r743"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r736"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r725"] }, "tela_PercentageOfExitFee": { "xbrltype": "percentItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "PercentageOfExitFee", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of the principal amount paid as an exit fee at the time of maturity or prepayment.", "label": "Percentage Of Exit Fee", "terseLabel": "Exit fee (as a percent)" } } }, "auth_ref": [] }, "tela_PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "PercentageOfPrepaymentPenaltyOnPrepaidPrincipalAmount", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of penalty to be paid on principal amount of debt for the third year after closing date and thereafter.", "label": "Percentage Of Prepayment Penalty On Prepaid Principal Amount", "terseLabel": "Percentage of prepayment penalty on prepaid principal amount" } } }, "auth_ref": [] }, "tela_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to service based restricted stock units.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance based restricted stock units" } } }, "auth_ref": [] }, "tela_PeriodOfNetSalesConsideredForCalculatingAdditionalFuturePaymentReceivableOnSaleOfDistributionRights": { "xbrltype": "durationItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "PeriodOfNetSalesConsideredForCalculatingAdditionalFuturePaymentReceivableOnSaleOfDistributionRights", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Period of net sales considered for calculating additional future payments receivable on sale of distributions rights of the product sold.", "label": "Period of Net Sales Considered for Calculating Additional Future Payment Receivable On Sale of Distribution Rights", "terseLabel": "Period of net sales considered for calculating additional future payment receivable" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r727"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r771"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r726"] }, "tela_PotentialCommonSharesAddedAnnuallyToEquityPlanEvergreenOptionPercentageOfSharesOutstandingLastDayOfFiscalYear": { "xbrltype": "percentItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "PotentialCommonSharesAddedAnnuallyToEquityPlanEvergreenOptionPercentageOfSharesOutstandingLastDayOfFiscalYear", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "documentation": "Potential Common Shares Added Annually To Equity Plan Evergreen Option, Percentage Of Shares Outstanding Last Day Of Fiscal Year", "label": "Potential Common Shares Added Annually to Equity Plan Evergreen Option, Percentage Of Shares Outstanding Last Day Of Fiscal Year", "terseLabel": "Potential common shares outstanding on the last day of the immediately preceding fiscal year" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, Par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r67", "r280"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r67", "r540"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r67", "r280"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r67", "r540", "r558", "r911", "r912"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r67", "r483", "r662"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r787"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails", "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sale of common stock, net", "verboseLabel": "Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r4"] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from the sale of product line", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r82"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r4", "r16"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [

```
"http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r118", "r132", "r134", "r143", "r150", "r157", "r163", "r166", "r167", "r227", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r351", "r354", "r355", "r358", "r359", "r372", "r386", "r478", "r489", "r515", "r560", "r578", "r579", "r649", "r650", "r685", "r790", "r822" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r406", "r479", "r488", "r662" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r724" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r724" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r299", "r306", "r333", "r334", "r335", "r343", "r378", "r418", "r427", "r444", "r496", "r498", "r506", "r531", "r532", "r585", "r587", "r589", "r590", "r592", "r610", "r611", "r626", "r633", "r646", "r654", "r655", "r659", "r660", "r673", "r678", "r821", "r824", "r859", "r873", "r874", "r875", "r876", "r877" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails", "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r246", "r247", "r248", "r249", "r299", "r306", "r333", "r334", "r335", "r343", "r378", "r418", "r427", "r444", "r496", "r498", "r506", "r531", "r532", "r585", "r587", "r589", "r590", "r592", "r610", "r611", "r626", "r633", "r646", "r654", "r655", "r659", "r660", "r673", "r678", "r821", "r824", "r859", "r873", "r874", "r875", "r876", "r877" ] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current", "terseLabel": "Accounts receivable, net of allowances of $230 and $416", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r662" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSaleOfProductLineNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r151", "r152", "r262", "r282", "r408", "r428", "r481", "r618", "r619" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r345", "r612", "r624", "r878" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "tela_ResearchAndDevelopmentExpensesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ResearchAndDevelopmentExpensesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value of current portion of obligation payable pertaining to Research and development.", "label": "Research And Development Expenses Payable Current", "terseLabel": "Research and development expenses" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r693", "r703", "r713", "r745" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r694", "r704", "r714", "r746" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r701", "r711", "r721", "r753" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r110", "r786", "r795" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Unvested restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r70", "r97", "r486", "r503", "r505", "r514", "r541", "r662" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r116", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r228", "r229", "r241", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r362", "r364", "r365", "r367", "r370", "r401", "r402", "r500", "r502", "r516", "r911" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails", "http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r106", "r107", "r180", "r185", "r186", "r188", "r190", "r191", "r192", "r194", "r297", "r298", "r445" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r562", "r613", "r620" ] }, "us-gaap_RisksAndUncertainties Abstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertainties Abstract", "lang": { "en-us": { "role": { "label": "Risks and Liquidity" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r762" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r762" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r168", "r307", "r775", "r802" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerCommonSharePotentiallyDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of dilutive securities excluded", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureLongTermDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of long term debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock based compensation expense categories in statement of operations", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock units (RSUs)", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that
```

were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r98"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r14", "r15", "r98"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrants outstanding to purchase common stock", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r39"] }, "tela_SecondYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "SecondYearMember", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information second year of term loan.", "label": "Second Year [Member]", "terseLabel": "Second year" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r687"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r689"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r192", "r193", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r528", "r529", "r530", "r586", "r588", "r591", "r593", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r614", "r635", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r678", "r826", "r880", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908"] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationExpensesDetails"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r78"] }, "tela_ServiceBasedRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ServiceBasedRestrictedStockUnitMember", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to service based restricted stock unit", "label": "Service Based Restricted Stock Unit [Member]", "terseLabel": "Service based restricted stock unit" } } }, "auth_ref": [] }, "tela_ServiceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ServiceBasedRestrictedStockUnitsMember", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Service Based Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r647"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Canceled/forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails", "http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r325"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Equity Instruments (per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r325"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r322", "r323"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r333"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r335"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual term (years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of exercised options", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r329"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled/forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r320"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r318"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average grant date fair value, Options (per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r328"] },

```
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of weighted average assumptions", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": [ "r41" ] },
"tela_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.telabio.com/20240930",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsInPeriod", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of inducement restricted stock units outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Inducement Grants in Period", "terseLabel": "Inducement grants" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r314", "r315" ] } },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at end of period (in dollars per share)", "periodStartLabel": "Balance at beginning of period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r314", "r315" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price per share" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at end of period", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r330" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest at end of period (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r330" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails",
"http://www.telabio.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r319" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled/forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r320" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted ( in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationTables" ], "lang": {
"en-us": { "role": { "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Schedule of performance-based (RSUs)", "documentation":
"Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares." } } }, "auth_ref": [ "r18" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vest Range", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r828" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate intrinsic value", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationNarrativesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r648" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r332" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"presentation": [ "http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r99" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [
"http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Vested and expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r330" ] }, "us-gaap_SharesIssuedPricePerShare": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
"http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails",
"http://www.telabio.com/role/DisclosureSubsequentEventDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "verboseLabel": "Offering price (in dollar per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at Ending period (in shares)", "periodStartLabel": "Balance at Beginning of period (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [
"http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares withheld for employee taxes (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": {
"label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r87", "r148" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"StatementClassOfStockAxis", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r115", "r125", "r126", "r127", "r150", "r171", "r172", "r174", "r176", "r182", "r183", "r227", "r250", "r252", "r253", "r254", "r257", "r258", "r280", "r281", "r284", "r287", "r294", "r386", "r510", "r511", "r512", "r513", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r540", "r561", "r580", "r594", "r595", "r596", "r597", "r598", "r774", "r796", "r804"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r13", "r68", "r71", "r72", "r116", "r136", "r137", "r138", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r181", "r228", "r229", "r241", "r296", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r362", "r363", "r364", "r365", "r366", "r367", "r370", "r391", "r392", "r393", "r394", "r395", "r396", "r401", "r402", "r407", "r491", "r500", "r501", "r502", "r516", "r580"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDisaggregatedDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r192", "r193", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r528", "r529", "r530", "r586", "r588", "r591", "r593", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r614", "r635", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r674", "r678", "r826", "r880", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r154", "r155", "r156", "r181", "r402", "r445", "r509", "r527", "r533", "r534", "r535", "r536", "r537", "r538", "r540", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r553", "r554", "r555", "r556", "r557", "r559", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r580", "r679"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r168", "r307", "r775", "r776", "r802"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r154", "r155", "r156", "r181", "r195", "r402", "r445", "r509", "r527", "r533", "r534", "r535", "r536", "r537", "r538", "r540", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r553", "r554", "r555", "r556", "r557", "r559", "r562", "r563", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r580", "r679"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r696", "r706", "r716", "r748"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r13", "r67", "r68", "r97"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails", "http://www.telabio.com/role/DisclosureSubsequentEventDetails", "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "netLabel": "Common stock issued and sold (in shares)", "positiveLabel": "Shares issued and sold", "verboseLabel": "Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r13", "r67", "r68", "r97", "r510", "r580", "r595"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Vesting of restricted stock units and exercise of stock options (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r13", "r67", "r68", "r97"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.telabio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r13", "r67", "r68", "r97", "r319"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under the employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r13", "r67", "r68", "r97"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails", "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "positiveLabel": "Gross proceeds", "verboseLabel": "Sale of common stock, net of underwriting discounts, commissions and offering costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r13", "r67", "r68", "r97", "r516", "r580", "r595", "r685"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets", "http://www.telabio.com/role/StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance at Ending period", "periodStartLabel": "Balance at Beginning of period", "totalLabel": "Total stockholders' (deficit) equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r68", "r71", "r72", "r89", "r542", "r558", "r581", "r582", "r662", "r686", "r798", "r814", "r864", "r911"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' (deficit) equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r94", "r149", "r279", "r281", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r296", "r369", "r583", "r584", "r599"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r397", "r410"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r397", "r410"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r397", "r410"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r397", "r410"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails", "http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r397", "r410"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Event." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEvent"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r409", "r411"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r742"] }, "us-gaap_TemporaryEquityByClassOfStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityByClassOfStockTable", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails", "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Temporary Equity, by Class of Stock [Table]", "documentation": "Disclosure of information about equity instrument classified as temporary equity. Includes, but not is limited to, description of share, value, share authorized, issued, and outstanding, redemption price per share, and subscription receivable." } } }, "auth_ref": ["r20", "r36"] }, "us-gaap_TemporaryEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityLineItems", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails", "http://www.telabio.com/role/DisclosureStockholdersEquityWarrantsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Temporary Equity [Line Items]", "terseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "tela_ThirdYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ThirdYearMember", "presentation": ["http://www.telabio.com/role/DisclosureLongTermDebtMidcapTermLoanDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information third year of term loan.", "label": "Third Year [Member]", "terseLabel": "Third year" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r734"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r741"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement." } } }, "auth_ref": ["r761"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r763"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.telabio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol",

"documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r275", "r292", "r368", "r385", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r492", "r651", "r652", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r663", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r810", "r811", "r812", "r813", "r855", "r858", "r859", "r860", "r861", "r863"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r764"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r765"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r765"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r763"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r763"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r766"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r764"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r760"] }, "us-gaap_UnusualRiskOrUncertaintyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualRiskOrUncertaintyLineItems", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Unusual Risk or Uncertainty [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_UnusualRiskOrUncertaintyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualRiskOrUncertaintyTable", "presentation": ["http://www.telabio.com/role/DisclosureRisksAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Unusual Risk or Uncertainty [Table]", "documentation": "Disclosure of information about unusual risk or uncertainty or both and their financial impact or potential financial impact." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.telabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r31", "r32", "r33", "r111", "r112", "r113", "r114"] }, "tela_ValueOfSharesSoldUnderEquityDistributionAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.telabio.com/20240930", "localname": "ValueOfSharesSoldUnderEquityDistributionAgreement", "crdr": "credit", "presentation": ["http://www.telabio.com/role/DisclosureStockholdersEquityPublicStockOfferingsDetails"], "lang": { "en-us": { "role": { "documentation": "Value Of Shares Sold Under Equity Distribution Agreement", "label": "Value Of Shares Sold Under Equity Distribution Agreement" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r730"] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.telabio.com/role/DisclosureSubsequentEventDetails"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r676", "r677", "r680", "r681", "r682", "r683"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r170", "r176"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.telabio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r169", "r176"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r728"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718",
"SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r45": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r49": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r51": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r53": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r55": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r57": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r84": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r86": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r90": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r91": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r93": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r94": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r95": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r97": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r102": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-
03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-
04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r108": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" },
"r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r112": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r114": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402",
"Paragraph": "a", "Publisher": "SEC" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r117": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r119": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r121": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
```

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r201": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)

(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name":

"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r774": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r776": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 60 0001558370-24-015050-xbrl.zip DOCUMENT begin 644 0001558370-24-015050-xbrl.zip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|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`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}-BK:LZ3;7O'49]K#N*3P1CB?9[;/C?!- M=T&WJ!<$O2D.KT5!*2KM0F'8JD=^9M2K$/03M&8B4Y"?OK5S(VV."+#"26 MH:JKN[&/CO2=[T@ZNOKK;^\3UWH%QC$EY[764;-F ;&I@\G+>_U^A^7PSO+H;8W 2(LFP$2X%AO6(RM)S]=(F+= V/8=:U+AIT7L*Q6 M\ZUAJM@$JG5CU^C=?QR7B,@TEE]^L?=0*7UP%ZB@$V[UJMQI=&N]D^E@K.FMVS MUJDUN |%[V791CA7TL7DKS/UUI[,T9(@"3^OC868GC4:;V]O1^ _/S#VB[$6F M;G8:H6!M+GGVSG%, ^JT3RK8:?]S?/=ICF* Z)EP@8B]3*35)Z5]J7J_AOY6B M')]Q/_T=M9'PS9Y;+BM50OVJAV)U]:C>:M<[K:-W[H3E6BM6#GCY%F?(+V! M^\6RYH9FU(4AC"P?XYF83>&\QO%DZBJE_K,J4@'3ZHJ09J_35$7\]5%(MVI5#75''J8L=Y067R%49/(X!!*]92OO/X6VL2$K3,Z9'-ITTU/N&CJ+&AY5X M\9_C!ZFP'QB^05QKNADRF ,A.-7N*-!*SA%(CV]<^K8S6!&%.T'0 MQ]QV*?<87-@V\|"Y?I]*,X&RVH,8 [OR&)-9WV%94!<+#+P/ F%7%]$V&>P8 MX1TE+T_)GUX%JJ)1)9=Y1EJ5=J<12#2X M-YGX EW'TBEJN08)M:VT4U*CC5S;<^>Z6D=^B_CK]O9(:/B=_)WD(DJT_8- M3QO$O L@#CB+IUBH+'J]$)6]-)M6W5JHE/^/;K4"M5:@5Q4^+++Y+[5@VKNI=_M*$LVEF^H$>+/OK4\7G]!:.IWI UP!0^?^([FVRUX\.<%YQ% TA+@RC!AY66C MK'(%52VS>(',GZ>=[NGI:4O6H^/C5K/7[;57*[AQAPL6QR!]-DE=9?,IF$DL*F5&1/>$P%U) M7<=DZ@8,I@B'86L8M>ITJ!HI]X3H39$&_!^;S3^50TDQ&\C04DAHJL^9JN S MO2IG)8G;H=7KGO;,8#R9UX) JM 6#X$+AFTY7E AQ]*{)Q.-EF\4D06 E&% M5CG2P.0RF"A;*?KT$>BTJ&70-9^-(RJW@#@,55$>1C]E5Z$PI=&6E:9:]!5& M$M!X8AB-MT0@\H)E4!XX(XCK=]OUU'+(=TJ=-^RZJ>%M?M)*D;HQH(#;4Y.; MU\ALK.SV'P6U_QI35Y:;JQ! S%) (SD]6+L;\8AOH@KI<1)TS#U$59D(B&++' M6>N"9K.86+I,#K-@56%]*VJ4<$'2"9FM')F8=.%(YC;TOL78,HS2(H8;Y: M'V$5*FJPL*==7U/E]XSC B!UQLUEC;(B$/2&6HD)S.96D]2"\ QE-;HNGL%D FLZ42 E,:@?FZX)F,Z@=Z&H"J]*\Y!6=3"CQ 64N]:Z(Q?%V3%A" MT"0E86E7!UL50J*!5 .R.7%RZ4R0W"=&=>%5H8)>. Z>%VN L'-+KM 4"Y0V MX94BO4_D%H%8A44%&;-[$V5Z"+8F1K>- WA*;3OS-HS] /(R>T'OZ*:(EKUR MB!U K*:\%#MYB3@7"-&,'GA$=Q]&&$;IR\FYB7<)W?8$*W.XL>Z!WQMK%KG M3O[^H/VK17::1PG*W-S:SM[K>TY;F9FB MA(HM,U\V4REECLG$'? A8UH35&=9/KZX:+$0K:3X;@,)6P(KT \N)%6D'V38,@6OV,Q MOO*XD/C98@%<+8G+/TYZR(^!)@,=((_&I)AH-[@-=9 KRF57H_8_^'-XP%ZQ M@#0M0?9]DXU[J\K_N^ S19R+"64" \|_GAHI;*MX+]SG@\R0_U2-\B=^*,< MBVSJ,FN)]J*X3WK=DQ-C6,WD)F'-JAA(0WOZ[T D?%?U+LX$$\R%,L8K M9!./,3%$ M.+*#227_5T">|Q^/B^!@L+_2-%"S#O*%$ P_>T)M/Q!1'(LLEQ MI,LP=22U#_-_Y>_Y1/+UNSU&Y 6&$NWU: 1V6JW][$*4LR= E7O Z"N67G,Y M^\E!%GHQ+KB0M>LUZWBAO@(3FZ52O&QE@\(VYC-T^FP^O9^Q:6$I8*!7;,G) M.LDY: TE,;VS#8? UES"2,NG+X 4T'((;;&L.K860LJ/M3U_4_-*3/ ;.5[:P MQ"=L1E^_B%8]\:W@JWD|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|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`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|*K[M"OP6KE"L^;'M);LPP(MG0E !"Z4OZR!(^1*U5S#&6[&W(?+VAA"/(? M>A7WV8\5M|+%#<2;4VD3"T1O2PKR4>/_RCV[&Z)+(>/Z=MI[VZ\C:S@ O'!;5.G/P")ZD M D2MJOR4,>@Z"<$K"!_A-<99^2R(8M&FTU2H-;]-'62)U'3T&G=FRW#FU5)Z ML N.QDU0CZBJ4>H3XT 2PZ/ .LG2!:N"]U?V 56'- SP)T@5"-AH0G>@MBA MTQ0D? &]D*/#QL)2>!BJ_Y"8 =(%% ^ MFY$+K$WF@+<9Y=R&.CB8O\W(1;IVFU&(K+UK"#\!.$?^:A$%/J\XEQ16?AV! M!VV*.C#?Q4!\)4$$RZ=.!CW(E00)DZ$&#G:N)321+J\FR) UKO:/E(SIC"S: MHNA!CPOJ/OH8BTH\ ML#-61LU'0,;&=#]@;[<*5/B?#*=Y-3N(;L%+Y;U@!!/R9Y#7NI/5=6K3AW!E MTKH7&[7F2- 3V23,E4V:Y\ #%=(N NY=5ZFC9* .-?/5D=K14J0;)]#!_ %E- MMLQB5B? F[%1Z$BQ%V#$4]4NU VTVA2P=?=%X G]#[6//>"9^LM MS)V 9E5**.);]-OZT[$&$.)DV=`&JSW1"K0##@^ZN8GVCJMM?3@8N#WVK!E8LO[>45$QA]+7%C5OJD);6.!4?&"Q,G=PL3?_E*5H'3;V+ (7\2*E M?3]]#4|E.M@+. ^,&*"'G5D>W/1EVU\#YCAG?PA3@&TCP(U@7)KXL5[6:C7S.'*= X3P]NHX=H&3W6)UVZ]"5G?H[^!ZX&,KW1P$+)M M%QT9C4^U.K? =^6.W&G05;U;/*)I%RDH1BE9ZQL-OYQ8/]%T+KUT7/@Q83UI; M2"([%V%FOLJTBA2A*8I(V#&Z'XYVN'Q# _LD^U'\J,*T1 ^O+R\BX%1#4Y"$(-QASNGIQ_?'QQ^. MC[U#K^R._%T=9OL!>W#F54? Z/Z\<.QDGN$9#*3 Z ./'DX |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| <8H_"*.Z?W MGVG>W@'N8\7A"#Z'UIQ_]F/:TNB;3!5H&4MVCMP&#*Z+K5@A].A^5N0TKI, M=ZSL(DUZI4G+=S EU!#'&Z\OHCBC5X@>*&L8]S!$ZS_TBM83%#V*HT>6EEZ. MIC^ _ ! H09O; (Q(82$#6[G1W @S(_HEF0O4AP; M>;[J;1+-I8__#3R(X=J8_7 ^6 ,[D#U,/^:(SIP?C*-ZM9J:8 +1;KU6+F+* MA[75S=S8:1DP.;6>#%6;9H#KZ(E*H1DD$J M5W% ^]>D3)ZDD+U<"[," :M W#5>2XA.52[$3KPZNKM11QZTCU9TKW@.,JWZ=O966$8'1R(2Y8* M&#=*7]'::D0X_V2&,3Q5 T.!&3CQ[[&-*/ MSD<3* G;8+GT)BL/TJQ_H)Q/"TDJBCCS09W924O87C5'/A56UPB[*$EWKR)@ M-_:L,G6226'4]J=AX*^MN[J!?B+9 M['È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Ē+@CGCL$ P!"3 OH,"Y\3F>598E 3!KM'#A!:",N#8K&GIF*=P5SQ7F M<TFBJM(4;852EVBDE,V+\E%,' MJO)U%=&E['5"P+)O51&7W]2!6*]&&LE*X_+LB"_[[J+XSL'EF,(8[OG+B6 ML0]F6PJFCS/[5-:&;::@6C,'+*Z=-4$N;-?E@8OV2Z_(B+KUB4CJZQKS<2 M9 ^)]94H\(6? KK_ V41!8M=I-@LP$WAZ] [7FX_;:U%!.P/#K3O$ RS@.5E MW5+\: 'IUKON[SC)3'Y>5[GHWZ,#T!>>-F.XO]6^3@C30%F(X\R/:V[VFU09?Y9-1G7MS(![!BUK1K][NZ,FZ, MZUQ57"HI8N](@:J%_.&:GGJ^O>BE(-4=8V:K.? 98)6.X>$Y1MG*FC)O%R4#) M)%<%K^^O^>W<\,R:FJTI,2<>ZJOA=PM3OD)*GR=KUX5K7EBFIT)!*]ET1Z;_ M!'%X!1';I*+|"T%X=L:2WP<0>+_ ^7=,&388(%:,?-]S1FA$4Y; ^#!V?;W;? 6H\|@#GCOS+-5/&=@F-4V;C!UDW#]1 M6>"SV1.L-YN:5:-23N1\DRZAF@M+#O9K2\]DK@LZV=`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|^%JSH&-'1$#OX! MU#+G\A5$Q4|43K0!-XV$"Y>$W%("]CJCE9WGEPV9SHX11G+>)NF"X >%W[" M73D-O5!H/;Q13;9WQF*.H7||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|Q$%!X/MO M2U[*%O!?)T6S$_Z3R;OO3KY_]\U+XGV5BP@_:S IFK\O?CCS]^RW\N MFS)"7EJVE>G^Z[?BQZ_^^D^$_#F. GI+-X3W_BG= [^A?ODK\[2X KOQO3S'= M- L9Q/&WT/ ;D#[*YP0M?P0MW_T:;/G?\C]?.P\T^(I R\^W5TI]?ZS1RCMQ M,;;1,J*U)==)C5=*^:J1V56C[(O<, >B@SR+W[*N8'%+H>\W^5=./OJ0T]*A7 M: @L6RASB;B[V$@';DU>@%$/T?.W'O4Y[_3N ?W$[L M/ Y^%C&@/'U(TMAQTX(2%_\O7S7]WL\:(#30.HWKDCNQ6 !B_ ^RP0][B6S=B M"'+9+3X+\P .#NFSC:-DLJV$4-/ X]>.C 80M5:GK$- (FRV*6]OJ@LOLK2I8BL M!8Q:-#SY?-=#Ÿ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

(XNQ:ZOJG"R818XQ^,I[5F[/&"0/MY]C$FT-'&B(XLC'^OPEQN: M3GY GI7X'Y++181@5C9 4!FVL,>NR1[SH=]#MSD>#LUQ\;+SQ64P88PVL],@I+VH[(;=.W2:_ M4/_QB<7:Z3.-G4?*?
SQW4GKI^/'/\.,"Z57.8"EP#F"6OXJ1?8MA(B"2Z%LP MA,7E0 GDA^B)(H7\)%= -"&@ @$=R,\-3ZL8^<4:,WT,TT6:)I4]5&M/)C*!,3=@3/Y.3?D]R)L=W*T%#;Y>XEAQ\4)CUT]H:>'[*%'"%[:4\L/$=Z<<
M(#19O^Y1H8_]30X%.GQ?+_[WTAX#Z)<"R[A?RCL=P$^W%S[GESA]?(SI(R"X M7YJ,PSA/4Q3%#ZSI3,5YP@)MY3\.]P8^12E?Z-I=9=$\=FF MY(<;L"><W=.\+9$.8X87FZ56>[%)9*54!OR &?
T5^3U-225)<,L-[K\R*?3^' M<4D,$CNJ 8^*VWJO"EC%:'49Q?F?H)T]>6-V(?Z2G$-SZ36;!Y48)_H!@W6X' M! @N!.0722017Q>$(5K M/*?U(VS?[V 2_PP9_FVC_MP?YU(VS?[V 2 @@>$K(!=[@7ER23-.8G<,DZ M?:+Q_9,3-
FY/F5XD]6>/&_GG_@Y&=DQZL:+]K-;P&;V3'';NI29<*'AO>-0 MO9F^M$WRN;\,)S?HH?H\#\9ZRFA?O/<601Y[(#!QJ;I[;3 M;>]C^\"ZI[D-7Q'#P>Z0Q%OYDL$M:)]4][M,)_EV\%K
,#25A8UDWKIUWD5UY:WQ-I[X,9G#6UE^&QICA?==(0>7GLWIPJ'8H(1*1BLR'LGX(\S MV'NC3*%[ZY-E77T6Z='J'!\U:.RS.JPT]=Z;IU\.?0AN_$J !(_=X&GH?G?@W
M"FN=O'1XXRLD/;KA]F]=O6NSWHX^>+U<6 +A#TMP!K5:?,FB*$*O>E9C%@?_ M0$,:.P%3_=3;^J'/9F@.%%K6\7+=OKA=O9<%9' 7ZHC7Z?N)/ C 5W#AGE_G M@\|+]H6HG|Y4G9H5S^DR#:
?#D8[SZ_7$[?H]M)<=7Z,;7K?O(_SP1PH$# ^[U M$A<4+I^_&4*]YE.Z7$2%];0[XW;\?C:0?5^O)U[W!RG_U_P6-G&FLD&/,=6 M5"C):VO(EQH6E0*5[]))VW&W41!<1C'\;#H)H(L9;FB9UL8FK_ V<|
(+71/K MB^&:KEP;^%<0DN12VGF##*G%JZ)0/+UF63<"CDW3^,;9E'S^, !Z_*[:9$S^ M$+!IZ'FOB1!SRJ?0Q!VEB]";"2X-6;K80G=20ME2E"%F8YE?@R:Z2YTX7:R1 M'NBC'X:|?
+S"5(L87.I9LA_B*%&=*D_#Z74/, "W6G:[8&F?S>@>9-F4Q#*#/' MZ?=PM\|LB\O*^-P$*?_QH%20+FSZ)]30@/ M@E"H^7.]?P9_FVC_MP?YU(VS?[V 2 @@>$K(!=[@7ER23-.8G<,DZ M?:+Q_9,3-FY/F5XD]6>/&_GG_@Y&=DQZL:+]K-;P&;V3'';NI29<*'AO>-0 MO9F^M$WRN;\,)S?HH?H\#\9ZRFA?O/<601Y[(#!QJ;I[;3 M;>]C^\"ZI[D-7Q'#P>Z0Q%OYDL$M:)]4][M,)_EV\%K
,#25A8UDWKIUWD5UY:WQ-I[X,9G#6UE^&QICA?==(0>7GLWIPJ'8H(1*1BLR'LGX(\S MV'NC3*%[ZY-E77T6Z='J'!\U:.RS.JPT]=Z;IU\.?0AN_$J !(_=X&GH?G?@W
M"FN=O'1XXRLD/;KA]F]=O6NSWHX^>+U<6 +A#TMP!K5:?,FB*$*O>E9C%@?_ M0$,:.P%3_=3;^J'/9F@.%%K6\7+=OKA=O9<%9' 7ZHC7Z?N)/ C 5W#AGE_G M@\|+]H6HG|Y4G9H5S^DR#:
?#D8[SZ_7$[?H]M)<=7Z,;7K?O(_SP1PH$# ^[U M$A<4+I^_&4*]YE.Z7$2%];0[XW;\?C:0?5^O)U[W!RG_U_P6-G&FLD&/,=6 M5"C):VO(EQH6E0*5[]))VW&W41!<1C'\;#H)H(L9;FB9UL8FK_ V<|
(+71/K MB^&:KEP;^%<0DN12VGF##*G%JZ)0/+UF63<"CDW3^,;9E'S^, !Z_*[:9$S^ M$+!IZ'FOB1!SRJ?0Q!VEB]";"2X-6;K80G=20ME2E"%F8YE?@R:Z2YTX7:R1 M'NBC'X:|?
+S"5(L87.I9LA_B*%&=*D_#Z74/, "W6G:[8&F?S>@>9-F4Q#*#/' MZ?=PM\|LB\O*^-P$*?_QH%20+FSZ)]30@/ M@E"H^7.]?P9_FVC_MP?YU(VS?[V 2 @@>$K(!=[@7ER23-.8G<,DZ M?:+Q_9,3-

*MP_]LF/F%[SU^[BW:LVDMWAZ3D>9J;5;5B\LZ,M2\H0!L.OF?9 E]'LG)# 9 MP,$P4K98WK6W(\2? G24&11]H9&2+**Q(.N//OB"W_{{-N/X>6C2!K81-F.V!=-&QABV7"(4&4'VR_/O-M237FCJ?^-_ MJE_R[5N=+!58)_7I`>-W MGT(AB&| XN>^SQYDV9F#H@VZ:N@:_&CM8*\%;$'6@.0*T_+5QKY5G9J5RCJU MXEA3VJY$QOPS;_+0I0@Z^ Y_]0D+A^=Z2C"X^QNVN[YD*L*0FVEZWWSV^J8E M"8=*!.4AR%)1RPJ&;_N*M\P26G_;57 M6QO=U5'0]G;=C@ 3 3/!!!%R#KU=45<]KY)OK^6!GIS/^U-@9QJX0T\O[*CP MMBL@Z]#/[7"269/)D>9Y^{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| MY2(_RX0C$Q%R,\? 7,^%/-<3I'-ZB&"V&?%>TWQ_K$50U$TLC^LE:FS)JG=2HQ;??SM3&5?76BI9!9KVK3>']5>9XI MK%=TK42NH \[Z<5C4CP;6NI7M6UT0+$NF'RQ-A]'.95.5%F'G94'S6MWOC]Q M50,1]U? UG%YV4RF%E66 P_]6)06N?7E5"S7B;&%HASCDX_]L /K$R/5"O9 M7)'3"CTF$GSQ_=W..>X8>#M'%T]_V"F]$$QIM_B'5U43%_9L @ M.A#^KHR5C4HIIU>.LRLZV,W+B)QW$2OPR$[:F4;P,35 M';6W5U>}3&3,DBB'[4F#X=CD1NU1-K VP:'5/7ZRU[''IYRS7>M5&H"0FR MWIK6YTFN+/#=^V4^L)H@<,.Q[_N3NCW%0)FJWZ()>7Y'9ML@:.RU2W<5^2^ME\ M<<>XJV1(? 68SKSWEY.F3&K)BD%39>FO<<;M3C(]&K6NS/Y^7G&VC'!L=/OX'V M;E2\0PQTUPNG!AJ3+BO3H\1]0QW5LN952?G+B(&@H\,R,;XE:&,7%>A35=9D MU5&?>8D? 0T\)XAN4IU=@J<561HUN.F3@AQ8_?Z,,,,,3[N$(:X M_NA5>7)<=]5E6V7.Y@25#YQK<@B7V\0(<7E!,>H_955#T5< M8 K5#=3V#=3#HK3M@DZX9,E&JSD)#]#JVN5ZW4(F42 =CERO@;/04>303[J^J,K'L7*.3EJ-:IR5 M30QR{(K2I&5R6+:RU'7+ETO[I"M'S'$Z:='H"$,@U!LC!]&&IT!K^7+UVWV M7E8G!3AZ>Q*=Q&:&QD0U6(8M\Z,*S12RK6SGN@%S29T4U%WH4^DD\,XQ*R[] M>6M:+\W"5&9&%^QD}). ^*6*.TTGMI6A;=MXN<)&RU72F\4&.38 }8=?Z+SXT$O6 M(IP ,OU.6'+$]"/C+Z[ZQ<<=HBT 38\=/" M=R:R*26A _7L9/1[4\MR%IC1_+ QGCKYQ""[7"HA3@S@^8P:(3)/ZEM]H+9U M@,I,Z5^CJEC6Z4*E&F%GC@43ZIY>,#NLVGRP*^358I4W93;9GDQ17 MY]CJ"CP:.^=SD2[M=WYU5 A2S_9)M6)(M2]J-6Y:2.GI.JCE[LMR%??B*^N MT99#/VD)VMAMASY594U6'36XC-9:ZI4$)78C)"@.5CW^X5'M!N^H\;]f&\IVM%L)1-%1Y,=A5IFK-I MJO/8[P?.| VC[*_DO#2@@MZ5&6YF%V0:.)\Y0 UHDDIY2V[7N<>QP"D*%T5 M4HUA74DT.X$3#OZ2;\]N)W'MA>D%G8^](O34_FWT'\U:1,B:G,S.%(VLDVO> MC$2[2\8, [+H&*CMQMY@Q>T3W/Z7SA5JLP7<+K#,K) '7]*T37&#>8 #O M?[JX>\O^0-61K4IFNC IHWLDT>8=A<+7)<47{S7NY2#€\Q<.,/:.!%$YRR=Z38J1SKZZUTBX RE QZ0AO#LY M7VS*#YDH.7.%SJQ44K3Y>!&\VK/GW[[_UL'8]V/OX&;[>[$'%15)9[!T !=I M1\: *RU7T4'@PCSGWZ3^UMA[OA%0239JV:S:,7-UN]C1,X"0)J4@&&&?*4<6S.QCO#BJ?^(;,P]GD[=R@U=- .@QA+E^Z7A8QN M%($2!%L E&6I;MIQM*T]J MM1^5V;BCD>7TLMGL2>L.>_X,SX{J:1U-=JF&*B(@_TR3!%/B+73CC\4OF^1B M-LAHZ6EOV>SH]VJ.D2-/QI_JWOK[VQLC_HW_'O\[_S-ZT1LOY=HYGF?T**L7 MIV-6CN52MCAT'K@M%]OO5,,*S$TE[N!//O!'&,IF?%),/T1JH'1R0NJ1J86 MQ*.QM9'H=XNU+>?K!!JYGP/\-2\GAD)^<<\YZGR!?:BE.VEQ2X,>XL$_W-" MG#R'V,/T]!9RFJI7U1 MD:#*RNKNOQUH$U!$#2R(E]X*VC]OW"2P7PMR]^B_OW!K2UX#V!%Z#?[Q'?R3 M0/|CO#_0"P1B8H+1OS_^TZEGX4?+$+2=5^*_[S3=5 7%[7;ACM=[]_W1Q@J M@-!!+:)$LV&ZX5Z@705%*@=T/=GG@C'NVNR M1VKW2U%O$+]0"'+_&IF?%),/T1JH'1R0NJ1J86 MQ*.QM9'H=XNU+>?K!!JYGP/\-2\GAD)^<<\YZGR!?:BE.VEQ2X,>XL$_W-" MG#R'V,/T]!9RFJI7U1 MD:#*RNKNOQUH$U!$#2R(E]X*VC]OW"2P7PMR]^B_OW!K2UX#V!%Z#?[Q'?R3 M0/|CO#_0"P1B9H+1OS_^TZEGX4?+$+2=5^*_[S3=5 7%[7;ACM=[]_W1Q@J M@-!!+:)$LV&ZX5Z@705%*@=T/=GG@C'NVNR M1VKW2U%O$+]0"'+_&IF?%),/T1JH'1R0NJ1J86 MQ*.QM9'H=XNU+>?K!!JYGP/\-2\GAD)^<<\YZGR!?:BE.VEQ2X,>XL$_W-" MG#R'V,/T]!9RFJI7U1 MD:#*RNKNOQUH$U!$#2R(E]X*VC]OW"2P7PMR]^B_OW!K2UX#V!%Z#?[Q'?R3 M0/|CO#_0"P1B8

<=4DD0)4<4D520HBA G$P(3*8V0%'2BR8Q*W^T14GIP?QF4R9=5 MA14PCNUN25O^HH0NAJHM\IPTPZD;UC#IL2!-9@(RG?3X?&LMXF+LH>U6ES3' MZ]S:K KM*L72&&L$@#+^T-:2+6X4J95!5(KI>+TRZPVIM4B C("GE&JSYY8X M@K4$:NZ,FX6B.]EQ>D@9G]-N-6P52E9=F%?Q?F%C(6QC 9X9?WU ||5AME9P M^)PPSRP7EMNI8^"A*/Z<=",,93HW9{Y0M,CFUNK/NLUU6R3C(]7<[*\2<7,M M86MM!EUS8V0Q!5 2L9'2A7YA5N(IOJO,4;*$-+G5;!U2QN:TY(OSW(:3&7Z[MJ,S$YH(G^YX>4L;G-&-PFA1EBG>F-'!L)"9KZD^>&A\3EQUVI?&AF$A5+-< MRB'];F8FDY(NNU8%+/Y)5\5%QS-C05YM=1%2HR[0\]4@|,,//;]:KXH-.=-M<]{=5/PIPX64L>D5(ESEHOEK)VV9P70[5? V/3\I=X.*>/3MT8K?I6SLJ9JMG2$ MY*>YZG -=4L:G+TJ#?IXT4<2D>-E=+/@C+KX[!0./37Y2"\KK*&@LDH(("5RZM M=6(0/34V?7OH3<5!RY\)15-Q!LF0,-1^.,(K7H;%'.% (7NHE:Q97O.B5M M&1MIT9]>'FKE/29M*!?/G=CLD'BB6]DA6:1=.BGUAI%FZ MA!]40QO\?%9M^.&)UO%4#ES+C@W5ZF[YH+NHY_AE<;%:(#5V5]RL 6D,)W:. MT=\M>?RQ9823, M3K1ROQ${3>67XT%6]'US9ZE"48}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{I? $+H(-"<[7353F!W9;J#VVA?K0?^E*^H1>%3=?X$& M1U]5PO9-D_?N8@]T&H"J.334%I*QCR&^1A2M&/O/FW2D*6GN_Y,>M4Z'5 M=Q*4 2T[KX3N\HJB: (1OPV/A@V0CBHB@Y\0.C;?-)]]9/+6=?G?9_ODO65953;LD M*[PZX:QD2;.LIB0_50FL;0I]UGKW""%*0K-4XLN%T]KD]8O:HF]OCR>+/)YOZ MC[$)1VT77$D&*56IP#;\#NA++H2_B%U?LA7)5<2HD;$G;MK(>CG.VIPVV+!]+ M3FF>QXU,`RX5]97,!/^0+IE(BCHB 4<3 R^B2M! ?NE'OFT[GG/G"L4%S M:FYC>]4^SA2U*NZ'C5[%IDU?B@W5CHAS#&ZS@?\LCINZWV=L_)}V,%<<_T!PE[*E>;BFAS?\W!N S<#WP.3"U0^A+=S4 MD *YNV_%QQM,E=^:E(@L5TQAULI@/*>'_JW8W2^,2!,TF281XC__?KIX5RH0 MB??%[;V1R4*)_SE:INZ-((30S8LB[A"\4S9UWB#SK"]/@J%@<)>&APS^$70 MCYZ&1Y_J>ON1/, #_@ /A- $6:%5N#1 LHW4KJK/$*FW07YD$\ !A <+"UV^/ M0UCX "S\$@AO2892MG-[V\X!(FJ,KN>H,'/$SWG&S?6=,:lO<*>%")[=X M( )BP/#='L;GMO:.F5+SY7AV9'@(URM\S$OF1U=249<3JT*Q335]&ZM:U6I MMT")T/Y@Z31"8#&P^!MJ%Q L/IP E2RP.+MVL<(:Q>]N*?81PRYTR8'OFF3_ MQ);#")j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|GE+R+QS(3ORC7D:5]9'T<\@ 4#)BG M?!-^W#<.[+YD!>H?S^L7S 6A22Z5QFA1$8(13G0UB:9EI1T>U\S=+X:!1S5$ MI L[=)..2,?V\4(F@))QC:F_4(F%@G'Q1?F6.:[G\6(?6_&LX+J,"7YU*%1G MTPWG>2Q-CX&?"/BI7]4\KRLI=N]"2ZT-? SI5+04L]&\WM"]MU&O(?4V\X%\Z M9S.V(.^^^\+#/N5H9L 6+CAN3]H,@ @X%MB7\(,_9LT^NRCSV[-<:EM\WLJW M"41JYYA-(S^I-H?K< &PNU\DCISNCLQW%BR85P2S;F]Y=R%_7SQ;]_-GY^V[M>3EE%G@^&)/74:.;[CWG_4?I8^+=3R*TH/5X()3U!X M?D)\@?FY,"\7,CC,YX4 #OD[.7G %U<0C^Q":,Y2AXS0U5@HLZ}6»)DA=KM M.5L ,A'@2'U5]OZC-]PF"DY<%W5EKP3'K_-FO&V;WMY;.C!AQB+D M^3SZ<4S#R^X\MV}TN\?!@V4L:@>Z1O:V-5G M*#94/V4YWM!N>"=E=]=PB+TPMXGC*$]J;V?_Y3W2Q27F.92BI?R'1?\F"!AA& MND@8Z<(\${1;WAO9HE[/KGP]5A;;Z/D.H%AKLKW5L MY\O%?M-L*$VAF<.8FKS(YR?]MHAB4#- 'F33S3V'-FI M^F[8Z+2&E4*SBV]-RB2-E;VL(&UQ'<$&_1{8N):LP,,,)D_>L%8!'X0,;2GA MEUG)BCHU27ZJJR[\",[W0H$CZ?TO8*O^\^_)-83FS^PF?2+:>"C:BA-,+#4) MLGV.SDJ<)S:U(Y:]#"&EN-MBC0JRJ25K.J{AMX(DTP=!DCY=-P%H,Q9:BEY,H?\YGL?X M%K'BO6K_^8'BXX6T0,T7U?7V(WE!9(A.N5G'IT -(5,INXN"WC2W2 04) *-M"! 0(++[F,8< <9HTVDHSC[26@_Z8K[*(45E,HU9E^L6J^V^:!!8[)!%*;=ZOF M@$6&OMM%6J2M [!@[G[A.)/&V=,U7X2(<6E9.C5B'$(!$#%.7Z1 *#-»MH$W M>"$C^GR^/+3[[>V)50VFL]I,M[D5+RS]=K8FST>##P9(#Z $]":IXO)0/T;LFO@<*QD[U8VRI'$TZ8=7T>*/WLTQA3ZP.::M6MO+&<<'Y@8TSM9SN;#.%%7@@0N<'1-F^9EA M@8M_1_42CB^:+\KBXVC@GO0A%(-]7T*E:/XB(,:CBFJ2+'A^A,HPHH3699$ M>+3,DV1&HN0X2#^+=W_1;ABOMR3-KN=[Y&@8[;97"-_K%K-K$1-1Y#El:,K, M#K,9_,P,2BS? 6RM,=5'615RDGU-:P\ B_#4MF$V4%-KU'#$5A79(&7\H4A_, M9KL"RR/-"3}SNTP!:1;6(@\RT\IL7:#XM:5-L(O65WL,DN&F])Z2!E[?843 M1ENOGL>08- >A:U0P5ZM+!\,SXZVN(T9NY@:0AP9!>8H,06G58\% 4CST5V]B9 MJC50S:)@V]V"1O:<>5LDXR-=#5>$fQ_08<+*8GGE!-C}.HZ MM99-3,I1Y4RG0?.X'E+&YB2T!TC5M;P 4:LR4\D;?7H\ Y3Q.;Z^CJ>+JWC6%\V M=LI_7 -C\||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|PR4|\/NVY]?A =FO?TV8X-W6XM?A A67,,:('7DQ M,_+K\(H"QJJLDFWC-Q,6)+X4$_3-DTWC9?/)-:UCVVDDR?.)#940Y>>_9!F M\? B:K/#LA',2)ADRH"27]D|&)]D;BHE1]+;K>PI"M CRSK,3&_M(A6 '6PX MB>L.O5H\Y Q^/EQW^F9+W]O'.N"###BAR#[@"SOUD|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|S&/<) MDF9$X72AX- D2ZDID1"RC#8E]*OX1\/Z90ZR.Q@<-$#RS.Z<1_>K*KLY41Q D M-CU+SM-ZWC-Y.8U/QALC$U?X2IDU!6R;GG1ZZT\=TN#A)H7T\,.PRE15Z*F(]N:Y^L!@#N M!V:JM[QERNL.5**P|_!9+>H3!S3[SD3D;<%!R^88KC-R\ 0>0S@^8%N%%! MMS1S T#P@>79\A2N*&5IDD$.2"Z7T[>+G"\4W>E$$@-;M0.9*8-1<8YXD\ MKV83CQT_V$(MV^W.E$EO/EAUQ QV6=*Q%,V2V*>O>S09>.,)\CLCK=[;(*0\0 MP2'NAQU_")_O^AGTK:1YXIW7 M^7*B*Y02Q6BP3R$R%/|;..Y^<(M9(V\X%|[O.$(*^^R/*%? Y=:+,"Z6\8@GYJN)Q[0XD /OC%YN*)3*GIUOO=NOE.\L620M,@FB_\NH2 M_KYZ\,W;M|^O[^GEE9GGN&A,3A?@V^M|_6[Z6.UN]8T*GVZ=E^E@9ZM9Q9+ MM;F1)I 2.#?%!>^-?F? Y(@A#PG,_]/(2!B=AO5]Y=0E_7ST<^.H]XCO[4=]7 MK5M.%ROG=KP2Y_G,G'=H.9=+#7@X>N1-?4&O^_2!OY!0 Z3DCW;!H:\H5Q;M,AP-TXJ2=G0F!U'?- \"7G6GT2;4H$@PC&]8GR.2)-B6 0P2 !C]MR WU:MI8#8S-CS=6;S;FGWA;8)OG -.DCR]&G&V\H_;V=LC<' MF\!MG:$EV#9M,('KVNK(@T226)3P*>'3*.4V7OO^S^<(;>R;3]P9X&/\A^!=P&F3AM16TRP46?1125>A466.=OQL+WC:CTZ56 ML5E,=Y!2A=Q9+VE5GS[^L?\)3CI: (PR@(L>XN2C*UO%=8X4U9'AJ%TGAANK MCH/RN.)"1^9X#-!U>OB!X[[;G7#B9/|\L8KDXOASR4@AT?%'YW*/+C3UKBIH M79ENC41MT1 9?CC@44$W]L>O9(QELC$F> |F*2438R#"?UX@<$;*ZBWX\VX9 M,D[192\%W9>JPF"\$*$Y\!HK:2J9Z1,G*Y)B#X$=0C]D)#;3XLZD4GN^AP" MW4ZFY4593RZ%?O;^@?:,_ OTX,4$(EJ/GQ*Y&*<5R*P!"\(1+@_*'N=, ($!#()(M6"S9.HA@?)&PVS%MKKA^8T?4Y.7-:3G&)39H6Z'A)<18/P&XN6QVD;2*O/U(W M$^_L]K^BC[\)7$HSG<^0K/5C(U5'\]FT ._^ZW_>"%^IV\3B(\OP^C!TZEZ#+Z MR=2CG5RB"UQ)-8 B2+8!R>0$AS_E9+JV[W?EXR2O?;$KWIL^/&0|_OGB"AW.; =?R1GU!;,+"]WJJPO!,V= MJ@TDKP.GOD*0DT20(Y6@AB!+()'ER4C8:T_\$R/+| [&QU5:!;B^&MP]"+4NK MU95VWZY.^UZ|8E_9]4Y=7[?027CY)I<4QC$15|ZJL"6 MC>W28/ADPOK#,,S'$/,D_]>H@(>W$X>?#9[0$/-5K*L-,$]#<C[H=.O:#9[MN>,,?@C<$;YZ-S[f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|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{FQA)4*3/+"RWZLHV>R;GEDM0;#C#RL3 M](16MF,[TZKMF]KSJ.D)#]QZV=O":.!!WYZU^[9Z9=/55;PS'>F9AL_]25X+K>-A>?,X"N M)=>^|=#O+]D.E/GQ*Y&*<5R*P!"!

TOQ>)O_OU(6AZ)W5Z-V@D=>O1$|Z\^ LL,;D=PHC91#;%A6OI M?XY)&#SQ-_VFIT/BR>]A#AWK*RU|(AGJ%G>T7QGX!\H,:B\H/,)|&=K?(8% M"[MCBSX<5s[#M9*Q-C,2S8DPI:>%:8%>-.K=P68P3;J#U0*0+W'@@-P;0^\ M&Z":UN$B43)4G?#K M3,^%KX%K.JK SE73AF[W44T(<:WEWZ=Q/!RE^E+&R(];@/_@C* UHM)_^,@ M&L.F$M1PX+1;2O5*!-4%,-Y0AG/H^\-L2*ZMKJF_@D7WVX5K'L,=`S "[GBL MVHY+0>*Z8RB<)KY39IL*G*@#ET!1X-B05}(S=.!2|!]Y6!%=@"FQ#E>@ # +4FU-M?3_F"""XCE&$-LI:F/2;8"-)-H!HA#4;&/5Q>>1(Q4M#(0?'0U?#GR@EJEM MX%JBAU 6H*D$V4V%9&!)"2)VT!\%NS.%@?I!RR=HR"VF \>- YR.]VDA7K=.MD:W=|:V6=*CM^1ST#R5WZ8?5+8=; (4'J{\G%6(ISYX ^YBY=Z^#,X$@:4$J M[R0"OG$,IQ?-$N-NG-;'4B /9L /9H M C[7UM6%!Y'$W7P,Z1]A$7.7,]9J$@/HJ82Y*L#N-NCI"}'>X95P!)HIA7& M!$@RG(T?B;G'3_P!9&&K4?N0YT%AT"%R!# EWC+(E;-C!;\B^J\(SSA0 _# M",Z0:XW),81/ 4T)NS.06,!?4$^0+<*#$0-,?'#>W;D(BJ<=S!{^748I[V1@ M[=Z'>L;P"8RG>W[Q6@7BCZSBM,[OOZ5P>1O.(&ZP)4@U15!A\)'7X_IX(_MJ=-\7BE?F)J2;8OW<'BE94M-T?'U?)BPT,_1=1NW\:,4ELC>GSF.?PR'G:IB8 M&+,%D+1 T"%YFBD#[\5W1\?4,Q14]!%74*F"]:@-^ TTB'@0 ML> ,"F*4.J8@!]KP%0&Q: F<)O (.=*C.70E@@98PD,B-A*T3QTG(:.P+`-?)W MV81?QT_#]4;ZE(>EPH"5(2VB !'VP-2$!0\"D5%=Z]&6%N@L";OX%#F9N6V MTH/VR0AJ5I!DPR_"?^!LJ3;4&]%$&FH#*&L*I\2,45B?@P"^2T", ^H#T@7NA MB\R;!^;@%S#>L5TQC\XR@6U)MKMI0O[DUZHCNE!K%!N0A,H:CQR.NX$914Q, M4@JCY5L#.EZKC87$L,\7P.3-,G!47PAR>&O<]KD @@./P>DLZRO&FK'A+P;4?^&K_1!$'_X.;GGX9LC;MO\3CG)EVHH#C"-:^HGQ6N,F!#-0ET9]38HI"@TL:1HA|"%\TTL MY%RCLC!JX*T"E##WJU,9J7\'2GC@QM@IA#92X48S5$<%:6G 1BHL5(A"NPER MI_\,13DAG=%/+PE-;-U$^0Y10)3CKJ^2~Z>; V@Y-%R1;?CL5OMHOVZ)+LFTB M*]O4?53Q)1+VMWL1A4:IP5_\M?5!]_MIM&XKA3B3A9LIY C4"52__""M@"NF M0-+<*07Y *J8+UUI#K\G90FAV_0<;ID)T7\-71B"1 ^<+#^J8.+37)F/L.+FA[^2P2 MHR!MH2V!WF7"24#FQ\HE'K^)'N% >1,<$W,\?5T"?<(7UBHNZZGN.H4GPP MMY%)@F@[ACT%*Q &L(5/G=#YUX"\]0%*D"#F_W6\!LBFUP)7F(V4> G"JFG\ MC8D0)#3W#5+!\W-FI6OFI.DB^U"%25Y(1H^0-%','F9'(§X++V,.:2E^5XAQ%,V MTLYMSW+!,UUTP§--3<\'*\,9P-/ ?M9-A/BN+K,?)=D FY+C!OV"# M,?C*-T0\;4# =QQ}+;@+V@?\&639^;\%7+;.36*GB-(:E\A#$]>V_B(§&"_P0T MW)&+=6>5XR\?\=C>QD=6+P2]L+0X(G(@*Q"Q#GQ5&MP[C<"Z1K7=W2.[7P78 M/8#B#@#N";D1H,TRPHY+Y&2#VZZ!A?100)%&;.,%1=9@E,T*OM6R59_U?*,(M#QAR_!0M*^QMS\NH"T\+EP)]^W@4<{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| ML(+Z.EOWN-O'EN)%?8[HFU?(0.R!N%!HXH#46H/"CR#IG9X)5N$Z*$2MH)#O-@2$4P(%$*>%A+PV[H++WO;3'.6HQATUP M&./^.P=/C[!NOU>0H%?+RM/#3,,V<%7XL.+[@>GO_YW1%<&;UD^$.BFXQYY MPV:>,@E>!F<%(*R:&U\<|U3$,6XH\ TB+EP' P0OP(%!P<'';E*2,;>-]:BEI M'GADUNX<6BA-CN&:.*'23=|*HC_ TP9\TW O#$R,X4(2-$'MV(U!\5H#L)*O(M*HVA##L>WFM|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`Q0 #?;',.5$1(-)0R@P'E'#>,.<0FIV! L MXK#RHVITUC%]RIZ]MQ'' (8H#1D$R(R$0<-8^QWA]^*O0IW/ GM2^K$<.QOC M,)P=C\8!NZ\CG7<731D.'*F1]074O3+7M M*$S^+0GI'/%C@>;]QQ/A'"'8EN.AU$) 5?/5CF^2(]J307ADN4]CIA"Y<"/T M4P_L70Z(,E@VH&IBVN!8NA43^#@0'!N'OJ]=IDSDVH'=^>F]?+1"DP)M+WZN M![0:R$T#_XMXLB(>0]"ZP(Y1%>R6^11GG Q-#CG)(2Y0/JR6+66 M:T&F:[5!2Q?H8][5L@?U"5(K'K=\$\+695QKTN@./[W;%4]>1'1D\;)EYW-]= MT;55%Y0&=&NAT \EHV"WIA.1/>VSN+Y/RWUO.:8@=0A3CL M#0T1PS7NEV4 MA--+H3K5U)9OCBBBQ5/;'+R8=HY.)SXL01* <@D!$!R(@#G2);8^9B(D'WZ)[2 M+7M\ZC9;=[_+#OT1D#$<#MN**#[T:%!3Q[5T>FWDUL@*0:GDCV3)3"=6C%T:^)8T> MJEGYZI#MEINKHM'JW0];2<4IEM<33EUTQ'2._\DPY%PN N=RUY;"B)'IR5"B M:],14FCU.[KE,;1*NIUU:9&!+Q[.IWTS/4FNU,FU0X[,H=F4S2PZ0VNLG/8)&?XA!IOS!(#[V'1 MJR:K(#NBKXU-1<7.@?1=6A7B+&=WAMN2DWI]=`S/WXETLDO!4Y$DR)H]6W0 MZD\U*6;>6*4=»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|\>$;NVK8)6!.H Q/D:!C;U[6V+3 M- :A'V\TGVN55EI)SQ? UI7;>2Z>68'&\HR4_B&U3/MLV)=L6V6)__;!NF Z=.MIXHSQVG2XYPW^?$+[CHG#$O!1=40,2$M+TIP.WI3WR-XJY(SZ>'=J$_KUOAA M_&"ZR'E,<';.0K^+50C2\[+(J?3CW>\NV4!A-''J3N_G"JO;SM=$T M7R]<7?I[46DHK#IC&@@9BG5T.5HU%;[WZ\2MD)FU-[^R4Y.9Y. MW7P]C?^OORHXNW%BI]D6)=6^E30M,9%U9_696TBN&XMH=6TFF;EBIO=L5L M[^YNA6EC6\H);+(_37BSW';30UO0Q6_]/U-%/U85:H?Q8#$[8IM$T*#P/M$?O M9D(=3.7[]86GQK'$XU =S 067#8$F9(+%|_3%&H$(+(O /**0KDFY0!-2Q M 79Z3 K70IRCB6I^ /(PX8SAJPB49HJ^;H0I2+HK">KFW\)H%)2Y#1)A0AFN0Z-]3!H!3@ ALJ94$Y9?@U68;)06H!:@7EA9(L"U(,%^Y%'WF(-M%2?4O%/]-C98>"KD=G]"$@5E$G$SI+D#M?9U#+|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s"XQ6% M'.U@4T;X0-\ M,.T_"0#8;W-P*\ZT04^.Z\RZ=CBP@X*W/UX;DYZB,[+/9HDD!76O58$ZE2#K M$sLEU(?2O76!(R,+$\&%86\8CJO+]-8% AE9ERBN"TT$)(+0X LFNO"W"\$ M4X[@NF1N%0OAN]RZ_,,E\OQ<-_4]=>/9XR-O952?+6*L69MU8IYM(WB<17JE*, MG+Z^&QL[(OU?#US?_@,I^-<&R-,-I^/_B8Z@_=!!/$[!HVK'1/:^B>R]O4+X M2]98U43+/UGV!<0_7O9_5XUW*S+_O+;]F?CC,@;Z=P2-EVSC=[\R^!HYB1]5 MB.B\9!)^0]%YR1K[2I)#U#.BGGUO]*

*_+TR:K0XU"@^2F6((S@V;/G\>X2DE.#Y;8/P MAZ]P?GLRT-=B!R(FGX(_< -3>MR>#'W7W9:7D\WE]\H\RS8,V1X9EF\]07FVP M"5,,C>%Z?0973 39_J4D&9^D@LU+*26^0($:WA%,XX-T6F%6_5W"K-QF[VLY M3"N%#=&C)/R[-A7LS\4-F"_I_YDN#[+^%E$:,V#(F_/[';1T=MFY'G=\FF/^ MJ+,&DNH&%NHBE.FP6$"R4I+OI':S.N\) [;5VO0V=\;;*_0A9.$-!?TC[/%E M-Y""+@?XF9([RQ1-QYGI5ID/A6TMY7;4<1U;Q PNVKDY)M< MJGDG9/K@>S"O0":\B;+_$,;\ X7YLS/FA[\R>0M??G)G:9@X\Y!%_9;[I($? M>,@8&;H0Q^FU/4+$<4H\0L12ARG1$R(XY0X3K^6X_39P_D"D(.S>0:?IBM$T*#P/M$?O M9D(=3.7[]86GQK'$XU =S 067#8$F9(+%|_3%&H$(+(O /**0KDFY0!-2Q 7G+6 M9MU8IYM(WB<17JE*, MG+Z^&QL[(OU?#US?_@,I^-<&R-,-I^/_B8Z@_=!!/$[!HVK'1/:^B>R]O4+X M2]98U43+/UGV!<0_7O9_5XUW*S+_O+;]F?CC,@;Z=P2-EVSC=[\R^!HYB1]5 MB.B\9!)^0]%YR1K[2I)#U#.BGGUO]*

+TR:K0XU"@^2F6((S@V;/G\>X2DE.#Y;8/P MAZ]P?GLRT-=B!R(FGX(< -3>MR>#'W7W9:7D\WE]\H\RS8,V1X9EF\]07FVP M"5,,C>%Z?0973 39_J4D&9^D@LU+*26^0($:WA%,XX-T6F%6_5W"K-QF[VLY M3"N%#=&C)/R[-A7LS\4-F"_I_YDN#[+^%E$:,V#(F_/[';1T=MFY'G=\FF/^ MJ+,&DNH&%NHBE.FP6$"R4I+OI':S.N\) [;5VO0V=\;;*_0A9.$-!?TC[/%E M-Y""+@?XF9([RQ1-QYGI5ID/A6TMY7;4<1U;Q PNVKDY)M< MJGDG9/K@>S"O0":\B;+_$,;\ X7YLS/FA[\R>0M??G)G:9@X\Y!%_9;[I($? M>,@8&;H0Q^FU/4+$<4H\0L12ARG1$R(XY0X3K^6X_39P_D"D(.S>0:?IBM$T*#P/M$?O M9D(=3.7[]86GQK'$XU =S 067#8$F9(+%|_3%&H$(+(O /**0KDFY0!-2Q 7G+6 M9MU8IYM(WB<17JE*, MG+Z^&QL[(OU?#US?_@,I^-<&R-,-I^/_B8Z@_=!!/$[!HVK'1/:^B>R]O4+X M2]98U43+/UGV!<0_7O9_5XUW*S+_O+;]F?CC,@;Z=P2-EVSC=[\R^!HYB1]5 MB.B\9!)^0]%YR1K[2I)#U#.BGGUO]*

*

1% V^+"^0*#,WU?J,B@:'!0-OAL>"2IC!D6#OZPD-MO>MJL5];B 9%@P/1^'V*!E=$(16Q*4$+Y(X)-W M/39$]T^6?,NXTD%[*9I#E (RA(S%2X!8Q?% 9?X,#'}&X$ +)]^"G\!7P%;_V* M>1I_2ZF-H"[.I>0'"W!$A:K6J'HJ4$1;.2%'R*XC=YY*;8G-/.7J?8XQ1+6\ M*5I\59LBX,-[YL.@Y,T'HJ';P8BMD\X")IFES*@\@\LQOU/WHPL+HQ4R'&^>JWE'UFUO#Y8S(0V+N MYS>Q-[*BR:.#BR?N7!G8<)<$%\S2/6?=3E^"0)K$=U=?[";-6KV2V[&6>GI(U! M=LH+JRQ)=BE={-8%F;.MJ[*C9CZ2)\5!IRFA1Z=MT/9*!D.6C89?K!KLIY3?:,,:V!3-6\42_10O2"7\F M9=6+*T%)\I^7.DUJ@FJ\(5;53L@8"$0SW@K$_4"9M35P0.Z@$"(-J6YOX M/XD6=@ZU &\;$&Y$:F(@ LF_T1#$/0#\V=X#FS'XU_" OPA'M*:$-R@G MH "%3F9:!NV:3T0G$EP$SCZ ;^)A1* $U5"!BKD;P+UU13AAE%U(F!ICT0; MOO69U_D)K29R;_W/59@N.J1BB.>H=U!C3NM1?4%3I"+5QK5D+!9=TPUR/Z8A M>LEKS)C+MU7.,,(;Q2*Z0R(7,'1GEDT_IF-"@U(&#N/;Q6,T2D-YD!#B(#&X; M\O1(L#K\DI8]%^: 71(?U!V&SC/V(18 M05B&SQA@(6]V2? N4L<3;=&N@ M0UK8*6P%"0Q^*T.4&G!YG 679<._3& ^$I^2W?RILF=O&77:0(<^B_#8^AGN MOS(WHX+4%@#+&0E*#0!7,%#A^9S$H]G#\7E>+D(08(Z@4((;6<6?Q3(@TH']\ MX$VD(+%8TY-)F_.F2,7*"\YF!O:.GH.?<+46'B &09:)Y? 8*%E5T(6'"'DSX M$!B/(6S00]MM^:.3+ 3SEU N @4A9-V1XCJ KX1 07^AD'O)A]!@6@0@FCZR4@N M8T!. 1 \+(D(T9* ;\X'YV@("EYMAY"@7H+S&RN,$T45O] 1=47:"!I.\)E M.Q(L$- @12@4PYF59VL$)1(8"]<.,31=842;X'XJ?XBX "-P3QX/+?3Q%^@+]+, M^"F;QX$B&U+Q"O_@CP4&5@T>]6PI\4NZ[>+0,XM?_E((M'+\[GT:.^PF'S&QA MXE',SP5\BTM; [N2]96@R_AXMC%,EP]8MWI?)IB;#M_,K=P <(4*&$ T,3_BX M+R?04I;_" E H0*Y X+=!17\'GZ-& 8:!+Z^@(H]*CS**'+G(]&P'D-,+%E MSM(@E*%2A$_@9]$;X4>(=U324("'''*@:?* [\"T0C]N"Y&>PWI,PST7]4RV@G M"\VGN9"7 2=0]+4+T_AGX'0JZ~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`O@+"=54. L4&ZI(F^%< 'T!@9QD5IHDGLN/<@'XHN MB]@?XID%?G@K_//4Q /=N!1B@N#'5H)95/55ME1GYA,IVT:#*>-YNH)TDJ8S# YIGI ,]0KAQ8=O[GD!WNV M3&-!P;9CC'L3VN:XY9I#T#8[Q8ZJ9EV2)4_)62KRJ@WM@./YG7'X?NQX8]_< MRFW9HQDZ'D0&J!Y8T<6{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{,$+/K++M<;+,K+ MU-6EW2K-]5;SB2JRL?0X,^MT"_HLWK@#)7(AL":.^8SA1(29U&J4R^W0-%-3 M6M<'"Q,W\Z#9?U38?.9)?G*$26Z:2"&7QG$STILKD?NDX#+<+N9'6#/?? T8A M5[.9,=7YWBANI^Y B=PG*\9OB707 B=\2C.E.OIL3+HAM:Q.E8BD6LKD4T_MZ6YK#-VJGVOQ.98.0DV+6=67 M3NEKP\#L+=VE6\!8?K**A$55NXYAB2>F?2 M\2"_N0LC(, M0QS96!2VH-"6X? __/TI1_X4O?B(^ M>E/@WS>/X-L]506NY-[>K9DHCU.TIWf(/UPE9X7 3R&X.0F@[\80)FZ2UL3@ M%"^"T%79>\&*'$HLDF7'G'(X[&L,B):)KA*A^0K1 /"T0(P-37'=BD@LXO]/ M#^-N!F:(@<0 5LD:N1X:H4AG21N3-RLU[',8(BZ M2UAPHHSB95@$)2EG-1H1F.9CPU,.BSE5:,],%:\T#@B[^.YGS'T[2@B+R=G@ M4E&J!LXM@X:% 729XX%P,J=]DQ5XGOAW2-J-H?9; <1#A!#]ED(?\03[+'P\> M=>*+;9S4!:?QDK$6X/'2N=QG[:#(Y6BH1N7X7C=1#;%BK-RGE-13@EGLIYW& MCB,=(!V=BA3I<+*- %H%YM07E)Z:@,XLX25D1P)=LSIAUR;E=0(1,L]4>VFUBD4 M*],5RY?.U @0E$A@)U(Y--$IFU^/,8T(=B&?_'Q*C>KYHKG2\;!OB4YO.OF M@9G7C'_UY?"4$PXZ 7M9:% DVY:)]I\N=3D/IL,9A\&>$C9W+/_ M&RH^%&M&$]D(YK&YPLGAGL*,!Y*T2D5M9_FD@'#)^8R^S$$;Y+-7 8E%<2,6 MW!CCSTVW>R2CV^2N. ^]?2#W^\.I;T7[P,M> (N)Q[^T#^D=X2#@@[I43^'\'%_ ;MM?J^\1*(K+M&2R#%[AQMB<<X+,.#+U?#R^C*V[SZ>7#][_S60\M^,@7,.#!&^ MYPG(^X!VBMD]}6;H9#/(3^K[^@F-.=Y!6=?OA/8:C? C=M__W8O^]INLM0'+7 M N3:'/126]P3 #Q7(899 H,737"Q?LD! [W-:KH_@M!%US7^H>;)GV2+?"E2 MN#9S)%X"R$5:BW] +-YQ-_$W0]NVO9CZ2I+SHZ;[71@C-Z:B@,,^A<-T0^2_ MBE5RWV2!{.O00^?8V MW]WM:^..WW#C$X,)\.O-!6DU)W66CK3T6IS,-5Y7G2TC@>)2M8]2GG>C5*99FX\ER1K&\[6J/8.7SA=&T.#:JIAI+ M09D2_?&'2CS&5C41^G(RY9/T+ [8Nf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|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f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l;_*E8*%O(L^[E39G K7]ME]'I'UTWWM!R(+ 9L;:HV0O4, MX[12D\\7<$5Y2M'LJ+I@\]&V/&U03MP(H;))](_L6L>GKX[OWR^6#AQPQIP M^[6])*_C=]?>YD: KR68^7 4]K<'0S57NH$Y R)"U:"I<9,)Q;K"L[XZDS M@=P>@]P>/RZU_&6X_3Y/.@'[WS?[?]SM\3KVKSV-8R0W'F=)<56<.\.L2*O- M&RC[=72]"L5+!*8O,:)5ZIMR0=5MH0/9/HL-,@CRN<_,5XPP" 1 (@$_59+Q. M +26O&5:.2O/ADIFPV9B@QA-WT #,O-I*2TV:S4I<8Q>LFI5']-(#KSDC$ MPA=W9]S:VX>]M>$>&8\(C%(8 %D#4=83.(\F\&_>&D5+7%*X=WN-\D* ?I*ZY?X M# I%;'.+GOORHF\A? R4S1K{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{=()$HE_>Z0*6Y1X^_F'?^.P7"A(G_H[OV+RX6LN!-% M@.OZ>9)!2M8]2GG>CS*99FX\ER1K&(^6Z8AC/"5-!N$) M:=&()QOV;+7N25RW)B:4<%Q5YRA_/OKC#S:2_Q0)<;G.'IZU>%]\LQ^#W?] ME=PQ?D^)/.02?)%W_X>;<*\H9GF"9%< M49=C\+1--#A[6B.[A4_T9;I5LP_,=1M[(%LP MSU_4,#?QO\O-X2 Y%,7)784BHUDZ[=DSNU*(^*=4'C+/;8N%(_NEN+4(&L; M8M_6ZKH;]HSQ'QROIPI=C>{_!L\;$?:)7Y^?8L-52,KF*8-!/CF375N+++- MW5)E&]HI[88CL?X@RBBCE 1BNET2. ^,HC49)I'1B<>(O1QT?Q?WY4% G_: M5T82:XDLJ:38S([H5])60I*$6C,11\3@:,M M<+3=N,MPZD\D('P'\AT8R &/K=["SWZ.T\\#SKE65BNEF$C..G46R0-T;PIU],FF[5]8& 2^N:_FFR-/A<6U@&Z! M;3X/37I]9X+PN(\X[^Z_>6GQ.]MI7XY4;]F,D]GQ=:L0EM+@V$E(;3N.WQN MGA]2TT%O-6!L<:86G$7#I/44ZCOBQL]1B8=$C/IK#NN:OR^(G[M8_Q:),/7 M")^;6[-PIS.=SZ10.KRN-_)-CJM.D+1=B#Y>+:?[O>2%_T?E_F^C<:Q=J@HQKS9*K#V\!DFNK)2I5F'FB!9X!G% MD>\|H[Z3<_3JF+MO)N_GK.#PAL#M549SGLH<*8ET/YM[]=NQ/_A#!.Y.P63B MTE;PG9WU/_F_VU\&N3 G?QWVLL7/"L7ISNA[^)6%%WV.YXT#+DE5XRCLH MDQ3:Q>&'6)AZH!)_CY,H<"'<'[N1O:U#OR(4W6LZ3DB;5U'97-L&(KRD0-3N+Z M-=Q(WDO'OF)8P9VQ2.!._B+V1?/4_K(AO1RE(_%B1VA(BC'IT0N]WXX,,+TC M0SJZ$T;SC"'|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|& M. 6(>!LBWA@|\:)N^+Q=WZX=S$MB^5-@X$^;@6L>&2*'AS^^AQ!$((]53SI?GA_/1:1_G MC)M>G.-@/.|S),"[!'B67XE OD1M'I?]:IV_RT4"N&;Q/48";,- ED.@*4Y?8 MKFM[WM=N/Q("\@7TUH85%QI9Q|&^OH+RN3!/W1&#O?("1+<-,#07!?B<DSZ/ MK*TL)LO>..-5\9>N?$_ JC_*(H,JTW-+WQ,^,;,\?!VEQO?%Z6CNCD/7$;+\LPS'(AR%Y, M*O98;OOE/J>L:#[(U2%_$\I@OA?:)>B)W\=,.(:>9@Q-B,G\6$X(ZI:@PGQK7X[+C#C>:0Q MI(Y'BG(Q;@Z%.2O-5^8\-BF%0%6<#.DA>3@R5\1'5MV86B"0DX,B9VGG-6: M#"/(?*

!7N#;LUB\5W^8NT;R-MD:2#N.$P\N6)=1FZR\PPB=1;Y6I-)HQ[9Q%OS,\P$,]8/H0EQR!Y%-7_Z;T MB??,V6{@#N|D*)+'YU#61I]'FCQWT.6.Q!#CN?LG&YBR{7E3@"]X{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{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s>.IZE5>5+T?&$OJERE*E>IRE4>24'#8;>*,:V\&%.G0#]K%63;K2GV5226 M'\;5A)WB DQM8.UNF(Y\40K){OIY8D8[..5SV%"#6J_=+MR(>G%$L!0W.D@B M6(X9'085M-NU?K]3N"7TTJA.6YT@%2P*F94.BIXG%;K34[!89.=Z\-54&C M9K'FZ;Z#1F\6#(V? $AM(KJ@W\S]OH?=> E?B\"]2[U#_G[T+,_HB8\WR[;GV?9-N$/ZQ(;OW&CJU9Y,$9X6XL-_+@8SP%@-[\>1IX"77G MCK$]=YA&JD5W;+FP"AP./Q.W@ FX R><3D7D>!@2C* |LP/L/;"K64"*S@1>3M'[=_^ K^#E?$(2'7X;X=_%R<- :Z@%5$,VW"MJRB\X>E+B@<6Q2CIQ7)%=A0;F(1]):QB*M%&O*D$H&H^_M/O5N+5@1- QA/[(@:D\=36!ND)&*'2[<29]"O6Z>!/@N<55@B3N!]$[B@B9WH MKV#W #SAV#'>@0F)0%S!^:X%;-^;K_"[^%C6]X8[B"Y">&>Z29\RYD#E&/A-A M!%0IH4++)7'-$C;<.?Q473:LYCF 029.(P9*.X$.VSGU0F^XI!JVFNU:H!V1 MEPKO/+OVO@L" ; 3P!4>!SP;UOJ-Y1^Y#WINP97VNZ\68?BUZ&?3D7=,M8 M\^?9/MNU3J^_M(-OYQ@CO.(`W4:=QVH>*:XUZ+B)(R)I)Y-M9&OXIZ+ZM^+6\5-4&D(&@+O8DZ)/P"^9P=7'JW+&IV;>SO2E MG&GVZLVGR)EFZW%R:H6<<1;.FYIN_L>>OLNB& M=>YK>*^-]39!#@#1?6,9?^-U+- WEU+X],FY,VD)'OA@G[^5CZC.RYO2'84Q2 M\GTD?-)>;79AWF8+%TU?PDFK_,6?V'|/Z 9?/+= A 6H)G9NAJ6^-&;Y8L%RY-D]F\1 MML;^0M]OA=?Q"_E[;4>0).H-WCQ"N/:&#WI*BE1MP"S8:VQ|/5C*L5$Q Q,- M_HW&4":ABQ2 3X+TA1;B .T? @?P;@7@V7NGZKTJHS5>4, &"X9^3O?,'63""QNGRX4K$K4]AET'*[.(F\44HG&PLA#6'I$,A[Y9A7!H"^$?EGF%>)HD9\Q8\KA+5>8!# M'(5XO?KP"7BW66.IX0T\$2>I.VGQN_3@-4*N!*M0>23#GR2/,%DAVK/0^6?14)00"Y\<"(_M_>)!$>ZM!;IA.JN!+>[4R34A2%] [5J4AK/@&?/WU]..^G%X0:L,;3I_!3=/.2 MW!6N]*(#IV49K-0UN"-ZNL:OMZT -N?8433'WUW;?DKW^-I@E#66N'(WZ#0W M?>$D*7 =8$&@^B5SBU3_6&_=?$40+JQ? M_X4*.N#>"RBB#AAD$2A3SYH(LP M&'L:L#|T^O/MH6TI0PS,IHV%0DGO K(@VY;5X0+L/=^O;>)[8&.U+I5%LS6 M?>H^&C505SX_-^>9X2V*YN5(L=^J-IS#*]B.9XRHN!? _$QZ^!0Y)9C;PM#)+< M9+3)4T<$#:0\,1+[>9Q2/X^M0#K70&11! YR4.XTE;/U1.7KV66@AJT\UT-MBW_DV/*$&MO^ZDCQ/KL$>Y5+L'()5B[!3=`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

*(%PFL"$MIYE*3=`9>H>VH=PZ-M/&[RD"%CB\4V*SCB+"HS3G$*Q;),W$1Y`.%R1C/5X,<0B!!#"8Z'>+-%TN.C M*MP,JM;VXA5PK>__:V,,<3D1,4&':]SO4Z#C&F%'Z9_PQ%5Y>?YW(R>?40(52\O,RD85U"6;= 9P>D)\#FOR% MF3]^<#1QNEVU$6T=JCQO>VZ!P3TB"&4=&46E(CLT0OS*G&.I#;,2KAYGTA%.M4T>)^0$GWKIU0@0@0K]>HJU8Q@(5[`Z'MD)Y.>=IVW&4?G$5[KUCR#'N)*DJ$&ALJNU!EQ )0.M4*6!>M:4Z!7U%,=UG91G5;3]BCAWI7>2^;5T6AVUG=XJ@\QH$;YGYZ!SZJ&@0*#]\ M1G#:M*(QI^ARC#I%<:TH55R\=??!,%)&]_'KSV-,#(E"-VJC!<#Z/=K0'MI4 MQFZ[Z"KRB@A*;?0.,!/.,1Z0-/ M<.W5D['5<34P1-R!HON6C!<:.@OI+`]*$T1HZK2?N=W=^:6JS8J37:N#YKS$Xa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f!P%LJ[!XMYOQ_"3<9&R2JX5!#*%?%5!K*<1R:O1\@\MNRVZF M8>8:MW?(=/NWFFZ)\N?C1WN_C4QMFCI2$F559*QZ.0_8UP+IVEH3L;(F-(M$S!OG$N3$3F1S>"RV+;TG$J3Y,I4&$?.K%7N55YJA?H=S8;M0,.I@,F\&M>R M+*5EX_/RP8[8=4,'!ZE_\H^2,F7A34WS,W*F%@*\18B7C1>:K"TTP4(DYU5< M@(+"\Y8RR=-O,/7'_B=K+9\.4=9XN]J5?(A5E<8$<#;J*,B%024*-P_E\$OG;P<0O[& N>L8>VFR M;AU[!9^18B-3R;4D .3/!"ZD%31392@Z.^\P+I0[A\>F#0Q9 M5QYV63 !Z;)$2+MO<$]^%DZG#VGO%-?I_,GWYU-/&Z MO6XCVCK4>=[UW_"#+X@@E'54DE2;[- *\=?FG"ECT4K[>,QD$DSS5X7\@(EW M:APP 9C@UU=H.Y91H]WWZ&M4%&M>-KU'&7O)78U MYR*O-S]7Z+O?J)SMPVT;Y>_!5LM?MOU/&ZAU+UV/(D';Y)=>2&;[@N1VK6BI M&>,H6ZS29I5-7 ,FG&&_:X6X-<;%"MF*>E,)WMP4.X %0HJAD(6_5#HU.!9__M51*L.]16A3M8,KL_?X7[`#M)[@HDC$VU/>T2$BE@G3H%K"K-A>#G%--]5G91 MW=43[NBAV55^D"5&9O[VANR72'\@>M7G@E55-@[^V9E%",$G_<+ MJ/&S=W2>%;]P0\IC;(@K*];D_OX7!BW"S=`CKS+K3YMNJO3I7Q^T_N.U?M|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`QR!A /%K+,(=JQ71^PLYB\W"MF$1<8.6K%7'&A?_"U?^?S3*;$;\$,T+]^FQ:&_$+5F@.5F>_O9^?S@,TZ-O> MV F!D?RA]K^[.S79]+VC!0THW+MIS0&/$#@9MAWQV,QHX2!$@W6C1$@#P1 M?^%8:VE?STYGU\'W7QZ$LRO+I_Y(C;XAN[1M[:],,$BDBD3REM.-JZ[<8\13Y!,",K!(L09*:RK>T;6Z"22 M:J;ONOU'":5]1]L0*G<$^512071ZAAR&$BX@-],,79>, *38\@Z[X<'&>Q*5 M-A($>#.[A[R70$]3=1L++%][QZY'2!,IEBJ6/ M3C+)LS7ZA8>,%FD/U%.2@.^P#Y7=T%62T C,*5NS\Q-T2GD/S;/(WG%_RE=0 MJ]9;SU,B2+A&L%+21*&AK/4:4$-2:$A26J"/&:\8@=+F/R"_.V7&^.]N=32 M(U^* 3W1F72| P65.VI_!N!X.Y_>ZU&:/I10 !ELC.Y)#I$!11BJXV(%Y=?Z MH&)%;S<'WF,#.LW!.A;A0#IP.TA5;LU+%5*HQ2D 9&I 2W2Z1?!`)821RFLMQ2JJ4DB%4N??'0IH6V@B-;D^V5"0E_\B\)PI(G1OL1?9A2)C&VA=#/$LM@-'MW7@3X.U`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{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{G>YWS%"\2]8#?,]PS:]0 >],.@F64N/?"HX M],3G#[^)G;ZWIQ!VFZ14?_GB&B,3@NLMI+SGXO*]I] HMD:?9("H@X*/#KE M8@FEW7]GXE #!E11GB 345<$0F,)A**A.T"]#]# KC(.9R-F$X-[+%.[0@& ML)0X$F M5A&;09]5.K=W2+S0F]"XMF1+9EHQL"\&RYFB4OCGFZ,;.@.=`MBS]1(%4Q0Q W M1Y[G94-&'8[V[HO8=]=YW0-*`$'FJQ=&7$#[HOHJ03-6XKC(R,KH7"&HOA-,_J1:V>L8=TE82V4I=) MU0"+QO+:(L^(9.%,]@QIC5!19:4B.(+VL)*DX_3]ATM+$",_.GC.#.+^M*Y-?F/\(S!TIU"'0#*?@_25;.63#=@S\G4!@"=8!J+N#D6D.MF;_XN.1^/.+ MJ$?BSZ,BZCN>"-T/QW4_5]<]K[A%>C?4(;)Z4*B(/A?0W;[*NK^A^[Z MT9+?OQ 4]"V VXI8WOL$S8Z^9C&UL4$L! A0#% @ M(!H631G;+\L)0 *RP" !4 M(!/AH '1E;&$M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0 (M +2 .%D/W[U^A50 !%\!0 5 " 9T_ !T96QA+3(P,C0P M.3,P7VQA8BYX;6Q02P$"% ,4 " "T@&A9^5B_=;|W `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end XML 61 tela-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001561921 us-gaap:SubsequentEventMember 2024-10-24 2024-10-24 0001561921 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-10-24 2024-10-24 0001561921 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-10-24 2024-10-24 0001561921 us-gaap:RetainedEarningsMember 2024-09-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001561921 us-gaap:RetainedEarningsMember 2024-06-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001561921 2024-06-30 0001561921 us-gaap:RetainedEarningsMember 2023-12-31 0001561921 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001561921 us-gaap:RetainedEarningsMember 2023-09-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001561921 us-gaap:RetainedEarningsMember 2023-06-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001561921 2023-06-30 0001561921 us-gaap:RetainedEarningsMember 2022-12-31 0001561921 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001561921 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001561921 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001561921 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001561921 us-gaap:CommonStockMember 2024-09-30 0001561921 us-gaap:CommonStockMember 2024-06-30 0001561921 us-gaap:CommonStockMember 2023-12-31 0001561921 us-gaap:CommonStockMember 2023-09-30 0001561921 us-gaap:CommonStockMember 2023-06-30 0001561921 us-gaap:CommonStockMember 2022-12-31 0001561921 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-10-24 0001561921 tela:ServiceBasedRestrictedStockUnitsMember 2024-09-30 0001561921 tela:PerformanceBasedRestrictedStockUnitsMember 2024-09-30 0001561921 tela:ServiceBasedRestrictedStockUnitsMember 2023-12-31 0001561921 tela:PerformanceBasedRestrictedStockUnitsMember 2023-12-31 0001561921 tela:ServiceBasedRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001561921 tela:PerformanceBasedRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001561921 srt:MinimumMember tela:PerformanceBasedRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001561921 srt:MaximumMember tela:PerformanceBasedRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001561921 us-gaap:EmployeeStockOptionMember tela:EquityIncentivePlan2019Member 2024-01-01 2024-09-30 0001561921 tela:ServiceBasedRestrictedStockUnitMember 2024-01-01 2024-09-30 0001561921 us-gaap:NonUsMember 2024-07-01 2024-09-30 0001561921 tela:OvitexPrsMember 2024-07-01 2024-09-30 0001561921 tela:OvitexMember 2024-07-01 2024-09-30 0001561921 tela:OtherCustomersMember 2024-07-01 2024-09-30 0001561921 us-gaap:NonUsMember 2024-01-01 2024-09-30 0001561921 tela:OvitexPrsMember 2024-01-01 2024-09-30 0001561921 tela:OvitexMember 2024-01-01 2024-09-30 0001561921 tela:OtherCustomersMember 2024-01-01 2024-09-30 0001561921 us-gaap:NonUsMember 2023-07-01 2023-09-30 0001561921 tela:OvitexPrsMember 2023-07-01 2023-09-30 0001561921 tela:OvitexMember 2023-07-01 2023-09-30 0001561921 tela:OtherCustomersMember 2023-07-01 2023-09-30 0001561921 us-gaap:NonUsMember 2023-01-01 2023-09-30 0001561921 tela:OvitexPrsMember 2023-01-01 2023-09-30 0001561921 tela:OvitexMember 2023-01-01 2023-09-30 0001561921 tela:OtherCustomersMember 2023-01-01 2023-09-30 0001561921 tela:MimedxGroupIncMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember tela:DisposalGroupTransactionMember 2024-01-01 2024-09-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001561921 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001561921 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001561921 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001561921 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001561921 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001561921 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001561921 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001561921 tela:MimedxGroupIncMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember tela:DisposalGroupTransactionMember 2024-01-01 2024-03-31 0001561921 tela:MimedxGroupIncMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember tela:DisposalGroupTransactionMember 2024-09-30 0001561921 tela:MidcapTermLoansMember 2024-09-30 0001561921 tela:MidcapTermLoansMember 2023-12-31 0001561921 tela:MidcapTermLoansMember 2022-05-26 0001561921 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-10-24 0001561921 tela:CommonStockWarrantsExpiringIn2028Member 2024-09-30 0001561921 tela:CommonStockWarrantsExpiringIn2027Member 2024-09-30 0001561921 2023-09-30 0001561921 2022-12-31 0001561921 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001561921 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001561921 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001561921 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001561921 tela:CommonStockWarrantsMember 2024-01-01 2024-09-30 0001561921 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001561921 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001561921 tela:CommonStockWarrantsMember 2023-01-01 2023-09-30 0001561921 tela:MidcapTermLoansMember 2024-07-01 2024-09-30 0001561921 tela:MidcapTermLoansMember 2023-07-01 2023-09-30 0001561921 tela:MidcapTermLoansMember 2023-01-01 2023-09-30 0001561921 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001561921 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001561921 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001561921 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001561921 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001561921 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001561921 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001561921 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001561921 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001561921 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001561921 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001561921 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001561921 tela:EquityDistributionAgreementMember 2023-01-01 2024-09-30 0001561921 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001561921 us-gaap:EmployeeStockOptionMember 2024-09-30 0001561921 tela:MimedxGroupIncMember 2024-01-01 2024-09-30 0001561921 tela:ThirdYearMember tela:MidcapTermLoansMember 2024-01-01 2024-09-30 0001561921 tela:SecondYearMember tela:MidcapTermLoansMember 2024-01-01 2024-09-30 0001561921 tela:FirstYearMember tela:MidcapTermLoansMember 2024-01-01 2024-09-30 0001561921 tela:MimedxGroupIncMember tela:DisposalGroupTransactionMember 2024-09-30 0001561921 tela:MimedxGroupIncMember tela:DisposalGroupTransactionMember 2024-07-01 2024-09-30 0001561921 tela:MimedxGroupIncMember tela:DisposalGroupTransactionMember 2024-01-01 2024-09-30 0001561921 tela:MimedxGroupIncMember srt:MinimumMember tela:DisposalGroupTransactionMember 2024-09-30 0001561921 tela:MimedxGroupIncMember srt:MaximumMember tela:DisposalGroupTransactionMember 2024-09-30 0001561921 tela:MimedxGroupIncMember srt:MinimumMember 2024-09-30 0001561921 tela:MimedxGroupIncMember srt:MaximumMember 2024-09-30 0001561921 tela:MidcapTermLoansMember 2024-01-01 2024-09-30 0001561921 tela:EquityIncentivePlan2019Member 2024-09-30 0001561921 tela:EquityDistributionAgreementMember 2023-11-30 0001561921 tela:CommonStockWarrantsExpiringIn2028Member 2024-01-01 2024-09-30 0001561921 tela:CommonStockWarrantsExpiringIn2027Member 2024-01-01 2024-09-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001561921 2023-07-01 2023-09-30 0001561921 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001561921 2023-01-01 2023-09-30 0001561921 srt:MinimumMember tela:MidcapTermLoansMember 2024-01-01 2024-09-30 0001561921 srt:MaximumMember tela:MidcapTermLoansMember 2024-01-01 2024-09-30 0001561921 2023-12-31 0001561921 2024-07-01 2024-09-30 0001561921 2024-11-01 0001561921 2024-01-01 2024-09-30 shares iso4217:USD tela:item pure iso4217:USD shares http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-*

gaap/2024#AccruedLiabilitiesCurrent 24717193 24494675 0001561921 --12-31 2024 Q3 false 0 0 http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 0 0 10-Q true 2024-09-30 false 001-39130 TELA Bio, Inc. DE 45-5320061 1 Great Valley Parkway, Suite 24 Malvern PA 19355 484 320-2930 Common Stock, $0.001 par value per share TELA NASDAQ Yes Yes true Non-accelerated Filer true false false 39388443 17301000 46729000 230000 416000 11222000 9737000 13600000 13162000 2009000 2098000 44132000 71726000 2423000 1984000 1834000 2119000 1796000 1954000 2566000 265000 265000 53016000 78048000 2479000 1667000 14379000 15300000 16858000 16967000 40970000 40515000 1460000 1685000 59288000 59167000 0.001 0.001 10000000 10000000 0 0 0.001 0.001 200000000 200000000 24717193 24494675 25000 24000 343076000 339655000 149000 91000 -349522000 -320889000 -6272000 18881000 53016000 78048000 18957000 15052000 51651000 41455000 6004000 4568000 16099000 12682000 95000 95000 285000 285000 12858000 10389000 35267000 28488000 16472000 14474000 50691000 42517000 3683000 3728000 11133000 10834000 2068000 2368000 6784000 6934000 22223000 20570000 68608000 60285000 7580000 -9365000 -10181000 -25761000 -31797000 1344000 1334000 4007000 3878000 337000 558000 1135000 1901000 -1007000 -776000 -2872000 -1977000 -10372000 -10957000 -28633000 -33774000 -0.42 -0.42 -0.45 -0.45 -1.16 -1.16 -1.51 -1.51 24703578 24703578 24483664 24483664 24648933 24648933 22322256 22322256 -10372000 -10957000 -28633000 -33774000 51000 51000 58000 -15000 -10321000 -10906000 -28575000 -33789000 24675832 25000 341897000 98000 -339150000 2870000 14702 31025 117000 117000 -4366 19000 19000 51000 51000 1081000 1081000 -10372000 -10372000 24717193 25000 343076000 149000 -349522000 -6272000 24494675 24000 339655000 91000 -320889000 18881000 217267 1000 225000 226000 58994 281000 281000 -53743 358000 358000 58000 58000 3273000 3273000 -28633000 -28633000 24717193 25000 343076000 149000 -349522000 -6272000 24475504 24000 336939000 84000 -297042000 40005000 2002 1000 1000 10602 88000 88000 -530 5000 5000 51000 51000 1369000 1369000 -10957000 -10957000 24487578 24000 338392000 135000 -307999000 30552000 19165027 19000 288361000 150000 -274225000 14305000 119240 101000 101000 10602 88000 88000 -26481 285000 285000 -15000 -15000 3791000 3791000 5219190 5000 46336000 46341000 -33774000 -33774000 24487578 24000 338392000 135000 -307999000 30552000 -28633000 -33774000 461000 362000 455000 447000 285000 285000 73000 33000 1563000 992000 3273000 3791000 7580000 1745000 1456000 2356000 3503000 -524000 -361000 636000 1535000 -967000 1373000 -93000 186000 -34064000 -29806000 725000 406000 5366000 4641000 -406000 46341000 226000 101000 358000 285000 281000 88000 149000 46245000 -154000 150000 -29428000 16183000 46994000 42019000 17566000 58202000 3552000 3431000 175000 23000 (1) Background TELA Bio, Inc. (the "Company") was incorporated in the state of Delaware on April 17, 2012 and wholly owns TELA Bio Limited, a company incorporated in the United Kingdom and TELA Bio GmbH, a company incorporated in Germany. The Company is a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. OviTex Reinforced Tissue Matrix ("OviTex"), the Company's first portfolio of products, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. OviTex PRS Reinforced Tissue Matrix ("OviTex PRS"), the Company's second portfolio of products, addresses unmet needs in plastic and reconstructive surgery. The Company's principal corporate office and research facility is located in Malvern, Pennsylvania. (2) Risks and Liquidity The Company's operations to date have focused on commercializing products, developing and acquiring technology and assets, business planning, raising capital and organization and staffing. The Company has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $349.5 million as of September 30, 2024. The Company anticipates incurring additional losses until such time, if ever, it can generate sufficient revenue from its products to cover its expenses. In March 2024, the Company sold its distribution rights for NIVIS Fibrillar Collagen Pack to MiMedx Group, Inc. in exchange for an initial $5.0 million payment and additional future payments aggregating between a minimum of $3.0 million and a maximum of $7.0 million based on net sales of NIVIS during the first two years following its launch by MiMedx Group, Inc. Subsequent to September 30, 2024, the Company completed an underwritten public offering which is described in Note 9, Subsequent Event. The operations of the Company are subject to certain risks and uncertainties including, among others, the uncertainty of product development, the impact of macroeconomic conditions, including any lingering effects of the COVID-19 pandemic or other public health crises, general economic uncertainty, including as a result of inflationary pressures and the measures undertaken by various governments to address them, banking instability, monetary policy changes, geopolitical factors such as the ongoing Russia-Ukraine conflict, the current conflicts in the Middle East (including any escalation or expansion) and increasing tensions between China and Taiwan, cybersecurity events affecting or disrupting normal hospital operations, constraints on the supply of critical surgical and hospital supplies necessary to facilitate the surgical procedures in which our products are utilized, technological uncertainty, commercial acceptance of any developed products, alternative competing technologies, dependence on collaborative partners, uncertainty regarding patents and proprietary rights, comprehensive government regulations, and dependence on key personnel. -349500000 5000000.0 3000000.0 7000000.0 P2Y (3) Summary of Significant Accounting Policies The Company's complete summary of significant accounting policies can be found in "Note 3, Summary of Significant Accounting Policies" in the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Any reference in these notes to applicable guidance is meant to refer to generally accepted accounting principles ("GAAP") in the U.S. as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") promulgated by the Financial Accounting Standards Board ("FASB"). Interim Financial Statements The accompanying unaudited interim consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the Securities and Exchange Commission ("SEC"), which permits reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying consolidated balance sheets and statements of operations and comprehensive loss, stockholders' equity and cash flows have been made. Although these interim consolidated financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements, management believes the disclosures are adequate to make the information presented not misleading. The unaudited interim results of operations and cash flows are not necessarily indicative of the results that may be expected for the full year. The unaudited interim consolidated financial statements and footnotes should be read in conjunction with the consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company's inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates. Revenue Recognition Under ASC Topic 606, Revenue from Contracts with Customers, ("ASC 606"), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. A significant portion of the Company's revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company's customer contracts, the only identified performance obligation is providing the product to the customer. Revenue is recognized at the estimated net sales price, which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records these rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue. Payment terms with customers do not exceed one year and, therefore, the Company does not account for a financing component in these arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one year. Fees charged to customers for shipping are recognized as revenue. The following table presents revenue disaggregated by the Company's portfolio of products (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;background:#cceeff;margin:0pt;padding:0pt;"> OviTex </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 10,159 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 28,240 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> OviTex PRS </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> 6,313 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> 4,812 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 17,054 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 13,063 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 181 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 81 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 475 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,052 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,455 </td></tr></table>   Sales outside of the U.S. were $2.8 million and $1.7 million, respectively, for the three months ended September 30, 2024 and 2023 and $7.5 million and $4.2 million, respectively, for the nine months ended September 30, 2024 and 2023. <p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company's financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The carrying amounts of the Company's Credit and Security Agreement approximates fair value due to its variable interest rate. The Company follows the provisions of ASC Topic 820, Fair Value Measurement, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</td></tr></table> The following fair value hierarchy table presents information about each major category of the Company's financial assets and liabilities measured at fair value on a recurring basis (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair value measurement at reporting date using </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> Quoted prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> active markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> Significant other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> Significant </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> for identical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> observable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> unobservable </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> inputs </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">(Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"> September 30, 2024: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> Cash equivalents - money market fund </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents - money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> 41,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr></table> Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted net loss per share are the same. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding for the periods presented, as they would be antidilutive. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.607872%;padding-left:0pt;padding-right:0pt;width:101.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"> 2,128,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2,202,264 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> 971,439 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> 864,427 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 88,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 88,556 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,188,857 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,155,247 </td></tr></table> Recently Issued Accounting Pronouncements The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options and Derivatives and Hedging - Contracts in Entity's Own Equity ("ASU 2020-06"). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity's own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance did not have a significant impact on the consolidated financial statements and related disclosures. In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures, which expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted, including adoption in any interim period. The Company is currently evaluating the expected impact that the standard could have on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, requiring entities to provide additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. The new accounting guidance requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. This guidance is effective for annual periods beginning after December 15, 2024, and should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the expected impact that the standard could have on its consolidated financial statements and related disclosures. Interim Financial Statements The accompanying unaudited interim consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the Securities and Exchange Commission ("SEC"), which permits reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying consolidated balance sheets and statements of operations and comprehensive loss, stockholders' equity and cash flows have been made. Although these interim consolidated financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements, management believes the disclosures are adequate to make the information presented not misleading. The unaudited interim results of operations and cash flows are not necessarily indicative of the results that may be expected for the full year. The unaudited interim consolidated financial statements and footnotes should be read in conjunction with the consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company's inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates. Revenue Recognition Under ASC Topic 606, Revenue from Contracts with Customers, ("ASC 606"), an entity recognizes revenue when its customer obtains control of the promised good, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods. The Company performs the following five steps to recognize revenue under ASC 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only recognizes revenue when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that will be transferred to the customer. A significant portion of the Company's revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. Revenue from the sale of consigned products is recognized when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is not held on consignment, the Company recognizes revenue when control transfers to the customer which occurs at the time the product is shipped or delivered. For all of the Company's customer contracts, the only identified performance obligation is providing the product to the customer. Revenue is recognized at the estimated net sales price, which includes estimates of variable consideration. The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. These rebates are based on contractual percentages. The Company estimates and records these rebates in the same period the related revenue is recognized, resulting in a reduction of product revenue. Payment terms with customers do not exceed one year and, therefore, the Company does not account for a financing component in these arrangements. There are no incremental costs of obtaining a contract that would rise to or enhance an asset other than product costs, which are a component of inventory. The Company expenses incremental costs of obtaining a contract with a customer (e.g., sales commissions) when incurred as the period of benefit is less than one year. Fees charged to customers for shipping are recognized as revenue. The following table presents revenue disaggregated by the Company's portfolio of products (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;background:#cceeff;margin:0pt;padding:0pt;"> OviTex </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 10,159 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 28,240 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> OviTex PRS </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> 6,313 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> 4,812 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 17,054 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 13,063 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 181 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 81 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 475 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,052 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,455 </td></tr></table> Sales outside of the U.S. were $2.8 million and $1.7 million, respectively, for the three months ended September 30, 2024 and 2023 and $7.5 million and $4.2 million, respectively, for the nine months ended September 30, 2024 and 2023.</p> 0 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents revenue disaggregated by the Company's portfolio of products (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">OviTex</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"> 12,463 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 34,122 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"> 28,240 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> OviTex PRS </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"> 6,313 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> 4,812 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 17,054 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"> 13,063 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 181 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 81 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 475 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152 </td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,052 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 41,455 </td></tr></table> 12463000 10159000 34122000 28240000 6313000 4812000 17054000 13063000 181000 81000 475000 152000 18957000 15052000 51651000 41455000 2800000 1700000 7500000 4200000 Fair Value of Financial Instruments Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction among market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments are made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company's financial instruments, including cash and cash equivalents, accounts receivable, other assets, and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The carrying amounts of the Company's Credit and Security Agreement approximates fair value due to its variable interest rate. The Company follows the provisions of ASC Topic 820, Fair Value Measurement, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</td></tr></table> The following fair value hierarchy table presents information about each major category of the Company's financial assets and liabilities measured at fair value on a recurring basis (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair value measurement at reporting date using </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> Quoted prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt

0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> active markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> Significant other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> Significant </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> for identical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> observable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> unobservable </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> inputs </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"> September 30, 2024: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"> Cash equivalents - money market fund </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents – money market fund</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> 41,561 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.13%;background:#ccceff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">‌</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#ccceff;margin:0pt;padding:0pt;"> — </td></tr></table> The following fair value hierarchy table presents information about each major category of the Company's financial assets and liabilities measured at fair value on a recurring basis (in thousands): ‌ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair value measurement at reporting date using </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> Quoted prices in </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> active markets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> Significant other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> Significant </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> for identical </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> observable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> unobservable </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"> assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"> inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"> inputs </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"> September 30, 2024: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"> Cash equivalents - money market fund </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:60.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr></table> 13786000 41561000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.29;margin:0pt 6pt 0pt 0pt;">Basic and diluted net loss per common share is determined by dividing net loss by the weighted-average shares of common stock outstanding during the reporting period. In periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share since dilutive shares are not assumed to have been issued if their effect is antidilutive. Therefore, the weighted-average shares used to calculate both basic and diluted net loss per share are the same. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.29;margin:0pt 6pt 0pt 0pt;">.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding for the periods presented, as they would be antidilutive.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.607872%;padding-left:0pt;padding-right:0pt;width:101.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:70.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,128,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2,202,264 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> 971,439 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;">

864,427 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 88,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 88,556 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,188,857 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,155,247 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.607872%;padding-left:0pt;padding-right:0pt;width:101.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;margin:0pt;padding:0pt;"> 2,128,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2,202,264 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> Unvested restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"> 971,439 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> 864,427 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 88,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 88,556 </td></tr><tr><td style="vertical-align:bottom;width:70.11%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,188,857 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,155,247 </td></tr></table> 2128862 2202264 971439 864427 88556 88556 3188857 3155247 Recently Issued Accounting Pronouncements The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options and Derivatives and Hedging - Contracts in Entity's Own Equity ("ASU 2020-06"), ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity's own equity that are currently accounted for as derivatives because of specific settlement provisions. The new guidance also modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those annual periods. The adoption of this guidance did not have a significant impact on the consolidated financial statements and related disclosures. In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures, which expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. This guidance is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted, including adoption in any interim period. The Company is currently evaluating the expected impact that the standard could have on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, requiring entities to provide additional information in the income tax rate reconciliation and additional disclosures about income taxes paid. The new accounting guidance requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. This guidance is effective for annual periods beginning after December 15, 2024, and should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the expected impact that the standard could have on its consolidated financial statements and related disclosures. (4) Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Compensation and related benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 9,216 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Third-party and professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,828 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,828 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts due to contract manufacturer </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 2,314 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2,024 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Current portion of operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 559 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 565 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 140 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 808 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 527 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,300 </td></tr></table> Accrued expenses and other current liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Compensation and related benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 9,216 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Third-party and professional fees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,828 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,828 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts due to contract manufacturer </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 2,314 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2,024 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Current portion of operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 559 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 565 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 16 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 140 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 808 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 527 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,300 </td></tr></table> 7854000 9216000 2828000 2828000 2314000 2024000 559000 565000 16000 140000 808000 527000 14379000 15300000 (5) Long-term Debt Long-term debt consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> MidCap term loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 40,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> End of term charge </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized end of term charge and issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,030) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,485) </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 40,515 </td></tr></table> MidCap Term Loan On May 26, 2022, the Company entered into the Credit and Security Agreement (the "MidCap Credit Agreement") with MidCap Financial Trust, as agent, and certain lender parties thereto. The MidCap Credit Agreement consists of $40.0 million in a term loan. Upon closing, the Company used a portion of the proceeds to repay borrowings under a previous credit facility and intends to use the remaining proceeds to fund operations and other general corporate purposes. Pursuant to the MidCap Credit Agreement, the Company provided a first priority security interest in all existing and future acquired assets, including intellectual property, owned by the Company. The MidCap Credit Agreement contains certain covenants that limit the Company's ability to engage in certain transactions that may be in the Company's long-term best interests, including the incurrence of additional indebtedness, effecting certain corporate changes, making certain investments, acquisitions or dispositions and paying dividends. The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) key permit events, (x) termination of a pension plan, (xi) regulatory matters, (xii) material adverse effect and (xiii) breach of material contracts. In addition, the Company must maintain minimum net revenue levels tested quarterly. In the event of default under the MidCap Credit Agreement, the Company would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%. The MidCap term loan matures on May 1, 2027 and bears interest at a rate equal to 6.25% plus the greater of one-month Term SOFR (as defined in the MidCap Credit Agreement) or 1.0%. The Company is required to make 36 monthly interest payments beginning on June 1, 2022 (the "Interest-Only Period"). If the Company is in covenant compliance at the end of the Interest-Only Period, the Company will have the option to extend the Interest-Only Period by 12 months to 48 monthly interest payments, followed by 12 months of straight-line amortization, with the entire principal payment due at maturity. If the Company is not in covenant compliance at the end of the Interest-Only Period, the Company is required to make 24 months of straight-line amortization payments, with the entire principal amount due at maturity. Subject to certain limitations, the MidCap term loan has a prepayment fee equal to 3.0% of the prepaid principal amount for the first year following the closing date of the MidCap term loan, 2.0% of the prepaid principal amount for the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. The Company is also required to pay an exit fee at the time of maturity or prepayment event equal to 5% of all principal borrowings (the "End of Term Charge") (or in the event of a prepayment event, the amount of principal being prepaid). Interest expense associated with the MidCap Credit Facility recorded for the three and nine months ended September 30, 2024 was $1.3 million and $4.0 million, respectively, of which $0.2 million and $0.5 million, respectively, was related to the amortization of debt issuance costs. Interest expense associated with the MidCap Credit Facility recorded for the three and nine months ended September 30, 2023 was $1.3 million and $3.9 million, respectively, of which $0.2 million and $0.4 million, respectively, was related to the amortization of debt issuance costs. Long-term debt consisted of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> MidCap term loan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 40,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> End of term charge </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,000 </td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized end of term charge and issuance costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,030) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,485) </td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"> Long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 40,515 </td></tr></table> 40000000 40000000 2000000 2000000 1030000 1485000 40970000 40515000 40000000.0 0.02 0.0625 0.010 P36M P12M P48M 0.030 0.020 0.010 0.05 1300000 4000000.0 200000 500000 1300000 3900000 200000 400000 (6) Stockholders' Equity In November 2023, the Company entered into an Equity Distribution Agreement (the "2023 Equity Agreement") with Piper Sandler & Co, ("Piper") in connection with the establishment of an at-the-market offering program under which the Company may sell shares of its common stock, from time to time through Piper as sales agent, in an initial amount of up to $50.0 million. The 2023 Equity Agreement superseded and replaced the Company's previous Equity Distribution Agreement with Piper dated December 18, 2020 (the "2020 Equity Agreement"), which is no longer effective. No sales were made under the 2023 Equity Agreement or the 2020 Equity Agreement during the nine months ended September 30, 2024 or 2023. Warrants The Company had the following warrants outstanding to purchase common stock at September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:65.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> Expiration </td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> dates </td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"> 8,379 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"> 28.65 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"> 2028 </td></tr><tr><td style="vertical-align:bottom;width:65.35%;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 80,177 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 28.65 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> 2027 </td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> There have been no grants, exercises or cancellations of warrants during the nine months ended September 30, 2024.

style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"> 28.65 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"> 2027 </td></tr><tr><td style="vertical-align:bottom;width:65.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 88,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> 8379 28.65 2028 80177 28.65 2027 88556 0 (7) Sale of Product Line In March 2024, the Company entered into an Asset Purchase Agreement (“APA”) with MiMedx Group, Inc. (“MDXG”) to sell certain assets (the “Transaction”) related to NIVIS Fibrillar Collagen Pack Device (“NIVIS”). These assets mainly included the Company’s existing inventory of NIVIS, with a net carrying value of $0.8 million, and certain intellectual property rights to sell NIVIS, with no carrying value. MDXG assumed the Company’s existing supply agreements, including the minimum obligations for NIVIS that the Company entered into in 2022 ahead of the initial sales of NIVIS. In exchange for entering into the Transaction, the Company received an initial $5.0 million upfront payment and is entitled to receive future revenue-sharing payments based on the net sales of NIVIS during the first two years following its launch by MDXG, which revenue-sharing payments would range from a minimum of $3.0 million to a maximum of $7.0 million in the aggregate. Any consideration in excess of $3.0 million up to $7.0 million is considered variable consideration that is fully constrained. The Company accounted for the Transaction as a sale of a nonfinancial asset group in accordance with ASC 610-20 and followed the principals of ASC 606 to determine the consideration of $8.4 million related to the Transaction. The Company transferred control of the nonfinancial asset group in March 2024 and recognized a gain of $7.6 million on the consolidated statement of operations and comprehensive loss during the three months ended March 31, 2024. Additionally, the Company recorded the minimum revenue-share payment of $3.0 million as a receivable at September 30, 2024, with $0.4 million representing the current portion in prepaid expenses and other assets in the consolidated balance sheet and $2.6 million representing the long-term portion in other long-term assets in the consolidated balance sheet. At each reporting date, the Company assesses the constraint of variable consideration and records increases in the transaction price in the period that the estimate of variable consideration changes. For the three and nine months ended September 30, 2024, no changes were made to the variable consideration. </p> 800000 0 5000000.0 3000000.0 7000000.0 3000000.0 7000000.0 8400000 7600000 3000000.0 400000 2600000 0 0 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(8) Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has two equity incentive plans: the 2012 Stock Incentive Plan and the Amended and Restated 2019 Equity Incentive Plan. New awards can only be granted under the Amended and Restated 2019 Equity Incentive Plan (the “Plan”). At September 30, 2024, 907,293 shares of common stock were available for future issuances under the Plan. The Plan is subject to an annual increase, subject to prior approval by the Company’s board of directors, equal to the lesser of (i) 432,442 shares, (ii) 4% of the shares outstanding on the last day of the immediately preceding fiscal year and (iii) such smaller number of shares as determined by the board of directors. The Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company’s board of directors. The Company estimates forfeitures that it expects will occur and adjusts expense for actual forfeitures in the periods they occur.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense ratably over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of the accompanying consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 318 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 507 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 1,375 </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 607 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 670 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 1,804 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 1,861 </td></tr><tr><td style="vertical-align:bottom;width:44.27%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 156 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 192 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 476 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 555 </td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"> Total stock-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,369 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,791 </td></tr></table> Stock Options The Company's stock options vest based on the terms in each award agreement and generally vest over four years and have a term of 10 years. . . The following table summarizes stock option activity: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> average </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> remaining </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> average exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> contractual term </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> price per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 2,162,453 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 259,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (255,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,128,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"> 10.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"> 6.12 </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> Vested and expected to vest at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,099,563 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> 10.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> 6.08 </td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,612,281 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"> 11.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"> 5.35 </td></tr></table> Included in outstanding options at September 30, 2024 were 319,684 stock options granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). At September 30, 2024, the aggregate intrinsic value of both outstanding options and exercisable options was immaterial. The weighted average grant-date fair value per share of options granted was $4.67 during the nine months ended September 30, 2024. The aggregate intrinsic value of options exercised was immaterial and $41,000 for the three and nine months ended September 30, 2024, respectively. At September 30, 2024, the total unrecognized compensation expense related to unvested employee and nonemployee stock option awards was $2.8 million, which is expected to be recognized in expense over a weighted-average period of approximately 2.2 years. The fair value of each option was estimated on the date of grant using the Black-Scholes option pricing model and the weighted average assumptions in the table below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:77.62%;background:#cceeff;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> 73.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:77.62%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> 4.29 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> Expected term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> 6.14 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr></table> Restricted Stock Units The Company has issued service-based and performance-based restricted stock units (“RSUs”). Vesting of the service-based RSUs is based on the terms in each award agreement and is generally over four years. Vesting of the performance-based RSUs is subject to continued service through 2026 and the achievement of certain performance milestones for fiscal year 2026. The amount of performance-based RSUs that will vest can range from 0% to 110% of the original number of RSUs granted. Expense for the performance-based RSUs is not recognized until the performance conditions are deemed probable of achievement. The Company has not recorded any expense related to the performance-based RSUs. The following table summarizes the service-based RSUs for the Plan: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> 657,054 </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> 411,825 </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> (178,836) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Canceled/forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (135,104) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 754,939 </td></tr></table><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> The following table summarizes the performance-based RSUs for the Plan: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#ccceff;margin:0pt;padding:0pt;"> Outstanding at January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#ccceff;margin:0pt;padding:0pt;"> 250,149 </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#ccceff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#ccceff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Canceled/forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (33,649) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#ccceff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 216,500 </td></tr></table> Included in outstanding RSUs at September 30, 2024 were 115,210 RSUs granted outside of the Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The weighted average grant-date fair value per RSU granted was $6.63 during the nine months ended September 30, 2024. The aggregate intrinsic value of RSUs outstanding was $2.5 million at September 30, 2024. The total unrecognized compensation expense at September 30, 2024 related to RSUs was $4.6 million, which is expected to be recognized in expense over a weighted-average period of approximately 2.6 years.</p> 2 907293 432442 0.04 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:44.27%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#ccceff;margin:0pt;padding:0pt;"> 318 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#ccceff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"> 993 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,375</p></td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,861</p></td></tr><tr><td style="vertical-align:bottom;width:44.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555</p></td></tr><tr><td style="vertical-align:bottom;width:44.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,273 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,791 </td></tr></table> 318000 507000 993000 1375000 607000 670000 1804000 1861000 156000 192000 476000 555000 1081000 1369000 3273000 3791000 P4Y P10Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> Weighted </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td></tr></table>

style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> average </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> remaining </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"> average exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> contractual term </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> price per share </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (years) </td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 2,162,453 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 259,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38,431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Canceled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (255,060)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt,"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,128,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"> 10.91 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"> 6.12 </td></tr><tr><td style="vertical-align:bottom;width:62.33%;margin:0pt;padding:0pt;"> Vested and expected to vest at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,099,563 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"> 10.94 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"> 6.08 </td></tr><tr><td style="vertical-align:bottom;width:62.33%;background:#cceeff;margin:0pt;padding:0pt;"> Exercisable at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,612,281 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"> 11.45 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"> 5.35 </td></tr></table> 2162453 11.48 259900 6.86 38431 5.88 255060 12.35 2128862 10.91 P6Y1M13D 2099563 10.94 P6Y29D 1612281 11.45 P5Y4M6D 319684 4.67 41000 2800000 P2Y2M12D <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended   </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:77.62%;background:#cceeff;margin:0pt;padding:0pt;"> Expected dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> 73.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:77.62%;background:#cceeff;margin:0pt;padding:0pt;"> Risk-free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;background:#cceeff;margin:0pt;padding:0pt;"> 4.29 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:77.62%;margin:0pt;padding:0pt;"> Expected term (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:17.59%;margin:0pt;padding:0pt;"> 6.14 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td></tr></table> 0.732 0.0429 P6Y1M20D P4Y 0 1.10 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> 657,054 </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> 411,825 </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> (178,836) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Canceled/forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (135,104) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 754,939 </td></tr></table> 657054 411825 178836 135104 754939 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> shares </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January 1, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> 250,149 </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:84.74%;margin:0pt;padding:0pt;"> Canceled/forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (33,649) </td></tr><tr><td style="vertical-align:bottom;width:84.74%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 216,500 </td></tr></table> 250149 33649 216500 115210 6.63 2500000 4600000 P2Y7M6D (9) Subsequent Event . On October 24, 2024, the Company completed an underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares of common stock, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so chose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering resulted in gross proceeds of $46.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no subsequent exercise of the pre-funded warrants. The exercise of the pre-funded warrants, if any, is not expected to provide significant additional funding to the Company. 14670000 2.25 5800000 2.2499 0.0001 46000000.0 false false false false